ACORDA THERAPEUTICS INC, 10-K filed on 2/27/2019
Annual Report
v3.10.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2018
Feb. 20, 2019
Jun. 29, 2018
Document And Entity Information [Abstract]      
Entity Registrant Name ACORDA THERAPEUTICS INC    
Entity Central Index Key 0001008848    
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Large Accelerated Filer    
Entity Public Float     $ 1,122,560,492
Entity Shell Company false    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   47,633,407  
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Trading Symbol ACOR    
v3.10.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 293,564,000 $ 307,068,000
Restricted cash 532,000 410,000
Short term investments 151,989,000 0
Trade accounts receivable, net of allowances of $2,681 and $845, as of December 31, 2018 and 2017, respectively 23,430,000 81,403,000
Prepaid expenses 19,384,000 13,333,000
Inventory, net 29,014,000 37,501,000
Other current assets 10,194,000 1,983,000
Total current assets 528,107,000 441,698,000
Property and equipment, net of accumulated depreciation 60,519,000 36,669,000
Goodwill 282,059,000 286,611,000
Intangible assets, net of accumulated amortization 428,570,000 430,603,000
Non-current portion of deferred cost of license revenue   1,638,000
Other assets 411,000 750,000
Total assets 1,299,666,000 1,197,969,000
Current liabilities:    
Accounts payable 48,859,000 27,367,000
Accrued expenses and other current liabilities 76,882,000 99,850,000
Current portion of deferred license revenue   9,057,000
Current portion of loans payable 616,000 645,000
Current portion of liability related to sale of future royalties 8,985,000 6,763,000
Current portion of acquired contingent consideration 4,914,000 278,000
Total current liabilities 140,256,000 143,960,000
Convertible senior notes (due 2021) 318,670,000 308,805,000
Non-current portion of acquired contingent consideration 163,086,000 112,722,000
Non-current portion of deferred license revenue   23,398,000
Non-current portion of loans payable 24,470,000 25,670,000
Deferred tax liability 7,483,000 22,459,000
Non-current portion of liability related to sale of future royalties 21,731,000 29,025,000
Other non-current liabilities 11,987,000 11,943,000
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value. Authorized 1,000,000 shares at December 31, 2018 and December 31, 2017; no shares issued as of December 31, 2018 and December 31, 2017
Common stock, $0.001 par value. Authorized 80,000,000 shares at December 31, 2018 and 2017; issued 47,508,505 and 46,441,428 shares, including those held in treasury, as of December 31, 2018 and 2017, respectively 48,000 46,000
Treasury stock at cost (87,737 and 16,151 shares at December 31, 2018 and 2017, respectively) (2,133,000) (389,000)
Additional paid-in capital 1,005,105,000 968,580,000
Accumulated deficit (393,843,000) (455,108,000)
Accumulated other comprehensive income 2,806,000 6,858,000
Total stockholders’ equity 611,983,000 519,987,000
Total liabilities and stockholders’ equity $ 1,299,666,000 $ 1,197,969,000
v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Statement Of Financial Position [Abstract]    
Trade accounts receivable, allowances (in dollars) $ 2,681 $ 845
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, Authorized shares 1,000,000 1,000,000
Preferred stock, issued shares 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, Authorized shares 80,000,000 80,000,000
Common stock, issued shares 47,508,505 46,441,428
Treasury stock, shares 87,737 16,151
v3.10.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenues:      
Total net revenues $ 471,433 $ 588,287 $ 519,601
Costs and expenses:      
Cost of sales 99,310 135,080 107,475
Cost of milestone and license revenue   634 634
Research and development 106,383 166,105 203,437
Selling, general and administrative 172,254 181,619 235,437
Asset impairment   296,763  
Changes in fair value of acquired contingent consideration 55,000 40,900 8,600
Total operating expenses 432,947 821,101 555,583
Operating income (loss) 38,486 (232,814) (35,982)
Other expense (net):      
Interest and amortization of debt discount expense (21,597) (18,664) (16,527)
Interest income 3,518 136 339
Other income (expense) 16 (543) 9,902
Total other expense (net) (18,063) (19,071) (6,286)
Income (loss) before taxes 20,423 (251,885) (42,268)
Benefit from income taxes 13,259 28,526 6,665
Net income (loss) 33,682 (223,359) (35,603)
Net (loss) attributable to non-controlling interest     (985)
Net income (loss) attributable to Acorda Therapeutics, Inc. $ 33,682 $ (223,359) $ (34,618)
Net income (loss) per share—basic $ 0.72 $ (4.86) $ (0.76)
Net income (loss) per share—diluted $ 0.71 $ (4.86) $ (0.76)
Weighted average common shares outstanding used in computing net income (loss) per share—basic 47,010 45,999 45,259
Weighted average common shares outstanding used in computing net income (loss) per share—diluted 47,341 45,999 45,259
Net Product Revenues      
Revenues:      
Total net revenues $ 459,739 $ 549,749 $ 493,358
Royalty Revenues      
Revenues:      
Total net revenues $ 11,694 29,481 17,186
License Revenue      
Revenues:      
Total net revenues   $ 9,057 $ 9,057
v3.10.0.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]      
Net income (loss) $ 33,682 $ (223,359) $ (35,603)
Other comprehensive income (loss):      
Foreign currency translation adjustment (3,927) 19,759 (12,901)
Unrealized losses on available-for-sale securities, net of tax (125)    
Reclassification of net losses to net income     119
Other comprehensive (loss) income, net of tax (4,052) 19,759 (12,782)
Comprehensive income (loss) attributable to Acorda Therapeutics, Inc. $ 29,630 $ (203,600) (48,385)
Comprehensive (loss) attributable to noncontrolling interests.     $ (1,095)
v3.10.0.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Private Placement
Common stock
Common stock
Private Placement
Treasury stock
Additional paid-in capital
Additional paid-in capital
Private Placement
Accumulated deficit
Accumulated other comprehensive income (loss)
Noncontrolling Interest
Balance at Dec. 31, 2015 $ 603,025   $ 43   $ (329) $ 812,782   $ (209,352) $ (119)  
Balance (in shares) at Dec. 31, 2015     42,999              
Increase (Decrease) in Stockholders' Equity                    
Compensation expense for issuance of stock options to employees 28,090         28,090        
Compensation expense for issuance of restricted stock to employees 8,296         8,296        
Compensation expense for issuance of restricted stock to employees (in shares)     236              
Exercise of stock options 3,427         3,427        
Exercise of stock options (in shares)     194              
Excess tax benefit from (charges for) share-based compensation arrangements (13)         (13)        
Private placement, net of issuance costs   $ 72,091   $ 3     $ 72,088      
Private placement, net of issuance costs (in shares)       2,251            
Acquisition of subsidiary 25,736                 $ 25,736
Purchase of noncontrolling interest (27,946)         (3,305)       (24,641)
Other comprehensive (loss) income, net of tax (12,893)               (12,782) (110)
Net income (loss) (35,603)             (34,618)   (985)
Balance at Dec. 31, 2016 664,211   $ 46   (329) 921,365   (243,970) (12,901) $ 0
Balance (in shares) at Dec. 31, 2016     45,680              
Increase (Decrease) in Stockholders' Equity                    
Adjustment to accumulated deficit (pursuant to adoption of ASU) | ASU 2016-09 12,221             12,221    
Compensation expense for issuance of stock options to employees 24,910         24,910        
Compensation expense for issuance of restricted stock to employees 7,904         7,904        
Compensation expense for issuance of restricted stock to employees (in shares)     263              
Exercise of stock options 10,479         10,479        
Exercise of stock options (in shares)     498              
Restructuring Cost pursuant to equity modification 967         967        
Purchase of Treasury Stock (60)       (60)          
Purchase of noncontrolling interest 2,955         2,955        
Other comprehensive (loss) income, net of tax 19,759               19,759  
Net income (loss) (223,359)             (223,359)    
Balance at Dec. 31, 2017 519,987   $ 46   (389) 968,580   (455,108) 6,858  
Balance (in shares) at Dec. 31, 2017     46,441              
Increase (Decrease) in Stockholders' Equity                    
Adjustment to accumulated deficit (pursuant to adoption of ASU) | ASU 2014-09 27,583             27,583    
Compensation expense for issuance of stock options to employees 15,182         15,182        
Compensation expense for issuance of restricted stock to employees 6,147         6,147        
Compensation expense for issuance of restricted stock to employees (in shares)     306              
Exercise of stock options $ 15,198   $ 2     15,196        
Exercise of stock options (in shares) 733   689              
Purchase of Treasury Stock $ (1,744)       (1,744)          
Purchase of Treasury Stock ,Shares     72              
Other comprehensive (loss) income, net of tax (4,052)               (4,052)  
Net income (loss) 33,682             33,682    
Balance at Dec. 31, 2018 $ 611,983   $ 48   $ (2,133) $ 1,005,105   $ (393,843) $ 2,806  
Balance (in shares) at Dec. 31, 2018     47,508              
v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net income (loss) $ 33,682 $ (223,359) $ (35,603)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Share-based compensation expense 21,252 32,814 36,386
Amortization of net premiums and discounts on investments (1,417)   467
Amortization of debt discount and debt issuance costs 15,822 12,153 9,717
Depreciation and amortization expense 11,479 23,234 21,582
Intangible asset impairment   296,763  
Change in contingent consideration obligation 55,000 40,622 8,600
Realized gain on foreign currency transaction   247 (9,856)
Non-cash royalty revenue (10,291) (2,705)  
Deferred tax benefit (14,505) (54,044) (11,190)
Excess tax charge (benefit) from share-based compensation arrangements     15
Changes in assets and liabilities:      
Decrease (increase) in accounts receivable 57,972 (29,112) (19,965)
(Increase) decrease in prepaid expenses and other current assets (15,402) 3,445 6,904
Decrease (increase) in inventory 8,440 5,505 (6,660)
Decrease in non-current portion of deferred cost of license revenue   634 634
Decrease in other assets 34 4,138 34
(Decrease) Increase in accounts payable, accrued expenses and other current liabilities (3,488) (2,099) 37,625
Decrease in non-current portion of deferred license revenue   (9,057) (9,057)
Increase in other non-current liabilities 52 1,491 17
Net cash provided by operating activities 150,793 97,136 29,649
Cash flows from investing activities:      
Purchases of property and equipment (33,328) (13,688) (6,192)
Purchases of intangible assets (587) (688) (893)
Acquisitions, net of cash received and gain on foreign currency transaction     (266,454)
Purchases of investments (249,107)   (40,215)
Proceeds from maturities of investments 98,273   239,968
Net cash used in investing activities (176,865) (10,713) (73,786)
Cash flows from financing activities:      
Debt issuance costs     (1,587)
Proceeds from issuance of common stock and option exercises 15,198 10,479 75,520
Repayment/(purchase) of non-controlling interest   2,722 (27,946)
Purchase of treasury stock (1,744) (60)  
Net proceeds from royalty monetizations   50,787  
Repayment of loans payable (657) (2,409)  
Excess tax (benefit) charge from share-based compensation arrangements     (15)
Repayments of revenue interest liability     (41)
Net cash provided by financing activities 12,797 61,519 45,931
Effect of exchange rate changes on cash and cash equivalents and restricted cash (412) 1,225 (2,159)
Net (decrease) increase in cash and cash equivalents and restricted cash (13,687) 149,167 (364)
Cash, cash equivalents and restricted cash at beginning of period 308,038 158,871 159,235
Cash, cash equivalents and restricted cash at end of period 294,351 308,038 158,871
Supplemental disclosure:      
Cash paid for interest 6,064 6,066 6,059
Cash paid for taxes 20,709 14,929 $ 4,250
Zanaflex      
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Gain on sale of assets   (3,534)  
Cash flows from investing activities:      
Net proceeds from sale of assets   $ 3,663  
Qutenza      
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Gain on sale of assets (7,837)    
Cash flows from investing activities:      
Net proceeds from sale of assets $ 7,884    
v3.10.0.1
Organization and Business Activities
12 Months Ended
Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization and Business Activities

(1) Organization and Business Activities

Acorda Therapeutics, Inc. (“Acorda” or the “Company”) is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

The management of the Company is responsible for the accompanying audited consolidated financial statements and the related information included in the notes to the consolidated financial statements.

v3.10.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires management to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include share‑based compensation accounting, which are largely dependent on the fair value of the Company’s equity securities, measurement of changes in the fair value of acquired contingent consideration which is based on a probability weighted discounted cash flow valuation methodology, estimated deductions to determine net revenue such as allowances for customer credits, including estimated discounts, rebates, and chargebacks, which are estimated based on available information that will be adjusted to reflect known changes in the factors that impact such allowances, estimates of reserves for obsolete and excess inventory, and estimates of unrecognized tax benefits and valuation allowances on deferred tax assets which are based on an assessment of recoverability of the deferred tax assets against future taxable income. Actual results could differ from those estimates.

Risks and Uncertainties

The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with original maturities of three months or less from date of purchase to be cash equivalents. All cash and cash equivalents are held in highly rated securities including a Treasury money market fund which is unrestricted as to withdrawal or use. To date, the Company has not experienced any losses on its cash and cash equivalents. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term and liquid nature. We maintain cash balances in excess of insured limits. We do not anticipate any losses with respect to such cash balances.

Restricted Cash

Restricted cash represents a bank account with funds to cover the Company’s self-funded employee health insurance. At December 31, 2018, the Company also held $0.3 million of restricted cash related to cash collateralized standby letters of credit in connection with obligations under facility leases, which is included with other assets in the consolidated balance sheet due to the long-term nature of the letters of credit. (see Note 10).

Investments

Short-term investments consist primarily of high-grade commercial paper and corporate bonds. The Company classifies marketable securities available to fund current operations as short-term investments in current assets on its consolidated balance sheets. Marketable securities are classified as long-term investments in long-term assets on the consolidated balance sheets if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all its investments as available-for-sale. Available-for-sale securities are recorded at the fair value of the investments based on quoted market prices.

Unrealized holding gains and losses on available-for-sale securities, which are determined to be temporary, are excluded from earnings and are reported as a separate component of accumulated other comprehensive loss.

Premiums and discounts on investments are amortized over the life of the related available-for-sale security as an adjustment to yield using the effective‑interest method. Dividend and interest income are recognized when earned. Amortized premiums and discounts, dividend and interest income are included in interest income. Realized gains and losses are included in other income.

Other Comprehensive Income (Loss)

The Company’s other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale securities and adjustments for foreign currency translation and is recorded and presented net of income tax. There was no income tax allocated to the foreign currency translation adjustment in Other Comprehensive Income (Loss) for the period ended December 31, 2018 and 2017. The cumulative foreign currency translation adjustment reported in Other Comprehensive Income (Loss) was $(3.9) million and $19.8 million for the period ended December 31, 2018 and 2017, respectively.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Cost is determined using the first-in, first-out method (FIFO) for all inventories. The Company’s inventory primarily consisted of finished goods as of December 31, 2018 and 2017. The Company establishes reserves as necessary for obsolescence and excess inventory. The Company records a reserve for excess and obsolete inventory based on the expected future product sales volumes and the projected expiration of inventory and specifically identified obsolete inventory. The Company recorded a charge for excess and obsolete inventory of $8.4 million and $0.7 million for the years ended December 31, 2018 and 2017, respectively.

Ampyra

The cost of Ampyra inventory manufactured by Alkermes plc (Alkermes) is based on agreed upon pricing with Alkermes. In the event Alkermes does not manufacture the products, Alkermes is entitled to a compensating payment for the quantities of product provided by Patheon, the Company’s alternative manufacturer. This compensating payment is included in the Company’s inventory balances.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation, except for assets acquired in a business combination, which are recorded at fair value as of the acquisition date. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which ranges from one to seven years. Leasehold improvements are recorded at cost, less accumulated amortization, which is computed on a straight-line basis over the shorter of the useful lives of the assets or the remaining lease term. Expenditures for maintenance and repairs are charged to expense as incurred.

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired in a business combination accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. We perform our impairment testing at the reporting unit level where we have determined that we have a single reporting unit and operating segment. We test goodwill for impairment using a quantitative method (primarily based on market capitalization). The impairment test for goodwill uses a two-step approach. Step one compares the estimated fair value of the reporting unit including goodwill to its carrying value. If the carrying value of the reporting unit exceeds the estimated fair value of the reporting unit, step two must be performed. Step two compares the carrying value of the reporting unit to the fair value of all of the assets and liabilities of the reporting unit as if the reporting unit was acquired in a business combination. If the carrying value of the reporting unit’s goodwill exceeds the implied fair value of its goodwill calculated in this manner, an impairment loss is recognized in an amount equal to the excess of the carrying value over the implied fair value. See Note 4 for a discussion of goodwill.

Intangible Assets

In Process Research and Development

The Company has indefinite lived intangible assets for the value of acquired in-process research and development. The cost of in-process research and development (IPR&D) acquired directly in a transaction other than a business combination is capitalized if the project will be further developed or have an alternative future use; otherwise it is expensed. The estimated fair value of IPR&D projects acquired in a business combination is capitalized. Several methods may be used to determine the estimated fair value of the IPR&D assets acquired in a business combination. The Company utilizes the "income method” which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, estimated pricing and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or impaired, as appropriate. These assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Events that could result in an impairment, or trigger an interim impairment assessment, may include actions by regulatory authorities with respect to us or our competitors, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug which could have a negative effect on cash flows and which could result in an impairment. If impairment indicators are present or changes in circumstance suggest that an impairment may exist, we perform an impairment analysis by comparing the sum of the estimated discounted future cash flows, or fair value, of each intangible asset to its carrying value on the consolidated balance sheet. We will recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value.

Finite-Lived Intangible Assets

The Company has finite lived intangible assets that are amortized on a straight line basis over the period in which the Company expects to receive economic benefit and are reviewed for impairment when facts and circumstances indicate that the carrying value of the asset may not be recoverable. The determination of the expected life will be dependent upon the use and underlying characteristics of the intangible asset. In the Company’s evaluation of the intangible assets, it considers the term of the underlying asset life and the expected life of the related product line. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the intangible asset and recognize an impairment loss in the statement of operations if the carrying value of the intangible asset exceeds its fair value. Fair value is generally estimated based on either appraised value or other valuation techniques. Events that could result in an impairment, or trigger an interim impairment assessment, may include actions by regulatory authorities with respect to us or our competitors, new or better products entering the market, changes in market share or market pricing, changes in the economic lives of the assets, changes in the legal framework covering patents, rights or licenses, and other market changes which could have a negative effect on cash flows and which could result in an impairment.

Contingent Consideration

The Company may record contingent consideration as part of the cost of business acquisitions. Contingent consideration is recognized at fair value as of the date of acquisition and recorded as a liability on the consolidated balance sheet. The contingent consideration is re-valued on a quarterly basis using a probability weighted discounted cash-flow approach until fulfillment or expiration of the contingency. Changes in the fair value of the contingent consideration are recognized in the statement of operations. See Note 16 for discussion on the Alkermes ARCUS agreement.

Impairment of Long-Lived Assets

The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful lives of its long-lived assets may warrant revision or that the carrying value of the assets may be impaired. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related assets. Any write‑downs are treated as permanent reductions in the carrying amount of the assets.

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties

As of October 1, 2017, the Company completed a royalty purchase agreement with HealthCare Royalty Partners, or HCRP (“Royalty Agreement”). In exchange for the payment of $40 million to the Company, HCRP obtained the right to receive Fampyra royalties payable by Biogen under the Collaboration and Licensing Agreement between the Company and Biogen, up to an agreed upon threshold of royalties. When this threshold is met, if ever, the Fampyra royalty revenue will revert back to the Company and the Company will continue to receive the Fampyra royalty revenue from Biogen until the revenue stream ends. The transaction does not include potential future milestones to be paid by Biogen to Acorda.

The Company maintained the rights under the license and collaboration agreement with Biogen, therefore, the Royalty Agreement has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement, in accordance with the relevant accounting guidance. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future net royalty payments to be made to HCRP over the term of the agreement up to the agreed upon threshold of royalties. The total threshold of net royalties to be paid, less the net proceeds received will be recorded as interest expense over the life of the liability. The Company imputes interest on the unamortized portion of the liability using the effective interest method and records interest expense based on the timing of the payments received over the term of the royalty agreement. The Company’s estimate of the interest rate under the arrangement is based on forecasted net royalty payments expected to be made to HCRP over the life of the royalty agreement. The Company estimated an effective annual interest rate of approximately 15%. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as required. Non-cash royalty revenue is reflected as royalty revenue and non-cash interest expense is reflected as interest and amortization of debt discount expense in the Statement of Operations.

Patent Costs

Patent application and maintenance costs are expensed as incurred.

Research and Development

Research and development expenses include the costs associated with the Company’s internal research and development activities, including salaries and benefits, occupancy costs, and research and development conducted for it by third parties, such as contract research organizations (CROs), sponsored university-based research, clinical trials, contract manufacturing for its research and development programs, and regulatory expenses. In addition, research and development expenses include the cost of clinical trial drug supply shipped to the Company’s clinical study vendors. For those studies that the Company administers itself, the Company accounts for its clinical study costs by estimating the patient cost per visit in each clinical trial and recognizes this cost as visits occur, beginning when the patient enrolls in the trial. This estimated cost includes payments to the trial site and patient-related costs, including laboratory costs related to the conduct of the trial. Cost per patient varies based on the type of clinical trial, the site of the clinical trial, and the length of the treatment period for each patient. For those studies for which the Company uses a CRO, the Company accounts for its clinical study costs according to the terms of the CRO contract. These costs include upfront, milestone and monthly expenses as well as reimbursement for pass through costs. As actual costs become known to the Company, it adjusts the accrual; such changes in estimate may be a material change in its clinical study accrual, which could also materially affect its results of operations. All research and development costs are expensed as incurred except when accounting for nonrefundable advance payments for goods or services to be used in future research and development activities. These payments are capitalized at the time of payment and expensed ratably over the period the research and development activity is performed.

Accounting for Income Taxes

The Company provides for income taxes in accordance with ASC Topic 740 (ASC 740). Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance for the amounts of any tax benefits which, more likely than not, will not be realized.

In determining whether a tax position is recognized for financial statement purposes, a two-step process is utilized whereby the threshold for recognition is a more likely-than-not test that the tax position will be sustained upon examination and the tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Revenue Recognition

On January 1, 2018, the Company adopted the new accounting standard ASC 606, “Revenue from Contracts with Customers” (Topic 606) (“ASC 606”) and the related amendments to all contracts with customers that were not completed as of the date of adoption using the modified retrospective method. ASC 606 supersedes prior revenue guidance under ASC 605 “Revenue Recognition” (“ASC 605”) and requires entities to recognize revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company completed its assessment of the new guidance and evaluated the new requirements as applied to its existing revenue contracts not completed as of the date of initial application. As a result of the assessment, with the exception of the changes to our recognition of license revenue as further described below, the Company determined that adoption of the new standard did not have a significant impact on its revenue recognition methodology. In accordance with ASC 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the good or service.

The Company determined that the revenue recognition methodology for the deferred license revenue changed as a result of the adoption of ASC 606. License revenue recorded by the Company prior to January 1, 2018 related exclusively to the recognition of the upfront payment received from Biogen upon the execution of the License and Collaboration agreement that granted Biogen an exclusive non sub-licensable license to sell Fampyra outside of the U.S. License revenue recorded prior to January 1, 2018 was recognized under ASC 605 on a pro rata basis as the Company’s obligations were satisfied throughout the duration of the license and collaboration agreement. As of January 1, 2018, the Company adopted ASC 606 which changed the Company’s determination of its distinct performance obligations resulting in an acceleration of the recognition of the revenue in the arrangement. The material performance obligations were completed prior to January 1, 2018, and as a result, the Company recognized its previously deferred license revenue and the associated deferred costs as a cumulative effect adjustment of $27.6 million within the accumulated deficit on the consolidated balance sheet as of January 1, 2018.

 

The cumulative effect of applying ASC 606 to the company’s consolidated balance sheet was as follows:

(In thousands)

 

Balance as of December 31, 2017

 

 

Net Adjustments

 

 

Balance as of

January 1, 2018

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

1,983

 

 

$

(634

)

 

$

1,349

 

Non-current portion of deferred cost of license revenue

 

 

1,638

 

 

 

(1,638

)

 

 

 

    Total Assets

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

23,398

 

 

 

(23,398

)

 

 

 

Deferred tax liability

 

 

22,459

 

 

 

2,600

 

 

 

25,059

 

Accumulated deficit

 

 

(455,108

)

 

 

27,583

 

 

 

(427,525

)

    Total liabilities and stockholders' equity

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

 

The impact of the adoption of ASC 606 on the Company’s consolidated balance sheet as of December 31, 2018 was as follows:

(In thousands)

 

Balance as of

December 31, 2018

Prior to Adoption

of ASC 606

 

 

Net Adjustments

 

 

Balance as of

December 31, 2018

as Reported

Under ASC 606

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

10,828

 

 

$

(634

)

 

$

10,194

 

Non-current portion of deferred cost of license revenue

 

 

1,004

 

 

 

(1,004

)

 

 

 

    Total Assets

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

14,341

 

 

 

(14,341

)

 

 

 

Deferred tax liability

 

 

6,988

 

 

 

495

 

 

 

7,483

 

Accumulated deficit

 

 

(415,108

)

 

 

21,265

 

 

 

(393,843

)

    Total liabilities and stockholders' equity

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

 

The impact of the adoption of ASC 606 on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:

(In thousands)

 

Year Ended December 31, 2018

Balance Prior to

Adoption of ASC 606

 

 

Effect of Change

 

 

Year Ended December 31, 2018

Balance as Reported

Under ASC 606

 

License revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Cost of license revenue

 

 

634

 

 

 

(634

)

 

 

 

Operating income (loss)

 

$

46,909

 

 

$

(8,423

)

 

$

38,486

 

(Benefit from) provision for income taxes

 

 

(15,364

)

 

 

2,105

 

 

 

(13,259

)

Net income (loss)

 

$

40,000

 

 

$

(6,318

)

 

$

33,682

 

Net income (loss) per share—basic

 

$

0.85

 

 

$

(0.13

)

 

$

0.72

 

Net income (loss) per share—diluted

 

$

0.84

 

 

$

(0.13

)

 

$

0.71

 

 

ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities.

ASC 606 outlines a five-step process for recognizing revenue from contracts with customers: i) identify the contract with the customer, ii) identify the performance obligations in the contract, (iii) determine the transaction price, iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company determines the performance obligations that are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to each respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon receipt of the product by the customer.

ASC 606 requires entities to record a contract asset when a performance obligation has been satisfied or partially satisfied, but the amount of consideration has not yet been received because the receipt of the consideration is conditioned on something other than the passage of time. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g. receivable), before the entity transfers a good or service to the customer. We did not have any contract assets or liabilities as of December 31, 2018.

Product Revenue, Net

Ampyra

Ampyra is available primarily through a network of specialty pharmacy providers that provide the medication to patients by mail and ASD Specialty Healthcare, Inc. (an AmerisourceBergen affiliate), which distributes Ampyra to the U.S. Bureau of Prisons, the U.S. Department of Defense, the U.S. Department of Veterans Affairs, or VA, and other federal agencies.

Qutenza

Prior to the sale of Qutenza assets, Qutenza was distributed in the U.S. by Besse Medical, Inc., a specialty distributor that furnishes the medication to physician offices; and by ASD Specialty Healthcare, Inc., a specialty distributor that furnishes the medication to hospitals and clinics.

Net revenue from product sales is recognized at the transaction price when the customer obtains control of the Company’s products, which occurs at a point in time, typically upon receipt of the product by the customer. The Company’s products are sold primarily to a network of specialty providers which are contractually obligated to hold no more than an agreed upon number of days of inventory. The Company’s payment terms are between 30 to 35 days.

The Company’s net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded for the Company’s estimate of cash consideration expected to be given by the Company to a customer that is presumed to be a reduction of the transaction price of the Company’s products and, therefore, are characterized as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.

Discounts and Allowances

Revenue from product sales are recorded at the transaction price, which includes estimates for discounts and allowances for which reserves are established and includes cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. Actual discounts and allowances are recorded following shipment of product and the appropriate reserves are credited. These reserves are classified as reductions of accounts receivable (if the amount is payable to the Customer and right of offset exists) or a current liability (if the amount is payable to a party other than a Customer). These allowances are established by management as its best estimate based on historical experience and data points available and are adjusted to reflect known changes in the factors that impact such reserves. Allowances for customer credits, chargebacks, rebates, data fees and wholesaler fees for services, returns, and discounts are established based on contractual terms with customers and analyses of historical usage of these items. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The nature of our allowances and accruals requiring critical estimates, and the specific considerations it uses in estimating their amounts are as follows:

Government Chargebacks and Rebates: We contract for Medicaid and other U.S. Federal government programs to allow for our products to remain eligible for reimbursement under these programs. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. Based upon our contracts and the most recent experience with respect to sales through each of these channels, we provide an allowance for chargebacks and rebates. We monitor the sales trends and adjust the chargeback and rebate percentages on a regular basis to reflect the most recent chargebacks and rebate experience. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Managed Care Contract Rebates: We contract with various managed care organizations including health insurance companies and pharmacy benefit managers. These contracts stipulate that rebates and, in some cases, administrative fees, are paid to these organizations provided our product is placed on a specific tier on the organization’s drug formulary. Based upon our contracts and the most recent experience with respect to sales through managed care channels, we provide an allowance for managed care contract rebates. We monitor the sales trends and adjust the allowance on a regular basis to reflect the most recent rebate experience. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Copay Mitigation Rebates: We offer copay mitigation to commercially insured patients who have coverage for our products (in accordance with applicable law) and are responsible for a cost share. Based upon our contracts and the most recent experience with respect to actual copay assistance provided, we provide an allowance for copay mitigation rebates. We monitor the sales trends and adjust the rebate percentages on a regular basis to reflect the most recent rebate experience.

Cash Discounts: We sell directly to companies in our distribution network, which primarily includes specialty pharmacies and ASD Specialty Healthcare, Inc. We generally provide invoice discounts for prompt payment for our products. We estimate our cash discounts based on the terms offered to our customers. Discounts are estimated based on rates that are explicitly stated in the Company’s contracts as it is expected they will take the discount and are recorded as a reduction of revenue at the time of product shipment when product revenue is recognized. We adjust estimates based on actual activity as necessary.

Product Returns: We offer no right of return except for products damaged in shipping to Ampyra customers or a limited right of return based on the product’s expiration date to previous Zanaflex customers. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The company currently estimates product return liabilities using historical sales information and inventory remaining in the distribution channel.

Data Fees and Fees for Services Payable to Specialty Pharmacies: We have contracted with certain specialty pharmacies to obtain transactional data related to our products in order to develop a better understanding of our selling channel as well as patient activity and utilization by the Medicaid program and other government agencies and managed care organizations. We pay a variable fee to the specialty pharmacies to provide us the data. We also pay the specialty pharmacies a fee in exchange for providing distribution and inventory management services, including the provision of inventory management data to the Company. We estimate our fee for service accruals and allowances based on sales to each specialty pharmacy and the applicable contracted rate.

Royalty Revenue

Royalty revenue recorded by the Company relates exclusively to the Company’s License and Collaboration agreement with Biogen which provides for ongoing royalties based on sales of Fampyra outside of the U.S. The Company recognizes revenue for royalties under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the following: 1) sale or usage of the products or 2) satisfaction of the performance obligations. The Company has satisfied its performance obligations and therefore recognizes royalty revenue when the sales to which the royalties relate are completed.

License Revenue

License revenue relates to the License and Collaboration agreement with Biogen which provides for milestone payments for the achievement of certain regulatory and sales milestones during the term of the agreement. Regulatory milestones are contingent upon the approval of Fampyra for new indications outside of the U.S. Sales milestones are contingent upon the achievement of certain net sales targets for Fampyra sales outside of the U.S. The Company recognizes license revenue under ASC 606, which provides constraints for entities to recognize license revenue which is deemed to be variable by requiring the Company to estimate the amount of consideration to which it is entitled in exchange for transferring the promised goods or services to a customer. The Company recognizes an estimate of revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the milestone is achieved. For regulatory milestones, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. For sales-based milestones, the Company recognizes revenue upon the achievement of the specific sale milestones. The Company did not recognize any license revenue related to milestones for the years ended December 31, 2018, 2017 or 2016.

The following table disaggregates our revenue by major source (in thousands):

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Net product revenues

 

$

459,739

 

 

$

549,749

 

 

$

493,358

 

Royalty revenues

 

$

11,694

 

 

 

29,481

 

 

$

17,186

 

License revenue

 

$

 

 

 

9,057

 

 

$

9,057

 

Total net revenues

 

$

471,433

 

 

$

588,287

 

 

$

519,601

 

 

 

Concentration of Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company does not require any collateral for its accounts receivable. The Company maintains cash, cash equivalents and restricted cash with approved financial institutions. The Company is exposed to credit risks and liquidity in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

The Company does not own or operate, and currently does not plan to own or operate, facilities for production and packaging of Ampyra or its other commercial product Qutenza. It relies and expects to continue to rely on third parties for the production and packaging of its commercial products and clinical trial materials for all of its products except Inbrija. The Company leases a manufacturing facility in Chelsea, Massachusetts which produces Inbrija for clinical trials and commercial supply.

The Company relies primarily on Alkermes for its supply of Ampyra. Under its supply agreement with Alkermes, the Company is obligated to purchase at least 75% of its yearly supply of Ampyra from Alkermes, and it is required to make compensatory payments if it does not purchase 100% of its requirements from Alkermes, subject to certain specified exceptions. The Company and Alkermes have agreed that the Company may purchase up to 25% of its annual requirements from Patheon, a mutually agreed-upon second manufacturing source, with compensatory payment. The Company and Alkermes also rely on a single third-party manufacturer, Regis, to supply dalfampridine, the active pharmaceutical ingredient, or API, in Ampyra. If Regis experiences any disruption in their operations, a delay or interruption in the supply of Ampyra product could result until Regis cures the problem or it locates an alternate source of supply.

The Company’s principal direct customers as of December 31, 2018 were a network of specialty pharmacies and ASD Specialty Healthcare, Inc. for Ampyra. The Company periodically assesses the financial strength of these customers and establishes allowances for anticipated losses, if necessary. Four customers individually accounted for more than 10% of the Company’s revenue or approximately 81% of total revenue in 2018. Four and Three customers individually accounted for more than 10% of the Company’s revenue in 2017 and 2016, respectively. Five customers individually accounted for more than 10% of the Company’s accounts receivable or approximately 88% of total accounts receivable as of December 31, 2018. Four customers individually accounted for more than 10% of the Company’s accounts receivable or approximately 69% of total accounts receivable as of December 31, 2017. The Company’s net product revenues are generated in the U.S.

Allowance for Cash Discounts

An allowance for cash discounts is accrued based on historical usage rates at the time of product shipment. The Company adjusts accruals based on actual activity as necessary. Cash discounts are typically settled with customers within 34 days after the end of each calendar month. The Company provided cash discount allowances of $6.4 million and $6.9 million for the years ended December 31, 2018 and 2017, respectively. The Company’s reserve for cash discount allowances were $0.4 million and $0.8 million as of December 31, 2018 and 2017, respectively.

(in thousands)

 

Cash

discounts

 

Balance at December 31, 2016

 

$

594

 

Allowances for sales

 

 

6,898

 

Actual credits

 

 

(6,648

)

Balance at December 31, 2017

 

$

844

 

Allowances for sales

 

 

6,371

 

Actual credits

 

 

(6,820

)

Balance at December 31, 2018

 

$

395

 

 

Allowance for Doubtful Accounts

A portion of the Company’s accounts receivable may not be collected. The Company provides reserves based on an evaluation of the aging of its trade receivable portfolio and an analysis of high-risk customers. The Company has not historically experienced material losses related to credit risk. The Company had no recognized allowance for doubtful accounts as of December 31, 2018 or December 31, 2017. There were no provisions and write-offs for the years ended December 31, 2018 and 2017. 

Allowance for Chargebacks

Based upon the Company’s contracts and the most recent experience with respect to sales with the US government, the Company provides an allowance for chargebacks. The Company monitors the sales trends and adjusts the chargebacks on a regular basis to reflect the most recent chargebacks experience. The Company recorded a charge of $18.9 million for the year ended December 31, 2018 for allowance related to chargebacks. The Company did not record any allowance for chargebacks for the year ended December 31, 2017. The Company made a payment of $16.7 million related to the chargebacks allowances for the year ended December 31, 2018. The Company’s reserve for chargebacks allowance was $2.2 million as of December 31, 2018.

Contingencies

The Company accrues for amounts related to legal matters if it is probable that a liability has been incurred and the amount is reasonably estimable. Litigation expenses are expensed as incurred.

Fair Value of Financial Instruments

The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Significant differences can arise between the fair value and carrying amounts of financial instruments that are recognized at historical cost amounts. The Company considers that fair value should be based on the assumptions market participants would use when pricing the asset or liability.

The following methods are used to estimate the fair value of the Company’s financial instruments:

 

(a)

Cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these instruments;

 

(b)

Short-term investments are recorded based primarily on quoted market prices;

 

(c)

Acquired contingent consideration related to the Civitas acquisition is measured at fair value using a probability weighted, discounted cash flow approach;

 

(d)

Convertible Senior Notes were measured at fair value based on market quoted prices of the debt securities; and

 

(e)

Capital and R&D loans were measured at fair value based on a discounted cash flow approach.

Earnings per Share

Basic net income (loss) per share and diluted net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding during the period plus the effect of additional weighted average common equivalent shares outstanding during the period when the effect of adding such shares is dilutive. Common equivalent shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method), the vesting of restricted stock and the potential dilutive effects of the conversion option on the Company’s convertible debt. In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options that are in-the-money. This results in the “assumed” buyback of additional shares, thereby reducing the dilutive impact of stock options. See Note 18 for discussion on earnings (loss) per share.

Share‑based Compensation

The Company has various share‑based employee and non-employee compensation plans, which are described more fully in Note 10.

The Company accounts for stock options and restricted stock granted to employees and non-employees by recognizing the costs resulting from all share-based payment transactions in the consolidated financial statements at their fair values. The Company estimates the fair value of each option on the date of grant using the Black‑Scholes closed-form option‑pricing model based on assumptions of expected volatility of its common stock, prevailing interest rates, an estimated forfeiture rate, and the expected term of the stock options, and the Company recognizes that cost as an expense ratably over the associated service period.

Foreign Currency Translation

The functional currency of operations outside the United States of America is deemed to be the currency of the local country, unless otherwise determined that the United States dollar would serve as a more appropriate functional currency given the economic operations of the entity. Accordingly, the assets and liabilities of the Company’s foreign subsidiary, Biotie, are translated into United States dollars using the period-end exchange rate; and income and expense items are translated using the average exchange rate during the period; and equity transactions are translated at historical rates. Cumulative translation adjustments are reflected as a separate component of equity. Foreign currency transaction gains and losses are charged to operations.

Segment and Geographic Information

The Company is managed and operated as one business which is focused on developing therapies that restore function and improve the lives of people with neurological disorders. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information to allocate resources to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment. Net product revenues reported to date are derived from the sales of Amypra and Qutenza in the U.S. for the year ended December 31, 2018 and Ampyra, Zanaflex and Qutenza in the U.S. for the years ended December 31, 2017 and 2016.

Accumulated Other Comprehensive Income

Unrealized gains (losses) from the Company’s investment securities and adjustments for foreign currency translation are included in accumulated other comprehensive income within the consolidated balance sheet.

Recent Accounting Pronouncements - Adopted

As noted above, in May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers” (Topic 606). This new standard replaced all previous U.S. GAAP guidance on this topic and eliminated all industry-specific guidance. The new standard requires the application of a five-step model to determine the amount and timing of revenue to be recognized. The underlying principle is that revenue is to be recognized for the transfer of goods or services to customers that reflects the amount of consideration that the Company expects to be entitled to in exchange for those goods or services. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. See discussion of the adoption above in Revenue Recognition.

In November 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows” (Topic 230); Restricted Cash (ASU 2016-18), which defines new requirements for the presentation of restricted cash and restricted cash equivalents in the statement of cash flows. The amendments in this ASU require retrospective application to each period presented. The Company adopted this guidance effective January 1, 2018 retrospectively. This ASU requires entities to present the statement of cash flows in a manner such that it reconciles beginning and ending totals of cash, cash equivalents, restricted cash or restricted cash equivalents. Also, when cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity should, for each period that a statement of financial position is presented, present on the face of the statement of cash flows or disclose in the notes to the financial statements, the line items and amounts of cash, cash equivalents, and restricted cash or restricted cash equivalents reported within the statement of financial position. The amounts, disaggregated by the line item in which they appear within the statement of financial position, shall sum to the total amount of cash, cash equivalents, and restricted cash or restricted cash equivalents at the end of the corresponding period shown in the statement of cash flows.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same amounts shown in the statement of cash flows:

 

 

December 31, 2018

 

 

December 31, 2017

 

 

December 31, 2016

 

(In thousands)

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

Cash and cash equivalents

 

$

307,068

 

 

$

293,564

 

 

$

158,537

 

 

$

307,068

 

 

$

153,204

 

 

$

158,537

 

Restricted cash

 

 

410

 

 

 

532

 

 

 

79

 

 

 

410

 

 

 

6,031

 

 

 

79

 

Restricted cash included in Other assets

 

 

560

 

 

 

255

 

 

 

255

 

 

 

560

 

 

 

 

 

 

255

 

Total Cash, cash equivalents and restricted cash per statement of cash flows

 

$

308,038

 

 

$

294,351

 

 

$

158,871

 

 

$

308,038

 

 

$

159,235

 

 

$

158,871

 

Amounts included in restricted cash represent those amounts required to be set aside to cover the Company’s self-funded employee health insurance. Restricted cash included in other assets on the statement of financial position relates to cash collateralized standby letters of credit in connection with obligations under facility leases, which is included with other assets in the consolidated balance sheet due to the long-term nature of the letters of credit.

In January 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” The main objective of this update is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The new guidance addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In August 2016, the FASB issued Accounting Standards Update ASU 2016-15 “Statement of Cash Flows” (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15), which specifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU requires retrospective application to all periods presented. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued Accounting Standards Update 2017-01, “Business Combinations” (Topic 805): Clarifying the Definition of a Business (ASU 2017-01), which provides additional clarification to aid in determining when a set of assets and activities is not a business. The amendments in this update require prospective applications. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued Accounting Standards Update 2017-09, “Compensation – Stock Compensation” (Topic 718): Scope of Modification Accounting (ASU 2017-09). This new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 allows for prospective application and is effective for fiscal years beginning after December 15, 2017, and interim periods therein with early adoption permitted for interim or annual periods. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements with employees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. ASC 505-50, before the amendments, differed significantly from ASC 718. However, FASB concluded that awards granted to employees are economically similar to awards granted to nonemployees and therefore two different accounting models were not justified. This ASU is effective for fiscal years beginning after December 15, 2018, and interim periods therein with early adoption permitted. The Company early adopted this guidance beginning April 1, 2018. The adoption of this guidance did not have an impact on its consolidated financial statements.   

In March 2018, the FASB issued ASU 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118’. The ASU adds seven paragraphs to ASC 740, Income Taxes, that contain SEC guidance related to SAB 118 (codified as SEC SAB Topic 5.EE, “Income Tax Accounting Implications of the Tax Cuts and Jobs Act”), which provides guidance for companies that are not able to complete their accounting for the income tax effects of the Tax Cuts and Jobs Act in the period of enactment which is the period that includes December 22, 2017. The measurement period should not extend beyond one year from the enactment date. The Company completed its accounting for the income tax effects for the year ended December 31, 2018. See note 17 for a discussion of the impact of the guidance on the Company’s consolidated financial statements.

Recent Accounting Pronouncements – Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842). The main objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; ASU No. 2018-11, Targeted Improvements and ASU No. 2018-20, Narrow-Scope Improvements for Lessors. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement.

This ASU is effective for the Company on January 1, 2019. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. We expect to adopt the new standard on January 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019.

The new standard provides a number of optional practical expedients in transition. We expect to elect the ‘package of practical expedients’, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We do not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.

While we continue to assess all of the effects of adoption, we currently believe the most significant effects relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate operating leases and (2) providing significant new disclosures for our leasing activities.

The new standard also provides practical expedients and certain exemptions for an entity’s ongoing accounting. We currently expect to elect the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. We also currently expect to elect the practical expedient to not separate lease and non-lease components for all of our leases. We have determined the completeness of our lease population as of January 1, 2019. We expect to complete our assessment of the full financial impact of ASC 842 during the first quarter of 2019, and will include all required presentation and disclosures under ASC 842 in our Form 10-Q for the three months ending March 31, 2019.

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04). This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 allows for prospective application and is effective for fiscal years beginning after December 15, 2019, and interim periods therein with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating whether it will adopt this guidance early. The Company does not expect the adoption of this guidance to have a significant impact on its consolidated financial statements.

In February 2018, the FASB issued ASU 2018-02, ‘Income Statement—Reporting Comprehensive Income’ (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02). This new standard provides entities with an option to reclassify stranded tax effects within AOCI to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act (or portion thereof) is recorded. ASC 740-10-35-4 requires that deferred tax assets and liabilities should be adjusted to account for any changes in tax laws or rates within the period that the enactment of these changes occurs and any adjustments to flow through income from continuing operations. Since the adjustments due to the Tax Cuts and Jobs Act are required to flow through income from continuing operations, the tax effects of items within accumulated other comprehensive income known now as “stranded tax effects,” do not reflect the appropriate tax rate. As such, FASB issued ASU 2018-02, in order to address these stranded income tax effects. The new standard requires entities to disclose the following:

 

A description of the accounting policy for releasing income tax effects from AOCI;

 

Whether they elect to reclassify the stranded income tax effects from the Tax Cuts and Jobs Act, and

 

Information about the other income tax effects that are reclassified.

 

The ASU is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In July 2018, the FASB issued ASU 2018-09, “Codification Improvements.” The ASU’s amendments clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2018-09 are not expected to have a significant effect on current accounting practices. Some of the amendments in this update do not require transition guidance and will be effective upon issuance of this update. However, many of the amendments in this update do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. The Company does not expect this ASU to have a significant impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 “Fair Value Measurement (Topic 820): “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The amendments in this ASU eliminate, add and modify certain disclosure requirements for fair value measurements as part of its disclosure framework project. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public business entities will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The ASU clarifies certain aspects of ASU 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which was issued in April 2015. Specifically, the ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).” The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In August 2018, the Securities Exchange Commission (“SEC”) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders’ equity as required under the new SEC guidance will be included in its Form 10-Q for the three-month period ended March 31, 2019.

In November 2018, the FASB issued ASU 2018-18, Collaborative arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The ASU is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

Subsequent Events

Subsequent events are defined as those events or transactions that occur after the balance sheet date, but before the financial statements are filed with the Securities and Exchange Commission. The Company completed an evaluation of the impact of any subsequent events through the date these financial statements were issued, and determined there were no subsequent events that required disclosure in our financial statements.

v3.10.0.1
Acquisitions
12 Months Ended
Dec. 31, 2018
Business Combinations [Abstract]  
Acquisitions

(3) Acquisitions

Biotie Therapies Ltd.

On April 18, 2016, the Company acquired a controlling interest in Biotie Therapies Ltd., formerly Biotie Therapies Corp. (“Biotie”), pursuant to a combination agreement entered into in January 2016. In accordance with the combination agreement, the Company closed a public tender offer for all of Biotie’s capital stock, pursuant to which the Company acquired approximately 93% of the fully diluted capital stock of Biotie for a cash purchase price of approximately $350 million. On May 4, 2016, the Company acquired an additional approximately 4% of Biotie’s fully diluted capital stock pursuant to a subsequent public offer to Biotie stockholders that did not tender their shares in the initial tender offer. The purchase consideration for the subsequent tender offer was approximately $14.5 million. The acquisition of the additional 4% of Biotie’s fully diluted capital stock resulted in the Company owning approximately 97% of the fully diluted capital stock of Biotie (the “Acquisition”) as of June 30, 2016.

On September 30, 2016, the Company acquired the remaining approximately 3% of Biotie’s fully diluted capital stock in exchange for the payment of a cash security deposit of approximately $13.5 million, as determined by the arbitral tribunal administering the redemption proceedings. Accordingly, the Company owned 100% of the fully diluted capital stock of Biotie as of September 30, 2016.

During the year ended December 31, 2017, the Company received a refund of the cash security deposit of approximately $2.7 million following the final determination and payment of the redemption price for the shares subject to the redemption proceedings. During the year ended December 31, 2017, the Company recorded final measurement period adjustments of approximately $6.4 million to its purchase price allocation with a corresponding offset to goodwill. The final measurement period adjustments included a reduction to current liabilities of approximately $3.8 million related to the  convertible capital loans as the Company was able to determine the fair market value of these loans, a reduction to other long-term liabilities of approximately $2.7 million due to the finalization of the valuation of the non-convertible capital loans and an increase to deferred tax liabilities of approximately $0.2 million due to the finalization of the provisional amounts recorded for deferred tax liabilities.

The following table presents the final allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

 

(In thousands)

 

Preliminary Allocation, as adjusted through

December 31, 2016

 

 

Measurement

Period

Adjustments

 

 

Final Allocation, as of April 18, 2017

 

Cash and cash equivalents

 

$

73,854

 

 

$

 

 

$

73,854

 

Other current assets

 

 

1,878

 

 

 

 

 

 

1,878

 

Other long-term assets

 

 

4,962

 

 

 

 

 

 

4,962

 

Intangible assets (indefinite-lived)

 

 

260,500

 

 

 

 

 

 

260,500

 

Intangible assets (definite-lived)

 

 

65,000

 

 

 

 

 

 

65,000

 

Current liabilities

 

 

(18,572

)

 

 

3,837

 

 

 

(14,735

)

Deferred taxes

 

 

(89,908

)

 

 

(156

)

 

 

(90,064

)

Other long-term liabilities

 

 

(25,690

)

 

 

2,740

 

 

 

(22,950

)

Fair value of assets and liabilities acquired

 

 

272,024

 

 

 

6,421

 

 

 

278,445

 

Goodwill

 

 

103,876

 

 

 

(6,421

)

 

 

97,455

 

Total purchase price

 

 

375,900

 

 

 

 

 

 

375,900

 

Less: Noncontrolling interests

 

 

(25,736

)

 

 

 

 

 

(25,736

)

Purchase consideration on date of acquisition

 

$

350,164

 

 

$

 

 

$

350,164

 

 

The Company accounted for the Acquisition as a business combination using the acquisition method of accounting. Under the acquisition method of accounting, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their fair values as of the date of acquisition. The Company incurred approximately $18.6 million in total acquisition related expenses, all of which were expensed and included in selling, general and administrative expenses in the consolidated statements of operations. For the year ended December 31, 2017 and 2016, the Company incurred approximately $0.6 million and $17.6 million, respectively, in acquisition related expenses, which were included in selling, general and administrative expenses in the consolidated statement of operations. The results of Biotie’s operations have been included in the consolidated statements of operations from the acquisition date of April 18, 2016.

The revenue of Biotie included in the consolidated statements of operations for the period April 18, 2016 through December 31, 2016 was $2.7 million. The net loss of Biotie included in the consolidated statement of operations for the period April 18, 2016 through December 31, 2016 was $37.5 million.

Noncontrolling Interests

The fair value of the noncontrolling interest comprised the fair value of Biotie’s equity interests not acquired by the Company. The fair value of the noncontrolling interest was determined by quoted market price, which is considered to be a Level 1 input under the fair value measurements and disclosure guidance. The noncontrolling interest in Biotie was presented as permanent equity in the Company’s consolidated balance sheet. Noncontrolling interests are generally adjusted for the net income or loss and other comprehensive income or loss attributable to the noncontrolling shareholders and any additional acquisition of noncontrolling interests. On May 4, 2016, the Company acquired an additional approximately 4% of Biotie’s fully diluted capital stock. On September 30, 2016, the Company acquired shares representing the remaining approximately 3% of Biotie’s fully diluted capital stock, which eliminated the noncontrolling interest as of September 30, 2016.

Financial Instruments

The Company does not enter into hedging transactions in the normal course of business. However, as a result of the Biotie acquisition which was completed in Euros, the Company was exposed to fluctuations in exchange rates between the U.S. dollar and the Euro until the completion of the transaction. To mitigate this risk, the Company entered into foreign currency options to limit its exposure to fluctuations in exchange rates between the U.S. dollar and the Euro until the transaction was completed. The foreign currency options were settled as of May 2, 2016. There were no foreign currency options outstanding as of December 31, 2017.

The Company had a realized gain on the foreign currency options of approximately $9.9 million, which is included in other income in the consolidated statements of operations for the year ended December 31, 2016.

Pro-Forma Financial Information Associated with the Biotie Acquisition (Unaudited)

The following table summarizes certain supplemental pro forma financial information for the year ended December 31, 2016 as if the acquisition of Biotie had occurred as of January 1, 2016. The unaudited pro forma financial information for the year ended December 31, 2016 reflects (i) the net impact to amortization expense based on the fair value adjustments to the intangible assets acquired from Biotie; (ii) the impact to operations resulting from the reversal of transaction costs related to the Acquisition; (iii) the impact to operations resulting from the reversal of the unrealized and realized gains on the foreign currency option; (iv) the impact to interest expense based on the fair value adjustments to the debt acquired from Biotie; (v) the tax effects of those adjustments; and (vi) the net loss attributable to the noncontrolling interests resulting from the acquisition.

The unaudited pro forma financial information was prepared for comparative purposes only and is not necessarily indicative of what would have occurred had the acquisitions been made at those times or of results which may occur in the future

 

 

Year ended

 

 

December 31, 2016

 

(In thousands)

Reported

 

 

Pro Forma

 

Net revenues

$

519,601

 

 

$

520,658

 

Net loss from continuing operations

    attributable to Acorda

$

(34,618

)

 

$

(57,925

)

v3.10.0.1
Intangible Assets and Goodwill
12 Months Ended
Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill

(4) Intangible Assets and Goodwill

Intangible Assets

Inbrija (levodopa inhalation powder) and ARCUS Technology IPR&D

In connection with the acquisition of Civitas in October 2014, the Company acquired global rights to Inbrija, a Phase 3 treatment candidate for Parkinson’s disease OFF periods, also known as OFF episodes. The acquisition of Civitas also included rights to Civitas’ proprietary ARCUS drug delivery technology, which the Company believes has potential to be used in the development of a variety of inhaled medicines. In December 2018, the FDA approved Inbrija for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.

In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the transaction to the underlying assets acquired and liabilities assumed by the Company, based upon the estimated fair values of those assets and liabilities at the date of acquisition and classified the fair value of the acquired IPR&D as an indefinite-lived intangible asset until the successful completion of the associated research and development efforts. The value allocated to the indefinite lived intangible asset was $423 million. In December 2018, the Company received FDA approval for Inbrija and accordingly reclassified the indefinite lived intangible asset to a definite lived intangible asset with amortization scheduled to begin upon launch in 2019.

Ampyra

In January 2010, the Company received marketing approval from the FDA for Ampyra triggering two milestone payments of $2.5 million to Alkermes and $0.8 million to Rush-Presbyterian St. Luke’s Medical Center (Rush) and an additional $2.5 million payable to Alkermes two years from date of approval. The Company made the milestone payments totaling $5.75 million, which were recorded as intangible assets in the consolidated financial statements.

The Company had a License Agreement with the Canadian Spinal Research Organization (CSRO) that granted the Company an exclusive and worldwide license under certain patent assets and know-how of CSRO. The agreement required the Company to pay royalties to CSRO based on a percentage of net sales of any product incorporating the licensed rights, including royalties on the sale of Ampyra and on the sale of dalfampridine for any other indication. During 2010, the Company purchased CSRO’s rights to all royalty payments under the agreement for $3.0 million. This payment was recorded as an intangible asset in the consolidated financial statements.

On March 31, 2017, the United States District Court for the District of Delaware upheld U.S. Patent No. 5,540,938 (the ‘938 patent), which was set to expire in July 2018. The claims of the ‘938 patent relate to methods for treating a neurological disease, such as MS, and cover the use of a sustained release dalfampridine formulation, such as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg for improving walking in people with MS. The District Court invalidated U.S. Patent Nos. 8,663,685, 8,007,826, 8,440,703, and 8,354,437, which pertain to Ampyra. In May 2017, the Company appealed the ruling on these patents. As a result of the District Court’s ruling, the Company performed an interim impairment test for the intangible assets related to Ampyra in connection with the preparation of the unaudited interim condensed consolidated financial statements for the first quarter of 2017. Based on the impairment test performed, the Company determined that these intangible assets were not impaired.

As a result of the invalidation of the patents, the estimated remaining useful lives of the Ampyra intangible assets were reviewed to determine if there was a change in the estimated useful lives of these assets. Based on the review, the Company determined that there was a change in the estimated useful lives of these assets that would require an acceleration of the amortization expense. The Company determined that the estimated useful lives of these intangible assets will coincide with the expiration of the ‘938 patent, unless the appeal is resolved favorably. The Company accounted for this change prospectively as a change in an accounting estimate beginning in the three-month period ended June 30, 2017. The acceleration of the amortization associated with the change in the estimated remaining useful lives of these intangible assets, did not have a material impact on the Company’s statement of operations for the year ended December 31, 2018 or December 31, 2017.

Tozadenant, SYN120, BTT1023 and Selincro IPR&D

In connection with the acquisition of Biotie (Note 3), the Company acquired global rights to tozadenant, SYN120, and BTT1023 (timolumab). Tozadenant was a potential treatment for Parkinson’s disease patients to reduce off periods. SYN120 is a potential treatment for Parkinson’s-related dementia. BTT1023 is a product candidate for the orphan disease Primary Sclerosing Cholangitis, or PSC, a chronic and progressive liver disease. The Company also acquired rights to Selincro, an orally administered drug used for the treatment of alcohol dependence. Selincro received European Medicines Agency approval in 2013 and is marketed across Europe by H. Lundbeck A/S, a Danish pharmaceutical company.

In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the transaction to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition. The Company classified the fair value of the acquired IPR&D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts. The Company classified the fair value of Selincro as a definite lived intangible asset. The value allocated to Selincro was $65 million, which was being amortized over the estimated remaining useful life of approximately 6 years. The value allocated to the indefinite lived intangible assets was $260.5 million.

In November 2017, the Company announced that it was discontinuing its clinical development program for tozadenant, including immediately discontinuing dosing of all participants that were already enrolled in tozadenant studies. The Company made this decision based on additional data obtained from the Phase 3 clinical trial related to previously disclosed agranulocytosis and associated serious adverse events. Based on the analysis of the additional data, the Company determined that tozadenant was fully impaired. The Company recorded a non-cash impairment charge in the amount of approximately $233.5 million to write-off the asset for the year ended December 31, 2017.

In December 2017, the Company received and reviewed the data read-out from the Phase II proof-of-concept study for SYN120. The data from the Phase II study showed that neither the primary nor key secondary endpoints achieved statistical significance. Based on the data from the study indicating a lack of statistical significance for the key endpoints in the study, management determined that SYN120 was fully impaired. The Company recorded a non-cash impairment charge in the amount of approximately $23.8 million to write-off the asset for the year ended December 31, 2017.

In the three-month period ended September 30, 2017, the Company determined the carrying value of Selincro was greater than the estimated fair market value. The Company recorded a non-cash impairment charge of $39.4 million representing the amount by which the carrying value exceeded the fair market value for the year ended December 31, 2017.

In November 2017, the Company executed an Amendment to its existing License and Commercialization Agreement with Lundbeck for the Company to provide to Lundbeck, a fully paid up royalty free license under the licensed IP for sales of Selincro outside of the U.S. in exchange for a payment of approximately $13.0 million (or approximately €11.0 million). Selincro is not approved for use in the U.S. The Company recorded the receipt of the payment from Lundbeck as royalty income for the year ended December 31, 2017 and accelerated the amortization of the remaining carrying value to account for the asset monetization. The Company recorded amortization expense related to Selincro of approximately $14.7 million (or approximately €12.4 million) in the three-month period ended December 31, 2017. As of December 31, 2017, the net book value of Selincro was $0.

Websites

Intangible assets also include certain website development costs which have been capitalized. The Company has developed several websites, each with its own purpose, including the general corporate website, product information websites and various other websites.

The Company continually evaluates whether events or circumstances have occurred that indicate that the carrying value of the intangible assets may be impaired or that the estimated remaining useful lives of these assets may warrant revision. As of December 31, 2018, the Company determined that the intangible assets were not impaired and that there are no facts or circumstances that would indicate a need for changing the estimated remaining useful lives of these assets.

Intangible assets consisted of the following:

 

 

 

 

 

 

December 31, 2018

 

 

December 31, 2017

 

(Dollars In thousands)

 

Estimated

Remaining

Useful Lives

(Years)

 

 

Cost

 

 

Accumulated

Amortization

 

 

Reclass to Definite-lived asset

 

 

Foreign

Currency

Translation

 

 

Net

Carrying

Amount

 

 

Cost

 

 

Accumulated

Amortization

 

 

Impairment

 

 

Foreign

Currency

Translation

 

 

Net

Carrying

Amount

 

In-process research &

   development (1)

 

Indefinite-lived

 

 

$

427,500

 

 

$

 

 

$

(423,000

)

 

$

(200

)

 

$

4,300

 

 

$

683,500

 

 

$

 

 

$

(257,317

)

 

$

1,317

 

 

$

427,500

 

Inbrija (2)

 

14

 

 

 

 

 

 

 

 

 

423,000

 

 

 

 

 

 

423,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selincro

 

n/a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

65,000

 

 

 

(27,932

)

 

 

(39,446

)

 

 

2,378

 

 

 

 

Ampyra milestones

 

n/a

 

 

 

5,750

 

 

 

(5,750

)

 

 

 

 

 

 

 

 

 

 

 

5,750

 

 

 

(4,438

)

 

 

 

 

 

 

 

 

1,312

 

Ampyra CSRO royalty

   buyout

 

n/a

 

 

 

3,000

 

 

 

(3,000

)

 

 

 

 

 

 

 

 

 

 

 

3,000

 

 

 

(2,642

)

 

 

 

 

 

 

 

 

358

 

Website development

   costs

 

3

 

 

 

13,857

 

 

 

(13,289

)

 

 

 

 

 

 

 

 

568

 

 

 

13,983

 

 

 

(12,816

)

 

 

 

 

 

 

 

 

1,167

 

Website development

   costs–in process

 

n/a

 

 

 

702

 

 

 

 

 

 

 

 

 

 

 

 

702

 

 

 

266

 

 

 

 

 

 

 

 

 

 

 

 

266

 

 

 

 

 

 

$

450,809

 

 

$

(22,039

)

 

$

 

 

$

(200

)

 

$

428,570

 

 

$

771,499

 

 

$

(47,828

)

 

$

(296,763

)

 

$

3,695

 

 

$

430,603

 

 

 

(1)

Includes the fair values of Inbrija: $423.0 million and BTT1023: $4.5 million as of December 31, 2017. 

 

(2)

In December 2018, the Company received FDA approval for Inbrija and accordingly reclassified the indefinite lived intangible assets to definite lived intangible assets with amortization scheduled to begin upon launch in 2019.

The Company recorded $2.4 million and $25.1 million in amortization expense related to these intangible assets for the years ended December 31, 2018 and 2017, respectively.

Estimated future amortization expense for intangible assets subsequent to December 31, 2018 is as follows:

 

(In thousands)

 

 

 

 

2019

 

$

30,796

 

2020

 

 

30,533

 

2021

 

 

30,424

 

2022

 

 

30,395

 

2023

 

 

30,395

 

Thereafter

 

 

271,024

 

 

 

$

423,567

 

The weighted-average remaining useful lives of all amortizable assets is approximately 17.0 years.

Goodwill

The following table presents the goodwill balances at December 31, 2018 and 2017 and the associated changes in goodwill through December 31, 2018.

 

(In thousands)

 

 

 

 

Balance at December 31, 2017

 

$

286,611

 

Foreign currency translation adjustment

 

 

(4,552

)

Balance at December 31, 2018

 

$

282,059

 

v3.10.0.1
Qutenza and Zanaflex Asset Sales
12 Months Ended
Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]  
Qutenza and Zanaflex Asset Sales

(5) Qutenza and Zanaflex Asset Sales

 

On May 22, 2018, the Company entered into an Asset Purchase Agreement (the “Agreement”) to sell to its rights and interests related to Qutenza assets for a purchase price of $7.9 million. The Company recognized a gain on the sale of approximately $7.8 million for the year ended December 31, 2018 after reflecting the net book value of the inventory transferred to the buyer. The Company is entitled to receive up to an additional $35.0 million in cash based on achievement of specified U.S. sales milestones for Qutenza. The gain on the sale is recognized in the Statement of Operations as a reduction to the selling, general and administrative expenses.

On November 13, 2017, the Company entered into an asset purchase agreement (“Agreement”) to sell its rights and interests related to its Zanaflex assets for a purchase price of $4.0 million. The Company recognized a gain on the sale of approximately $3.5 million for the year ended December 31, 2017 after reflecting the direct costs to complete the transaction and the net book value of the inventory transferred to the buyer. The gain on the sale is recognized in the Statement of Operations as a reduction to the selling, general and administrative expenses.

v3.10.0.1
Investments
12 Months Ended
Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]  
Investments

(6) Investments

The Company has determined that all of its investments are classified as available-for-sale. Available-for-sale debt securities are carried at fair value with interest on these investments included in interest income and are recorded based on quoted market prices. Available-for-sale investments consisted of the following at December 31, 2018:

 

Type

(In thousands)

 

Amortized

Cost

 

 

Gross

unrealized

gains

 

 

Gross

unrealized

losses

 

 

Estimated

fair

value

 

Commercial Paper

 

$

47,149

 

 

$

 

 

$

(41

)

 

$

47,108

 

Corporate Bonds

 

 

104,965

 

 

 

6

 

 

 

(90

)

 

 

104,881

 

Total Short-term Investments

 

$

152,114

 

 

$

6

 

 

$

(131

)

 

$

151,989

 

 

Short-term investments with maturities of three months or less from date of purchase have been classified as cash equivalents, and amounted to approximately $9.6 million as of December 31, 2018. Short-term investments have original maturities of greater than 3 months but less than 1 year and amounted to approximately $152.0 million as of December 31, 2018. The aggregate fair value of short-term investments in an unrealized loss position amounted to approximately $139.6 million as of December 31, 2018. The Company held no short-term investments at December 31, 2017. Short-term investments at December 31, 2018 primarily consisted of high-grade commercial paper and corporate bonds. Long-term investments have original maturities of greater than 1 year. There were no investments classified as long-term at December 31, 2018 or December 31, 2017. The Company has determined that there were no other-than-temporary declines in the fair values of its investments as of December 31, 2018 as the Company does not intend to sell its investments and it is not more likely than not that the Company will be required to sell its investments prior to the recovery of its amortized cost basis.

Unrealized holding gains and losses, which relate to debt instruments, are reported within accumulated other comprehensive income (AOCI) in the statements of comprehensive income. The changes in AOCI associated with the unrealized holding losses on available-for-sale investments during the year ended December 31, 2018, were as follows (in thousands):

       

(In thousands)

 

Net Unrealized

Gains (Losses) on

Short-term Investments

 

Balance at December 31, 2017

 

$

 

Other comprehensive loss before reclassifications:

 

 

(125

)

Amounts reclassified from accumulated other

   comprehensive loss

 

 

 

Net current period other comprehensive loss

 

 

(125

)

Balance at December 31, 2018

 

 

(125

)

v3.10.0.1
Property and Equipment
12 Months Ended
Dec. 31, 2018
Property Plant And Equipment [Abstract]  
Property and Equipment

(7) Property and Equipment

Property and equipment consisted of the following:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

 

Estimated

useful lives used

Machinery and equipment

 

$

24,798

 

 

$

24,956

 

 

2-7 years

Leasehold improvements

 

 

25,047

 

 

 

23,978

 

 

Lesser of useful life or

remaining lease term

Computer equipment

 

 

21,472

 

 

 

21,560

 

 

1-3 years

Laboratory equipment

 

 

9,021

 

 

 

8,542

 

 

2-5 years

Furniture and fixtures

 

 

2,599

 

 

 

2,635

 

 

4-7 years

Construction in progress

 

 

34,489

 

 

 

4,995

 

 

 

 

 

 

117,426

 

 

 

86,666

 

 

 

Less accumulated depreciation

 

 

(56,907

)

 

 

(49,997

)

 

 

 

 

$

60,519

 

 

$

36,669

 

 

 

 

Depreciation and amortization expense on property and equipment was $9.0 million and $11.0 million for the years ended December 31, 2018 and 2017, respectively.

v3.10.0.1
Preferred Stock
12 Months Ended
Dec. 31, 2018
Equity [Abstract]  
Preferred Stock

(8) Preferred Stock

Stockholder Rights Plan

On August 31, 2017, the Board of Directors of the Company adopted a stockholder rights plan (Rights Plan) to preserve the ability of the Board to protect the interests of stockholders in transactions that may result in an acquisition of control of the Company, including tender offers and open market purchases of the Company’s securities. In general terms, the Rights Plan works by significantly diluting the stock ownership of any person or group that acquires 15% or more of the outstanding common stock of the Company without the approval of the Board (such person, an Acquiring Person). The rights plan exempts any person or group owning 15% or more of the Company’s outstanding common stock when we announced the rights plan, however the exemption does not apply to additional shares acquired after the announcement.

Under the Rights Plan, on August 31, 2017, the Board authorized and declared a dividend of one preferred share purchase right (Right) for each outstanding share of common stock, par value $0.001 per share, of the Company. The dividend was payable to the stockholders of record on September 11, 2017 (Record Date). Each Right, when it becomes exercisable, entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company at a price of $110 per one one-thousandth of a Preferred Share, subject to adjustment. As of December 31, 2018 and 2017, there were 1,000,000 preferred shares authorized and no such shares issued and outstanding. In addition, one Right will automatically attach to each Common Share that becomes outstanding between the Record Date and the earliest of the Distribution Date, the redemption of the Rights or the expiration of the Rights. The Distribution Date is the close of business on the tenth day after the first date of public announcement that any person has become an Acquiring Person or such earlier date as a majority of the Board becomes aware of the existence of an Acquiring Person. Until a Right is exercised, the holder thereof, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. The Rights were not exercisable until the Distribution Date. The Rights expired at the close of business on August 31, 2018. There were no rights excerised prior to the expiration.

v3.10.0.1
Common Stock Options and Restricted Stock
12 Months Ended
Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Common Stock Options and Restricted Stock

(9) Common Stock Options and Restricted Stock

On January 12, 2006, the Company’s board of directors approved the adoption of the Acorda Therapeutics, Inc. 2006 Employee Incentive Plan (the 2006 Plan). The 2006 Plan served as the successor to the Company’s 1999 Plan, as amended, and no further option grants or stock issuances were to be made under the 1999 Plan after the effective date, as determined under Section 14 of the 2006 Plan. All employees of the Company were eligible to participate in the 2006 Plan, including executive officers, as well as directors, independent contractors, and agents of the Company. The 2006 Plan also covered the issuance of restricted stock.

The 2006 Plan was administered by the Compensation Committee of the Board of Directors, which selected the individuals to be granted options and restricted stock, determined the time or times at which options and restricted stock were to be granted, determined the number of shares to be granted subject to any option or restricted stock and the duration of each option and restricted stock, and made any other determinations necessary, advisable, and/or appropriate to administer the 2006 Plan. Under the 2006 Plan, each option granted expires no later than the tenth anniversary of the date of its grant. The number of shares of common stock authorized for issuance under the 2006 Plan as of December 31, 2018 was 14,912,048 shares. The total number of shares of common stock available for issuance under the 2006 Plan, including shares of common stock subject to the then outstanding awards, automatically increased on January 1 of each year during the term of the 2006 Plan, beginning 2007, by a number of shares of common stock equal to 4% of the outstanding shares of common stock on that date, unless otherwise determined by the Board of Directors. As of December 31, 2018, the Company had granted an aggregate of 11,398,450 shares as restricted stock or subject to issuance upon exercise of stock options under the 2006 Plan, of which 5,037,630 shares remained subject to outstanding options.

On June 9, 2015, the Company’s stockholders approved the adoption of the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan (the 2015 Plan). The 2015 Plan serves as the successor to the Company’s 2006 Plan, as amended, and no further option or stock grants will be made under the 2006 Plan after the effective date, as determined under Section 1 of the 2015 Plan. All employees of the Company are eligible to participate in the 2015 Plan, including executive officers, as well as directors, consultants, advisors and other service providers of the Company or any of its subsidiaries. The 2015 Plan also covers the issuance of restricted stock.

The 2015 Plan is administered by the Compensation Committee of the Board of Directors, which selects the individuals to be granted options, restricted stock, and restricted stock units, determines the time or times at which options, restricted stock, and restricted stock units are to be granted, determines the number of shares to be granted subject to any option, restricted stock or restricted stock unit and the duration of each option, restricted stock, and restricted stock unit, and makes any other determinations necessary, advisable, and/or appropriate to administer the 2015 Plan. Under the 2015 Plan, each option granted expires no later than the tenth anniversary of the date of its grant. Since inception, the number of shares of common stock authorized for issuance under the 2015 Plan as of December 31, 2018 is 8,100,000 shares. As of December 31, 2018, the Company had granted an aggregate of 4,595,489 shares either as restricted stock or shares subject to issuance upon the exercise of stock options under the 2015 Plan, of which 3,116,439 shares remained subject to outstanding options.

On April 14, 2016 the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) approved the Acorda Therapeutics, Inc. 2016 Inducement Plan (the “2016 Plan”) to provide equity compensation to certain individuals of the Company (or its subsidiaries) in order to induce such individuals to enter into employment with the Company or its subsidiaries. The only equity awards issued under this plan were issued to individuals employed by Biotie Therapies Ltd., formerly Biotie Therapies Corp., and its subsidiary Biotie Therapies, Inc. (collectively, “Biotie”) in connection with our acquisition of Biotie. The number of shares of common stock authorized for issuance under the 2016 Plan for these awards is 366,950 shares. As of December 31, 2018, the Company had granted an aggregate of 147,850 shares either as restricted stock or shares subject to issuance upon the exercise of stock options under the 2016 Plan, of which 40,000 shares remained subject to outstanding options.

The fair value of each option granted is estimated on the date of grant using the Black‑Scholes option‑pricing model with the following weighted average assumptions:

 

 

 

Year ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Employees and directors:

 

 

 

 

 

 

 

 

 

 

 

 

Estimated volatility%

 

 

52.29

%

 

 

48.02

%

 

 

44.63

%

Expected life in years

 

 

6.16

 

 

 

6.15

 

 

 

5.99

 

Risk free interest rate%

 

 

2.76

%

 

 

2.08

%

 

 

1.46

%

Dividend yield

 

 

 

 

 

 

 

 

 

 

The Company estimated volatility for purposes of computing compensation expense on its employee and director options using the historic volatility of the Company’s stock price. The expected life used to estimate the fair value of employee and director options is based on the historical life of the Company’s options based on exercise data.

The weighted average fair value per share of options granted to employees and directors for the years ended December 31, 2018, 2017 and 2016 amounted to approximately $12.71, $10.70, and $13.26, respectively. No options were granted to non-employees for the years ended December 31, 2018, 2017 and 2016.

During the year ended December 31, 2018, the Company granted 781,135 stock options to employees and directors under all plans. The stock options were issued with a weighted average exercise price of $24.81 per share. As a result of these grants, the total compensation charge to be recognized over the service period is $9.2 million, of which $2.9 million was recognized during the year ended December 31, 2018.

Compensation costs for options and restricted stock granted to employees and directors amounted to $21.3 million, $32.8 million, and $36.4 million, for the years ended December 31, 2018, 2017 and 2016, respectively. There were no compensation costs capitalized in inventory balances. Compensation expense for options and restricted stock granted to employees and directors are classified between research and development, and selling, general and administrative expense based on employee job function. The following table summarizes share-based compensation expense included within the Company’s consolidated statements of operations:

 

 

 

Year ended December 31,

 

(In thousands)

 

2018

 

 

2017

 

 

2016

 

Research and development

 

$

5,560

 

 

$

9,683

 

 

$

10,610

 

Selling, general and administrative

 

 

15,692

 

 

 

23,131

 

 

 

25,777

 

Total

 

$

21,252

 

 

$

32,814

 

 

$

36,387

 

 

A summary of share‑based compensation activity for the year ended December 31, 2018 is presented below:

Stock Option Activity

 

 

 

Number

of Shares

(In thousands)

 

 

Weighted Average

Exercise Price

 

 

Weighted Average

Remaining

Contractual Term

 

 

Intrinsic

Value

(In thousands)

 

Balance at December 31, 2017

 

 

8,929

 

 

$

29.46

 

 

 

 

 

 

 

 

 

Granted

 

 

781

 

 

 

24.81

 

 

 

 

 

 

 

 

 

Forfeited and expired

 

 

(784

)

 

 

29.26

 

 

 

 

 

 

 

 

 

Exercised

 

 

(733

)

 

 

20.74

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

 

8,193

 

 

$

29.81

 

 

 

5.5

 

 

$

162,119

 

Vested and expected to vest at December 31, 2018

 

 

8,168

 

 

$

29.83

 

 

 

5.5

 

 

$

162,050

 

Vested and exercisable at December 31, 2018

 

 

6,842

 

 

$

30.40

 

 

 

5.0

 

 

$

160,597

 

 

 

 

Options Outstanding

 

 

Options Exercisable

 

Range of exercise price

 

Outstanding

as of

December 31,

2018

(In thousands)

 

 

Weighted-

average

remaining

contractual life

 

 

Weighted-

average

exercise price

 

 

Exercisable

as of

December 31,

2018

(In thousands)

 

 

Weighted-

average

exercise price

 

$13.80 - $24.35

 

 

1,857

 

 

 

6.4

 

 

$

20.60

 

 

 

1,281

 

 

$

19.74

 

$24.45 - $28.15

 

 

1,682

 

 

 

5.9

 

 

 

26.84

 

 

 

1,216

 

 

 

26.79

 

$28.30 - $32.55

 

 

1,642

 

 

 

4.4

 

 

 

30.79

 

 

 

1,587

 

 

 

30.84

 

$32.56 - $35.74

 

 

1,952

 

 

 

5.4

 

 

 

35.21

 

 

 

1,722

 

 

 

35.18

 

$35.84 - $44.50

 

 

1,061

 

 

 

5.2

 

 

 

39.19

 

 

 

1,036

 

 

 

39.21

 

 

 

 

8,194

 

 

 

5.5

 

 

$

29.81

 

 

 

6,842

 

 

$

30.40

 

 

Restricted Stock Activity

 

Restricted Stock

 

Number of Shares

(In thousands)

 

Nonvested at December 31, 2017

 

 

698

 

Granted

 

 

 

Vested

 

 

(334

)

Forfeited

 

 

(132

)

Nonvested at December 31, 2018

 

 

232

 

 

Unrecognized compensation cost for unvested stock options and restricted stock awards as of December 31, 2018 totaled $19.3 million and is expected to be recognized over a weighted average period of approximately 1.7 years.

v3.10.0.1
Debt
12 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
Debt

(10) Debt

Convertible Senior Notes

On June 17, 2014, the Company issued $345 million aggregate principal amount of 1.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering. The net proceeds from the offering were $337.5 million after deducting the Underwriter’s discount and offering expenses paid by the Company.

The Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, under certain circumstances as outlined in the indenture, based on an initial conversion rate, subject to adjustment, of 23.4968 shares per $1,000 principal amount of Notes (representing an initial conversion price of approximately $42.56 per share).

The Company may redeem for cash all or part of the Notes, at the Company’s option, on or after June 20, 2017, under certain circumstances as outlined in the indenture.

The Company pays 1.75% interest per annum on the principal amount of the Notes, payable semiannually in arrears in cash on June 15 and December 15 of each year. The Notes will mature on June 15, 2021.

If the Company undergoes a “fundamental change” (as defined in the Indenture), subject to certain conditions, holders may require the Company to repurchase for cash all or part of their Notes in principal amounts of $1,000 or an integral multiple thereof. The Indenture contains customary terms and covenants and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Notes by notice to the Company and the Trustee, may declare 100% of the principal of and accrued and unpaid interest, if any, on all the Notes to be due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal and accrued and unpaid interest, if any, on all of the Notes will become due and payable automatically. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture consists exclusively of the right to receive additional interest on the Notes.

The Notes will be senior unsecured obligations and will rank equally with all of the Company’s existing and future senior debt and senior to any of the Company’s subordinated debt. The Notes will be structurally subordinated to all existing or future indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries and will be effectively subordinated to the Company’s existing or future secured indebtedness to the extent of the value of the collateral. The Indenture does not limit the amount of debt that the Company or its subsidiaries may incur.

In accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Notes as a whole. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.

The outstanding note balance as of December 31, 2018 and 2017 consisted of the following:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Liability component:

 

 

 

 

 

 

 

 

Principal

 

$

345,000

 

 

$

345,000

 

Less: debt discount and debt issuance costs , net

 

 

(26,330

)

 

 

(36,195

)

Net carrying amount

 

 

318,670

 

 

$

308,805

 

Equity component

 

$

61,195

 

 

$

61,195

 

 

In connection with the issuance of the Notes, the Company incurred approximately $7.5 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total $7.5 million of debt issuance costs, $1.3 million were allocated to the equity component and recorded as a reduction to additional paid-in capital and $6.2 million were allocated to the liability component and recorded as a reduction in the carrying amount of the debt liability on the balance sheet. The portion allocated to the liability component is amortized to interest expense over the expected life of the Notes using the effective interest method.

The Company determined the expected life of the debt was equal to the seven year term on the Notes. The fair value of the Company’s convertible senior notes was approximately $289.4 million as of December 31, 2018.

As of December 31, 2018, the remaining contractual life of the Notes is approximately 2.5 years. The effective interest rate on the liability component was approximately 4.8% for the period from the date of issuance through December 31, 2018.

The following table sets forth total interest expense recognized related to the Notes for the years ended December 31, 2018 and 2017:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

Contractual interest expense

 

$

6,038

 

 

$

6,038

 

Amortization of debt issuance costs

 

 

913

 

 

 

871

 

Amortization of debt discount

 

 

8,952

 

 

 

8,539

 

Total interest expense

 

$

15,903

 

 

$

15,448

 

    Non-Convertible Capital Loan

Prior to and subsequent to the acquisition of Biotie on April 18, 2016, Biotie held non-convertible capital loans granted by Business Finland (formerly Tekes). The non-convertible capital loans had an adjusted acquisition-date fair value of $20.5 million (€18.2 million) and a carrying value of $23.2 million as of December 31, 2018. The loans are comprised of fourteen non-convertible loans. The loans bear interest based on the greater of 3% or the base rate set by Finland’s Ministry of Finance minus one (1) percentage point. The maturity dates of the loans range from eight to ten years from the date of issuance, however, according to certain terms and conditions of the loans, the Company may repay the principal and accrued and unpaid interest of the loans only when the consolidated retained earnings of Biotie is sufficient to fully repay the loans.

     Research and Development Loans

Research and Development Loans (“R&D Loans”) were granted by Business Finland with an acquisition-date fair value of $2.9 million (€2.6 million) and a carrying value of $1.8 million as of December 31, 2018. The R&D Loans bear interest based on the greater of 1% or the base rate set by Finland’s Ministry of Finance minus three (3) percentage points. The repayment of these loans began in January 2017. The loan principal will be paid in equal annual installments over a 5 year period, ending January 2021.

Letters of Credit

As of December 31, 2018, the Company has $0.3 million of cash collateralized standby letters of credit outstanding (see Note 2).

v3.10.0.1
Liability Related to Sale of Future Royalties
12 Months Ended
Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]  
Liability Related to Sale of Future Royalties

(11) Liability Related to Sale of Future Royalties

As of October 1, 2017, the Company completed a royalty purchase agreement with HealthCare Royalty Partners, or HCRP (“Royalty Agreement”). In exchange for the payment of $40 million to the Company, HCRP obtained the right to receive Fampyra royalties payable by Biogen under the License and Collaboration Agreement between the Company and Biogen, up to an agreed upon threshold of royalties. When this threshold is met, if ever, the Fampyra royalty revenue will revert back to the Company and the Company will continue to receive the Fampyra royalty revenue from Biogen until the revenue stream ends. The transaction does not include potential future milestones to be paid.

The Company maintained the rights under the license and collaboration agreement with Biogen, therefore, the Royalty Agreement has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement, in accordance with the relevant accounting guidance. The Company recorded the receipt of the $40 million payment from HCRP and established a corresponding liability in the amount of $40 million, net of transaction costs of approximately $2.2 million. The net liability is classified between the current and non-current portion of liability related to sale of future royalties in the consolidated balance sheets based on the recognition of the interest and principal payments to be received by HCRP in the next 12 months from the financial statement reporting date. The total net royalties to be paid, less the net proceeds received will be recorded to interest expense using the effective interest method over the life of the royalty agreement. The Company will estimate the payments to be made to HCRP over the term of the Agreement based on forecasted royalties and will calculate the interest rate required to discount such payments back to the liability balance. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as necessary.

The following table shows the activity within the liability account from the inception of the royalty agreement in November 2017 to December 31, 2017 and December 2018.

(In thousands)

 

December 31, 2018

 

 

Inception Date through

December 31, 2017

 

Liability related to sale of future royalties - beginning balance

 

$

35,788

 

 

$

 

Proceeds from sale of future royalties

 

 

 

 

 

40,000

 

Deferred transaction costs amortized

 

 

784

 

 

 

(2,115

)

Non-cash royalty revenue payable to HCRP

 

 

(10,291

)

 

 

(2,705

)

Non-cash interest expense recognized

 

 

4,435

 

 

 

608

 

Liability related to sale of future royalties - ending balance

 

$

30,716

 

 

$

35,788

 

 

The interest and debt discount amortization expense is reflected as interest and amortization of debt discount expense in the Statement of Operations.

v3.10.0.1
Corporate Restructuring
12 Months Ended
Dec. 31, 2018
Restructuring And Related Activities [Abstract]  
Corporate Restructuring

(12) Corporate Restructuring

On April 5, 2017, the Company announced a corporate restructuring to reduce its cost structure and focus its resources on its then late-stage program, Inbrija.

The adoption of this restructuring plan followed the previously announced decision by the United States District Court for the District of Delaware invalidating certain patents pertaining to Ampyra.

As part of this restructuring, the Company reduced headcount by approximately 20%. For the years ended December 31, 2018 and December 31, 2017, the Company incurred pre-tax severance and employee separation related expenses of approximately $1.3 million and $7.6 million associated with the restructuring. The pre-tax charges incurred include a cash component of approximately $1.1 million and $6.6 million representing employee charges for severance payments and benefits and a non-cash component of approximately $0.2 million and $1.0 million representing stock compensation charges for the years ended December 31, 2018 and December 31, 2017, respectively. Of the pre-tax severance and employee separation related expenses incurred, $1.2 million and $5.5 million were recorded in research and development expenses and $0.1 million and $2.1 million were recorded in selling, general and administrative expenses for the years ended December 31, 2018 and December 31, 2017, respectively.

A summary of the restructuring costs for the years ended December 31, 2018 and 2017 is as follows:

(In thousands)

 

Restructuring Costs

 

Restructuring Liability as of December 31, 2016

 

$

 

2017 Restructuring costs

 

 

7,646

 

2017 Payments

 

 

(7,142

)

Restructuring Liability as of December 31, 2017

 

$

504

 

2018 Restructuring costs

 

 

1,316

 

2018 Payments

 

 

(1,820

)

Restructuring Liability as of December 31, 2018

 

$

 

v3.10.0.1
Accrued Expenses and Other Current Liabilities
12 Months Ended
Dec. 31, 2018
Accrued Expenses And Other Current Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities

(13) Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Product allowances accruals

 

$

26,931

 

 

$

37,604

 

Bonus payable

 

 

18,381

 

 

 

10,730

 

Accrued inventory

 

 

14,254

 

 

 

15,324

 

Sales force commissions and incentive payments payable

 

 

3,453

 

 

 

1,654

 

Administrative expenses

 

 

2,651

 

 

 

2,276

 

Vacation accrual

 

 

2,395

 

 

 

2,449

 

Research and development expense accruals

 

 

2,374

 

 

 

9,092

 

Commercial and Marketing expense accruals

 

 

1,933

 

 

 

1,643

 

Royalties payable

 

 

509

 

 

 

3,707

 

Other accrued expenses

 

 

4,001

 

 

 

15,371

 

Total

 

$

76,882

 

 

$

99,850

 

v3.10.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

(14) Commitments and Contingencies

The Company’s long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. Under certain supply agreements and other agreements with manufacturers and suppliers, the Company is required to make payments for the manufacture and supply of its clinical and approved products. The Company’s major outstanding contractual obligations are for payments related to its convertible notes, capital loans, operating leases and commitments to purchase inventory. The following table summarizes the contractual obligations at December 31, 2018 and the effect such obligations are expected to have on the Company’s liquidity and cash flow in future periods:

 

 

 

Payments due by period (1) (3) (7)

 

(In thousands)

 

Total

 

 

Less than

1 year

 

 

1-3 years

 

 

4-5 years

 

Convertible Senior Notes (2)

 

$

359,214

 

 

$

6,038

 

 

$

353,176

 

 

$

 

Research and development loans (4)

 

 

1,848

 

 

 

616

 

 

 

1,232

 

 

 

 

Operating leases (5)

 

 

36,090

 

 

 

7,382

 

 

 

15,538

 

 

 

13,170

 

Inventory purchase commitments (6)

 

 

2,281

 

 

 

2,281

 

 

 

 

 

 

 

Total

 

$

399,433

 

 

$

16,317

 

 

$

369,946

 

 

$

13,170

 

 

(1)

Excludes a liability for uncertain tax positions totaling $7.7 million. This liability has been excluded because the Company cannot currently make a reliable estimate of the period in which the liability will be payable, if ever.

(2)

Represents the future payments of principal and interest to be made on the Convertible Senior Notes issued in June 2014. The Notes will mature and will be payable on June 15, 2021. See Note 10.

(3)

Excludes a liability for the non-convertible capital loans totaling $23.2 million. The non-convertible capital loans have a stated maturity of less than one year. However, the repayment of the non-convertible capital loans and payment of accrued interest thereon are governed by a restrictive condition, according to which the loan principal may only be repaid if Biotie’s consolidated restricted equity is fully covered. Accrued interest may only be paid if Biotie, including its subsidiaries, has sufficient funds for profit distribution as of the most recently ended fiscal year. Interest accrues in the interim. This liability has been excluded because the Company cannot currently make a reliable estimate of the period in which the liability will be payable, if ever.

(4)

Represents the future principal payments on the R&D loans acquired with Biotie. The repayment is made in equal annual installment with last payment due in January 2021. See Note 10.

(5)

Represents payments for the operating leases of the Company’s Ardsley, NY headquarters, the Company’s manufacturing facility in Chelsea, MA, and lab and office space in Waltham, MA, and excludes field auto leases which are for a one year term.

(6)

Represents Ampyra inventory commitments. The Ampyra inventory commitment is an estimate as the price paid for Ampyra inventory is based on a percentage of the net product sales during the quarter Alkermes ships inventory to us. Under our supply agreement with Alkermes, we provide Alkermes with monthly written 18-month forecasts, and with annual written five-year forecasts for our supply requirements of Ampyra. In each of the three months for Ampyra following the submission of our written 18-month forecast we are obligated to purchase the quantity specified in the forecast, even if our actual requirements are greater or less. We have agreed to purchase at least 75% of our annual requirements of Ampyra from Alkermes, unless Alkermes is unable or unwilling to meet its requirements, for a percentage of net product sales and the quantity of product shipped by Alkermes to us.

(7)

Pursuant to the UCB Termination and Transition Agreement, Biotie is required to pay up to $4.1 million (€ 3.9 million) to UCB. The amount that will be paid will be determined based on a percentage of future consideration Biotie will receive from tozadenant. The liability is excluded as the Company cannot currently estimate the period in which the liability will be payable, if ever.

Operating Leases

Ardsley, New York

In June 2011, the Company entered into a 15-year lease for an aggregate of approximately 138,000 square feet of office and laboratory space in Ardsley, New York. In 2014, the Company exercised its option to expand into an additional 25,405 square feet of office space, which the Company occupied in January 2015. The Company has options to extend the term of the lease for three additional five-year periods, and the Company has an option to terminate the lease after 10 years subject to payment of an early termination fee. Also, the Company has a right of first refusal until mid-2020 to lease up to approximately 95,000 additional square feet of space in additional buildings at the same location. The Company’s extension, early termination, and expansion rights are subject to specified terms and conditions, including specified time periods when they must be exercised, and are also subject to limitations including that the Company not be in default under the lease.

The Ardsley lease provides for monthly payments of rent during the lease term. These payments consist of base rent, which takes into account the costs of the facility improvements funded by the facility owner prior to the Company’s occupancy, and additional rent covering customary items such as charges for utilities, taxes, operating expenses, and other facility fees and charges. The base rent is currently $4.6 million per year, which reflects an annual 2.5% escalation factor as well as the expansion, described above.

Chelsea, Massachusetts

Through our Civitas subsidiary, we lease a manufacturing facility in Chelsea, Massachusetts with commercial-scale capabilities. The approximately 90,000 square foot facility also includes office and laboratory space. Civitas leases this facility from North River Everett Ave, LLC pursuant to a lease with a term that expires on December 31, 2025, and Civitas has two additional extension options of five years each. The base rent under the lease is currently $1.5 million per year, which reflects an annual escalation factor of 2.5% as well as an amendment to the lease to add additional property at the Chelsea, Massachusetts site as further described below.

In 2017, the Company’s Civitas subsidiary amended its existing Chelsea, Massachusetts lease. The amendment added expansion property located in Chelsea, Massachusetts next to the existing facility. The additional property includes land being used for parking and a free-standing warehouse building on the same site. The base rent for the additional property under the lease included in the rent number above, is currently $0.5 million per year with an annual escalation factor of 3.0%.

In 2018, the Company initiated a renovation and expansion of the Chelsea facility that will increase the size of the facility to approximately 95,000 square feet. The project will add a new manufacturing production line for Inbrija and other ARCUS products that has greater capacity than the existing manufacturing line, and it will create additional warehousing space for manufactured product. Pursuant to a 2018 lease amendment that enabled the renovation and expansion, upon completion of the project, annual rent under the lease will increase to $1.7 million. Construction of the project is scheduled for completion in the third quarter of 2019, though we cannot be assured that the project will meet this schedule, and it will take additional time after completion of construction to obtain the FDA approval needed for use of the new production line for commercial manufacture.

Additional Facilities

In October 2016, we entered into a 10-year lease agreement with a term commencing January 1, 2017, for approximately 26,000 square feet of lab and office space in Waltham, MA. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $1.0 million per year.

Through Biotie and its U.S. subsidiary, we previously indirectly leased office space in Turku, Finland and South San Francisco, California. We terminated the Turku, Finland lease in mid-2017, and the South San Francisco, California lease expired at the end of 2018.

Future minimum commitments under all non-cancelable operating leases subsequent to December 31, 2018 are as follows:

 

(In thousands)

 

 

 

2019

$

7,382

 

2020

 

7,669

 

2021

 

7,869

 

2022

 

10,071

 

2023

 

3,100

 

Later years

 

7,769

 

 

$

43,860

 

 

Rent expense under these operating leases during the years ended December 31, 2018, 2017 and 2016 was approximately $8.2 million, $8.1 million, and $6.0 million, respectively.

License Agreements

Under the Company’s Ampyra license agreement with Alkermes, the Company is obligated to make milestone payments to Alkermes of up to $15.0 million over the life of the contract and royalty payments as a percentage of net product sales and the quantity of product shipped by Alkermes to Acorda. Further milestone amounts are payable in connection with additional indications.

Under the Company’s Ampyra supply agreement with Alkermes, payments for product manufactured by Alkermes are calculated as a percentage of net product sales and the quantity of product shipped by Alkermes to Acorda. Under this agreement, Acorda also has the option to purchase up to an agreed upon quantity of product from a second source. However, if Acorda obtains supply from the second source, Acorda must make a compensating payment to Alkermes for the quantities of product provided by the second source.

Under the Company’s license agreement with Rush-Presbyterian-St. Luke’s Medical Center, it was obligated to make royalty payments as a low single digit percentage of net Ampyra and Fampyra sales in the United States and in countries other than the United States. The Company believes this license agreement and the royalty obligations expired in 2018.

Under the Company’s supply agreement with Alkermes, it provides Alkermes with monthly written 18-month forecasts, and annual written five-year forecasts for its supply requirements of Ampyra. In each of the three months for Ampyra following the submission of its written 18-month forecast, the Company is obligated to purchase the quantity specified in the forecast, even if its actual requirements are greater or less. Inventory purchase commitments were $2.3 million as of December 31, 2018.

In addition, under the Company’s various other research, license and collaboration agreements with other parties, it is obligated to make milestone payments of up to an aggregate of approximately $51.6 million over the life of the contracts.

Under certain agreements, we are required to pay royalties for the use of technologies and products in our R&D activities and in the commercialization of products. The amount and timing of any of the foregoing payments are not known due to the uncertainty surrounding the successful research, development and commercialization of the products.

Employment Agreements

The Company has employment agreements with all of its executive officers which provide for, among other benefits, certain severance, bonus and other payments and COBRA premium coverage, as well as certain rights relating to their equity compensation awards, if their employment is terminated for reasons other than cause or if they terminate their employment for good reason (as those terms are defined in the agreements). The agreements also provide for certain increased rights if their employment terminates following a change in control (as defined in the agreements). Our contractual commitments table does not include these severance payment obligations.

Other

The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for amounts related to legal matters if it is probable that a liability has been incurred and the amount is reasonably estimable. While losses, if any, are possible the Company is not able to estimate any ranges of losses as of December 31, 2018. Litigation expenses are expensed as incurred. The Company is currently a party to various legal proceedings which are principally patent litigation matters. The Company has assessed such legal proceedings and does not believe that it is probable that a liability has been incurred or that the amount of any potential liability or range of losses can be reasonably estimated. As a result, the Company did not record any loss contingencies for any of these matters. While it is not possible to determine the outcome of these matters, the Company believes that the resolution of all such matters could potentially have a material adverse effect on its consolidated financial position or liquidity and could potentially be material to the Company's consolidated results of operations in any one accounting period.

v3.10.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements

(15) Fair Value Measurements

The Company defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts. The Company bases fair value on the assumptions market participants would use when pricing the asset or liability.

The Company utilizes a fair value hierarchy which requires it to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company primarily applies the market approach for recurring fair value measurements. There were no changes in valuation techniques during the year ended December 31, 2018. The standard describes three levels of inputs that may be used to measure fair value:

 

Level 1 Quoted prices in active markets for identical assets or liabilities.

 

Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Recurring

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 and December 31, 2017, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

 

(In thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

Assets Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,586

 

 

$

 

 

$

 

Commercial paper

 

 

 

 

 

47,108

 

 

 

 

Corporate bonds

 

 

 

 

 

104,881

 

 

 

 

Liabilities Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Acquired contingent consideration

 

 

 

 

 

 

 

 

168,000

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

Assets Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,163

 

 

$

 

 

$

 

Liabilities Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Acquired contingent consideration

 

 

 

 

 

 

 

 

113,000

 

 

The following table presents additional information about assets and/or liabilities measured at fair value on a recurring basis and for which the Company utilizes Level 3 inputs to determine fair value.

Acquired contingent consideration

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

Acquired contingent consideration:

 

 

 

 

 

 

 

 

Balance, beginning of period

 

$

113,000

 

 

$

72,100

 

Fair value change to contingent consideration (unrealized)

   included in the statement of operations

 

 

55,000

 

 

 

40,900

 

Balance, end of period

 

$

168,000

 

 

$

113,000

 

 

The Company estimates the fair value of its acquired contingent consideration using a probability weighted discounted cash flow valuation approach based on estimated future sales expected from Inbrija (levodopa inhalation powder), an FDA approved drug for the treatment of OFF periods of Parkinson’s disease and our ARCUS program for acute migraine. Using this approach, expected future cash flows are calculated over the expected life of the agreement and discounted to estimate the current value of the liability at the period end date. Some of the more significant assumptions made in the valuation include (i) the estimated revenue forecasts for Inbrija and our ARCUS program for acute migraine, (ii) probabilities of success, and (iii) discount periods and rate. The probability of achievement of revenue milestones ranged from 26.3% to 100.0% with milestone payment outcomes ranging from $0 to $70 million in the aggregate for Inbrija and our ARCUS program for acute migraine. The valuation is performed quarterly. Gains and losses representing changes in the fair value of the contingent consideration are included in the statement of operations. For the year ended December 31, 2018, changes in the fair value of the acquired contingent consideration were primarily due to an increase in the probability of success reflecting the FDA approval of Inbrija, recalculation of cash flows for the passage of time and updates to certain other estimated assumptions. Refer to Note 16 for more information about the Alkermes ARCUS agreement.

The acquired contingent consideration has been classified as a Level 3 liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach including, but not limited to, assumptions involving probability adjusted sales estimates for Inbrija and our ARCUS program for acute migraine and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.

v3.10.0.1
License, Research and Collaboration Agreements
12 Months Ended
Dec. 31, 2018
Collaborative Arrangement Disclosure [Abstract]  
License, Research and Collaboration Agreements

(16) License, Research and Collaboration Agreements

Alkermes plc

The Company is a party to a 2003 amended and restated license agreement and a 2003 supply agreement with Alkermes for Ampyra (“Agreement”). Under the license agreement, the Company has exclusive worldwide rights to Ampyra, as well as Alkermes’ formulation for any other mono or di-aminopyridines, for all indications, including multiple sclerosis and spinal cord injury. The Company is obligated to pay Alkermes milestone payments and royalties based on a percentage of net product sales and the quantity of product shipped by Alkermes to Acorda.

Subject to early termination provisions, the Alkermes license terminates on a country by country basis on the latter to occur of fifteen years from the date of the agreement, the expiration of the last Alkermes patent to expire or the existence of competition in that country.

Under the supply agreement, Alkermes has the right to manufacture for the Company, subject to certain exceptions, Ampyra and other products covered by these agreements at specified prices calculated as a percentage of net product sales of the product shipped by Alkermes to Acorda. In the event Alkermes does not manufacture 100% of the products, it is entitled to a compensating payment for the quantities of product provided by the alternative manufacturer.

Supply Agreement

The Company is a party to a 2003 supply agreement with Alkermes relating to the manufacture and supply of Ampyra by Alkermes. The Company is obligated to purchase at least 75% of its annual requirements of Ampyra from Alkermes, unless Alkermes is unable or unwilling to meet its requirements, for a percentage of net product sales and the quantity of product shipped by Alkermes to Acorda. In those circumstances, where the Company elects to purchase less than 100% of its requirements from Alkermes, the Company is obligated to make certain compensatory payments to Alkermes. Alkermes is required to assist the Company in qualifying a second manufacturer to manufacture and supply the Company with Ampyra subject to its obligations to Alkermes.

As permitted by the agreement with Alkermes, the Company has designated Patheon, Inc. (Patheon) as a qualified second manufacturing source of Ampyra. In connection with that designation, the Company entered into a manufacturing agreement with Patheon, and Alkermes assisted the Company in transferring manufacturing technology to Patheon. The Company and Alkermes have agreed that a purchase of up to 25% of annual requirements from Patheon is allowed if compensatory payments are made to Alkermes. In addition, Patheon may supply the Company with Ampyra if Alkermes is unable or unwilling to meet the Company’s requirements. The Company did not make any compensatory payment in 2018.

Rush-Presbyterian St. Luke’s Medical Center

The Company entered into a license agreement with Rush in 2003 in which Rush granted the Company an exclusive worldwide license to its know-how relating to dalfampridine for the treatment of MS.

Under the Company’s license agreement with Rush-Presbyterian-St. Luke’s Medical Center, the Company was obligated to make royalty payments as a low single digit percentage of net Ampyra and Fampyra sales in the United States and in countries other than the United States. The Company believes the license and the royalty obligations expired in 2018.

As of December 31, 2018, 2017 and 2016, the Company made or accrued royalty payments totaling $66.6 million, $59.9 million and $48.1 million, respectively.

Biogen Inc.

The Company has an exclusive collaboration and license agreement with Biogen Inc., (Biogen) to develop and commercialize Ampyra (known as Fampyra outside the U.S.) in markets outside the United States (the Collaboration Agreement). Under the Collaboration Agreement, Biogen was granted the exclusive right to commercialize Ampyra and other products containing aminopyridines developed under that agreement in all countries outside of the U.S., which grant includes a sublicense of the Company’s rights under an existing license agreement between the Company and Alkermes plc (Alkermes). Biogen has responsibility for regulatory activities and future clinical development of Fampyra in ex-U.S. markets worldwide. The Company also entered into a related supply agreement with Biogen (the Supply Agreement), pursuant to which the Company will supply Biogen with its requirements for the licensed products through the Company’s existing supply agreement with Alkermes.

Under the Collaboration Agreement, the Company received an upfront payment of $110.0 million in July 2009, and a $25 million milestone payment in August 2011 upon approval of the product in the European Union. The Company is also entitled to receive additional payments based on the successful achievement of future regulatory and sales milestones. Biogen is also required to make double-digit tiered royalty payments to the Company on ex-U.S. sales. Also under the terms of the Collaboration Agreement, the Company will participate in overseeing the development and commercialization of Ampyra and other licensed products in markets outside the U.S. Acorda will continue to develop and commercialize Ampyra independently in the U.S.

As of June 30, 2009, the Company recorded deferred revenue of $110.0 million for the upfront payment from Biogen under the Collaboration Agreement. Also, as a result of such payment to Acorda, a payment of $7.7 million was made to Alkermes and recorded as a deferred expense.

The Company considered the following deliverables with respect to the revenue recognition of the $110.0 million upfront payment: (1) the license to use the Company’s technology, (2) the Collaboration Agreement to develop and commercialize licensed product in all countries outside the U.S., and (3) the Supply Agreement. Due to the inherent uncertainty in obtaining regulatory approval, the applicability of the Supply Agreement is outside the control of the Company and Biogen. Accordingly, the Company has determined the Supply Agreement is a contingent deliverable at the onset of the agreement. As a result, the Company has determined the Supply Agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement. The Company has also determined that there is no significant and incremental discount related to the supply agreement since Biogen will pay the same amount for inventory that the Company would pay and the Company effectively acts as a middle man in the arrangement for which it adds no significant value due to various factors such as the Company does not have any manufacturing capabilities or other know-how with respect to the manufacturing process.

The Company has determined that the identified non-contingent deliverables (deliverables 1 and 2 immediately preceding) would have no value on a standalone basis if they were sold separately by a vendor and the customer could not resell the delivered items on a standalone basis, nor does the Company have objective and reliable evidence of fair value for the deliverables. Accordingly, the non-contingent deliverables are treated as one unit of accounting. As a result, the Company recognized the non-refundable upfront payment from Biogen as revenue and the associated payment to Alkermes as expense ratably over the estimated term of regulatory exclusivity for the licensed products under the Collaboration Agreement as the Company had determined this was the most probable expected benefit period. The Company recognized $9.1 million in amortized license revenue, a portion of the $110.0 million received from Biogen, and $0.6 million in cost of license revenue, a portion of the $7.7 million paid to Alkermes, during each of the years ended December 31, 2017 and 2016. On January 1, 2018, we adopted the new accounting standard ASC 606, “Revenue from Contracts with Customers” (Topic 606) (“ASC 606”) and the related amendments to all contracts with customers that were not completed as of the date of adoption using the modified retrospective method. As a result of the adoption of ASC 606, the Company determined that the revenue recognition methodology for the deferred license revenue changed under the new guidance. License revenue recorded by the Company prior to January 1, 2018 related exclusively to the recognition of the upfront payment received from Biogen upon the execution of the License and Collaboration agreement that granted Biogen an exclusive non sub-licensable license to sell Fampyra outside of the U.S. License revenue recorded prior to January 1, 2018 was recognized under ASC 605 on a pro rata basis as the Company’s obligations were satisfied throughout the duration of the license and collaboration agreement. As of January 1, 2018, the Company adopted ASC 606 which changed the Company’s determination of its distinct performance obligations resulting in an acceleration of the recognition of the revenue in the arrangement. The material performance obligations were completed prior to January 1, 2018, and as a result, the Company recognized its previously deferred revenue as a cumulative effect adjustment of $27.6 million within the beginning accumulated deficit balance on the consolidated balance sheet as of January 1, 2018 (See Note 2).

Actavis/Watson

Prior to the Company’s sale of its Zanaflex assets, the Company had an agreement with Actavis, a subsidiary of Teva Pharmaceuticals and formerly Watson Pharma, to market tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules, which was launched in February 2012. In accordance with the agreement, the Company received a royalty based on Actavis’ gross margin, as defined by the agreement, of the authorized generic product. During the years ended December 31, 2017 and 2016, the Company recognized royalty revenue of $2.6 million and $3.9 million, respectively, related to the gross margin of the Zanaflex Capsule authorized generic. During the years ended December 31, 2017 and 2016, the Company also recognized revenue and a corresponding cost of sales of $3.0 million and $2.7 million, respectively, related to the purchase and sale of the related Zanaflex Capsule authorized generic product to Actavis, which is recorded in net product revenues and cost of sales.

Alkermes (ARCUS products)

In December 2010, Civitas, the Company’s wholly-owned subsidiary, entered into the Asset Purchase and License Agreement (“Alkermes Agreement”), in which Civitas licensed or acquired from Alkermes certain pulmonary development programs and INDs, underlying intellectual property and laboratory equipment associated with the pulmonary business of Alkermes. The assets acquired includes (i) patents, patent applications and related know-how and documentation; (ii) a formulation of inhaled L-dopa; (iii) several other pulmonary development programs and INDs, which are part of the platform device and formulation IP; (iv) instruments, laboratory equipment and apparatus; and (v) inhalers, inhaler molds, tools, and the associated assembled equipment. In addition, Civitas leased the facility where the Alkermes operations were previously housed in Chelsea, Massachusetts.

Under the terms of the Alkermes Agreement, Civitas will also pay to Alkermes royalties for each licensed product as follows: (i) for all licensed products sold by Civitas, Civitas will pay Alkermes a mid-single digit percentage of net sales of such licensed products and (ii) for all licensed products sold by a collaboration partner, Civitas will pay Alkermes the lower of a mid-single digit percentage of net sales of such licensed products in a given calendar year or a percentage in the low-to-mid-double digits of all collaboration partner revenue received in such calendar year. Notwithstanding the foregoing, in no event shall the royalty paid be less than a low-single digit percentage of net sales of a licensed product in any calendar year.

As consideration for the agreement with Alkermes, Civitas issued stock and also agreed to pay Alkermes royalties on future net product sales from products developed from licensed technology under the Alkermes Agreement. The fair value of the future royalties is classified as contingent consideration. The Company estimates the fair value of this contingent consideration based on future revenue projections and estimated probabilities of receiving regulatory approval and commercializing such products. Refer to Note 15 – Fair Value Measurements for more information about the contingent consideration liability.

Roche (Tozadenant and SYN120)

Our Biotie subsidiary has an exclusive, worldwide license from Roche Palo Alto, LLC, Hoffman-La Roche, Inc. and F. Hoffman-La Roche, Ltd. to certain patents and know-how relating to tozadenant and certain patents and know-how relating to SYN120.

v3.10.0.1
Income Taxes
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes

(17) Income Taxes

On December 22, 2017, the U.S. enacted Public Law No. 115-97 ("Act"), originally introduced as the Tax Cuts and Jobs Act, which significantly modified the Internal Revenue Code. The Act reduced the U.S. federal corporate tax rate from 35.0% to 21.0%, created a territorial-type tax system with an exemption for foreign dividends, and imposed a one-time deemed repatriation tax on a U.S. company's historical undistributed earnings and profits of foreign affiliates. Among other provisions, the Act also increased expensing for certain business assets, created new taxes on certain foreign sourced earnings, adopted limitations on business interest expense deductions, repealed deductions for income attributable to domestic production activities, and added other anti-base erosion rules. The effective dates for the provisions set forth in the Act vary as to when the provisions will apply to the Company.

In response to the Act, the U.S. Securities and Exchange Commission ("SEC") provided guidance by issuing Staff Accounting Bulletin No. 118 ("SAB 118"), which has since been codified by the release of ASU No. 2018- 05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. ASU 2018-05 allows companies to record provisional amounts during a measurement period with respect to the impacts of the Act for which the accounting requirements under ASC Topic 740 are not complete, but a reasonable estimate has been determined. The measurement period under ASU 2018-05 ends when a company has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC Topic 740, but cannot exceed one year.

As of December 31, 2018, the Company has completed the accounting for the effects of the Act. The Company has included the impact of the Act on its annual effective tax rate and has recorded a total tax benefit of $14.8 million for the remeasurement of deferred tax assets and liabilities, of which $1.6 million of the benefit was recorded in the fourth quarter of 2018.

The domestic and foreign components of (loss) income before income taxes were as follows:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Domestic

 

$

19,211

 

 

$

(172,560

)

 

$

(36,454

)

Foreign

 

 

1,211

 

 

 

(79,325

)

 

 

(5,814

)

Total

 

$

20,422

 

 

$

(251,885

)

 

$

(42,268

)

 

The benefit from (provision for) income taxes in 2018, 2017 and 2016 consists of current and deferred federal, state and foreign taxes as follows:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

2,991

 

 

$

(11,948

)

 

$

(852

)

State

 

 

(4,143

)

 

 

(12,653

)

 

 

(4,517

)

Foreign

 

 

(93

)

 

 

(91

)

 

 

781

 

 

 

 

(1,245

)

 

 

(24,692

)

 

 

(4,588

)

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

13,790

 

 

 

42,322

 

 

 

9,465

 

State

 

 

714

 

 

 

5,377

 

 

 

1,788

 

Foreign

 

 

 

 

 

5,519

 

 

 

 

 

 

 

14,504

 

 

 

53,218

 

 

 

11,253

 

Total benefit from (provision for) income taxes

 

$

13,259

 

 

$

28,526

 

 

$

6,665

 

 

As of December 31, 2018, Acorda’s U.S. consolidated Tax Group had utilized all of its available Federal net operating loss (NOL) carryforwards to offset its consolidated U.S. federal taxable income. The NOL carryforward of approximately $131.6 million as of December 31, 2018 represents the NOL’s of Biotie US, which files a separate company federal income tax return. These NOLs are offset entirely by a valuation allowance and are expected to begin to expire in 2026. Based on a recently completed IRC Section 382 analysis, the Company has determined that there were additional NOL’s that will be expiring of approximately $16.0 million.

The Company’s research and development and orphan drug credit carry-forwards of $17.1 million and $34.5 million as of December 31, 2018 and 2017, respectively, begin to expire in 2031. The Company expects to pay cash taxes in various U.S. states and Puerto Rico where it has operations and NOL carryforwards are not available or are limited.

The Company was subject to the alternative minimum tax during 2016 and 2015. The alternative minimum tax credit carryforwards of $4.8 million at December 31, 2017 and 2016 can be used to offset future regular income tax liability. As of December 31, 2018, the Company is expected to utilize approximately $4.5 million and the remaining $0.3 million of unused credits under the Act, will become refundable over the next four years.

The Company had available state NOL carryforwards of approximately $170.1 million, $167.9 million and $170.9 million as of December 31, 2018, 2017 and 2016, respectively. The state losses are expected to begin to expire in 2027, although not all states conform to the federal carryforward period and occasionally limit the use of net operating losses for a period of time.

The Company is no longer subject to federal income tax audits for tax years prior to 2015 however, such net operating losses utilized by the Company in years subsequent to 2002 is subject to review. The Internal Revenue Service completed its examination of the Company’s U.S. income tax return for 2015 in the third quarter of 2018 that resulted in an immaterial adjustment.

The Internal Revenue Service commenced its examination of the Company’s wholly-owned subsidiary, Biotie Therapies, Inc.’s, U.S. income tax return for the short period ended December 31, 2016 in the third quarter of 2018. There have been no proposed adjustments at this stage of the examination.

The New York State Department of Tax commenced an examination of the Company’s income tax returns for the years 2014 through 2016 in the third quarter of 2018. There have been no proposed adjustments at this stage of the examination.

The Internal Revenue Code of 1986 contains certain provisions that can limit a taxpayer's ability to utilize net operating loss and tax credit carryforwards in any given year resulting from cumulative changes in ownership interests in excess of 50 percent over a three-year period. These provisions were unchanged by the Act. The Company has determined that these limiting provisions were triggered during a prior year for both Acorda Therapeutics, Inc. and Neuronex, Inc., its wholly owned subsidiary. An additional limitation was triggered in 2014 for Civitas Therapeutics, Inc. and in 2016 for Biotie Therapies, Inc., both wholly owned subsidiaries of Acorda Therapeutics, Inc. The Company believes that such limitations are not expected to result in the expiration or loss of any of its federal net operating loss carryforwards and income tax credit carryforwards for Acorda and the Neuronex, Inc. and Civitas Therapeutics, Inc. acquisitions. Based on a recently completed IRC Section 382 analysis by the Company, the limitation triggered by the acquisition of Biotie Therapies, Inc. will result in an estimated $31.5 million of unused federal net operating loss carryforwards and $5.1 million of unused federal credit carryforwards expiring before they can be utilized. Future ownership changes may further limit the use of these carryforwards. Under the Act, U.S. net operating losses generated after December 31, 2017 can be carried forward indefinitely.

The Company has $67.6 million of net operating loss carryforwards outside of the U.S. as of December 31, 2018, that begin to expire in 2019 all of which are fully reserved with a valuation allowance.

The temporary differences between the book and tax treatment of income and expenses results in deferred tax assets and liabilities, which are included within the consolidated balance sheet. The Company must assess the likelihood that any recorded deferred tax assets will be recovered against future taxable income. To the extent the Company believes it is more likely than not that any portion of the deferred tax asset will not be recoverable, a valuation allowance must be established. To the extent the Company establishes a valuation allowance or changes the allowance in a future period, income tax expense will be impacted. The Company continued to maintain a full valuation allowance against its net U.S. and net foreign deferred tax assets of Biotie and recorded a benefit of $3.8 million and $0.7 million in each jurisdiction respectively. The $3.8 million benefit was primarily due to the completion of the 382 study which determined that additional NOLs would expire. Additionally, the Company had a net release of $23.1 million of valuation allowance against certain U.S. federal and state deferred taxes.

The reconciliation of the statutory U.S. federal income tax rate to the Company’s effective income tax rate is as follows:

 

 

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

U.S. federal statutory tax rate

 

 

21.0

%

 

 

35.0

%

 

 

35.0

%

State and local income taxes

 

 

8.7

%

 

 

(0.1

)%

 

 

(3.8

)%

Foreign income tax

 

 

 

 

 

 

 

 

1.2

%

Stock option compensation

 

 

0.7

%

 

 

(0.5

)%

 

 

(3.8

)%

Stock option shortfall

 

 

12.6

%

 

 

(1.5

)%

 

 

(6.5

)%

Research and development and orphan drug credits

 

 

5.6

%

 

 

1.2

%

 

 

28.9

%

Uncertain Tax Positions

 

 

(0.7

)%

 

 

(0.3

)%

 

 

(4.8

)%

Other nondeductible and permanent differences

 

 

(5.0

)%

 

 

(0.4

)%

 

 

(1.1

)%

Valuation allowance, net of foreign tax rate

    differential

 

 

(107.9

)%

 

 

(19.8

)%

 

 

(31.6

)%

Transaction cost

 

 

 

 

 

 

 

 

(5.9

)%

Gain or loss on hedging

 

 

 

 

 

 

 

 

8.2

%

NOL Write-off

 

 

16.6

%

 

 

 

 

 

 

Federal return to provision differences

 

 

(16.6

)%

 

 

 

 

 

 

Tax reform

 

 

 

 

 

(2.3

)%

 

 

 

Effective income tax rate

 

 

(65.0

)%

 

 

11.3

%

 

 

15.8

%

 

The Company’s overall effective tax rate is affected primarily by the release of the U.S valuation allowance, Biotie U.S. and foreign losses for which no benefit has been recognized and the related foreign tax rate differential, state taxes, federal return to provision adjustments including the related tax reform impact and stock compensation. The effective tax rate related to state taxes is primarily driven by Acorda’s state tax return filings as a stand-alone entity, without the benefit of Civitas and Biotie’s losses. The state taxes reflect the deferred impact of customary state tax law and apportionment changes that occurred during the year; the state effective tax rate is not necessarily indicative of the company’s expected state tax rate for the foreseeable future. U.S. income taxes are not provided for unremitted earnings of international subsidiaries and affiliates where our intention is to reinvest these earnings permanently.

Provisions have been made for deferred taxes based on the differences between the basis of the assets and liabilities for financial statement purposes and the basis of the assets and liabilities for tax purposes using currently enacted tax rates and regulations that will be in effect when the differences are expected to be recovered or settled. The components of the deferred tax assets and liabilities are as follows:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss and other carryforwards

 

$

51,543

 

 

$

53,632

 

Tax credits

 

 

19,401

 

 

 

31,699

 

Deferred revenue

 

 

 

 

 

5,597

 

Stock based compensation

 

 

22,733

 

 

 

24,531

 

Contingent consideration

 

 

38,594

 

 

 

26,041

 

Employee compensation

 

 

3,677

 

 

 

3,212

 

Legal reserve

 

 

 

 

 

 

Rebate and returns reserve

 

 

5,798

 

 

 

8,215

 

Capitalized R&D

 

 

10,791

 

 

 

11,295

 

Other

 

 

13,881

 

 

 

12,368

 

Total deferred tax assets

 

$

166,418

 

 

$

176,590

 

Valuation allowance

 

$

(71,570

)

 

$

(98,609

)

Total deferred tax assets net of valuation allowance

 

$

94,848

 

 

$

77,981

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Intangible assets

 

 

(94,771

)

 

 

(91,991

)

Convertible debt

 

 

(5,971

)

 

 

(8,449

)

Depreciation

 

 

(1,256

)

 

 

 

Other

 

 

(333

)

 

 

 

Total deferred tax liabilities

 

$

(102,331

)

 

$

(100,440

)

Net deferred tax liability

 

$

(7,483

)

 

$

(22,459

)

 

The Company follows authoritative guidance regarding accounting for uncertainty in income taxes, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

The beginning and ending amounts of unrecognized tax benefits reconciles as follows:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Beginning of period balance

 

$

7,397

 

 

$

6,856

 

 

$

4,835

 

Increases for tax positions taken during a prior period

 

 

55

 

 

 

687

 

 

 

570

 

Decreases for tax positions taken during a

    prior period

 

 

(194

)

 

 

(146

)

 

 

 

Increases for tax positions taken during the

    current period

 

 

 

 

 

 

 

 

1,451

 

 

 

$

7,258

 

 

$

7,397

 

 

$

6,856

 

 

Due to the amount of the Company’s tax credit carryforwards, it has not accrued interest relating to these unrecognized tax benefits. Accrued interest and penalties, however, would be disclosed within the related liabilities lines in the consolidated balance sheet and recorded as a component of income tax expense. All of its unrecognized tax benefits, if recognized, would impact the effective tax rate.

The Company is subject to taxation in the United States and various state and foreign jurisdictions. The Company has operations in the United States and Puerto Rico, as well as filing obligations in Finland, Switzerland and Germany. Typically, the period for the statute of limitations ranges from 3 to 5 years, however, this could be extended due to the Company’s NOL carryforward position in a number of its jurisdictions. The tax authorities generally have the ability to review income tax returns for periods where the statute of limitations has previously expired and can subsequently adjust the NOL carryforward or tax credit amounts. Accordingly, the Company does not expect to reverse any portion of the unrecognized tax benefits within the next year.

The beginning and ending amounts of valuation allowances reconcile as follows:

 

 

 

Balance at

 

 

 

 

 

 

 

 

 

 

Balance at

 

(In thousands)

 

Beginning of Period

 

 

Additions

 

 

Deductions

 

 

End of Period

 

Valuation allowance for deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2016

 

$

5,277

 

 

 

57,948

 

 

 

 

 

$

          63,225

 

Year ended December 31, 2017

 

$

63,225

 

 

 

39,007

 

 

 

(3,623

)

 

$

98,609

 

Year ended December 31, 2018

 

$

98,609

 

 

 

5,465

 

 

 

(32,504

)

 

$

71,570

 

 

v3.10.0.1
Earnings Per Share
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Earnings Per Share

(18) Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2018, 2017 and 2016:

 

(In thousands, except per share data)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Basic and diluted

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

33,682

 

 

$

(223,359

)

 

$

(34,618

)

Weighted average common shares outstanding used in

   computing net income (loss) per share—basic

 

 

47,010

 

 

 

45,999

 

 

 

45,259

 

Plus: net effect of dilutive stock options and unvested

   restricted common shares

 

 

331

 

 

 

 

 

 

 

Weighted average common shares outstanding used in

   computing net income (loss) per share—diluted

 

 

47,341

 

 

 

45,999

 

 

 

45,259

 

Net income (loss) per share—basic

 

$

0.72

 

 

$

(4.86

)

 

$

(0.76

)

Net income (loss) per share—diluted

 

$

0.71

 

 

$

(4.86

)

 

$

(0.76

)

 

The difference between basic and diluted shares is that diluted shares include the dilutive effect of the assumed exercise of outstanding securities. The Company’s stock options and unvested shares of restricted common stock could have the most significant impact on diluted shares.

Securities that could potentially be dilutive are excluded from the computation of diluted earnings per share when a loss from continuing operations exists or when the exercise price exceeds the average closing price of the Company’s common stock during the period, because their inclusion would result in an anti-dilutive effect on per share amounts.

The following amounts were not included in the calculation of net income per diluted share because their effects were anti-dilutive:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Denominator

 

 

 

 

 

 

 

 

 

 

 

 

Stock options and restricted common shares

 

 

7,370

 

 

 

8,804

 

 

 

7,749

 

Convertible note

 

 

 

 

 

 

 

 

10

 

 

Additionally, the impact of the convertible debt was determined to be anti-dilutive and excluded from the calculation of net income per diluted share for the years ended December 31, 2018, 2017 and 2016.

v3.10.0.1
Employee Benefit Plan
12 Months Ended
Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]  
Employee Benefit Plan

(19) Employee Benefit Plan

Effective September 1, 1999, the Company adopted a defined contribution 401(k) savings plan (the 401(k) plan) covering all employees of the Company. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The plan includes an employer match contribution to employee deferrals. For each dollar an employee invests up to 6% of his or her earnings, the Company will contribute an additional 50 cents into the funds. The Company’s expense related to the plan was $2.4 million, $2.4 million and $2.6 million for the years ended December 31, 2018, 2017, and 2016, respectively.

v3.10.0.1
Quarterly Consolidated Financial Data (unaudited)
12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Consolidated Financial Data (unaudited)

(20) Quarterly Consolidated Financial Data (unaudited)

 

(In thousands, except per share amounts)

 

2018

 

 

 

 

March 31

 

 

June 30

 

 

September 30

 

 

December 31

 

 

Total net revenues

 

$

106,165

 

 

$

153,302

 

 

$

142,814

 

 

$

69,152

 

 

Gross profit

 

 

84,815

 

 

 

122,208

 

 

 

117,423

 

 

 

47,678

 

 

Net (loss) income (1)

 

 

(8,199

)

 

 

46,197

 

 

 

(13,911

)

 

 

9,595

 

 

Net (loss) income per share—basic

 

$

(0.18

)

 

$

0.99

 

 

$

(0.29

)

 

$

0.20

 

 

Net (loss) income per share—diluted

 

$

(0.18

)

 

$

0.98

 

 

$

(0.29

)

 

$

0.20

 

 

 

 

 

2017

 

 

 

March 31

 

 

June 30

 

 

September 30

 

 

December 31

 

Total net revenues

 

$

119,386

 

 

$

139,438

 

 

$

141,065

 

 

$

188,398

 

Gross profit

 

 

94,044

 

 

 

109,614

 

 

 

110,914

 

 

 

137,999

 

Net loss (2) (3)

 

 

(18,904

)

 

 

(8,196

)

 

 

(25,195

)

 

 

(171,064

)

Net loss attributable to Acorda Therapeutics, Inc.

   —basic and diluted

 

 

(18,904

)

 

 

(8,196

)

 

 

(25,195

)

 

 

(171,064

)

Net loss per share—basic and diluted

 

$

(0.41

)

 

$

(0.18

)

 

$

(0.55

)

 

$

(3.70

)

 

  

(1) In the fourth quarter of 2018, the Company recognized a gain of approximately $7.8 million on the sale of Qutenza assets. See Note 5 for a discussion of the gain on the sale. In the fourth quarter of 2018, the Company recognized a charge of approximately $8.4 million related to inventory obsolescence reserve. See Note 2 for a discussion of the inventory reserve charges.

 

(2) In the third quarter of 2017, the Company recognized an asset impairment charge of $39.4 million. See Note 4 for a discussion of the impairment charges.

 

(3) In the fourth quarter of 2017, the Company recognized an asset impairment charge of $257.3 million. See Note 4 for a discussion of the impairment charges.

v3.10.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) and include the results of operations of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements requires management to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include share‑based compensation accounting, which are largely dependent on the fair value of the Company’s equity securities, measurement of changes in the fair value of acquired contingent consideration which is based on a probability weighted discounted cash flow valuation methodology, estimated deductions to determine net revenue such as allowances for customer credits, including estimated discounts, rebates, and chargebacks, which are estimated based on available information that will be adjusted to reflect known changes in the factors that impact such allowances, estimates of reserves for obsolete and excess inventory, and estimates of unrecognized tax benefits and valuation allowances on deferred tax assets which are based on an assessment of recoverability of the deferred tax assets against future taxable income. Actual results could differ from those estimates.

Risks and Uncertainties

Risks and Uncertainties

The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with original maturities of three months or less from date of purchase to be cash equivalents. All cash and cash equivalents are held in highly rated securities including a Treasury money market fund which is unrestricted as to withdrawal or use. To date, the Company has not experienced any losses on its cash and cash equivalents. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term and liquid nature. We maintain cash balances in excess of insured limits. We do not anticipate any losses with respect to such cash balances.

Restricted Cash

Restricted Cash

Restricted cash represents a bank account with funds to cover the Company’s self-funded employee health insurance. At December 31, 2018, the Company also held $0.3 million of restricted cash related to cash collateralized standby letters of credit in connection with obligations under facility leases, which is included with other assets in the consolidated balance sheet due to the long-term nature of the letters of credit. (see Note 10).

Investments

Investments

Short-term investments consist primarily of high-grade commercial paper and corporate bonds. The Company classifies marketable securities available to fund current operations as short-term investments in current assets on its consolidated balance sheets. Marketable securities are classified as long-term investments in long-term assets on the consolidated balance sheets if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all its investments as available-for-sale. Available-for-sale securities are recorded at the fair value of the investments based on quoted market prices.

Unrealized holding gains and losses on available-for-sale securities, which are determined to be temporary, are excluded from earnings and are reported as a separate component of accumulated other comprehensive loss.

Premiums and discounts on investments are amortized over the life of the related available-for-sale security as an adjustment to yield using the effective‑interest method. Dividend and interest income are recognized when earned. Amortized premiums and discounts, dividend and interest income are included in interest income. Realized gains and losses are included in other income.

Other Comprehensive Income (Loss)

Other Comprehensive Income (Loss)

The Company’s other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale securities and adjustments for foreign currency translation and is recorded and presented net of income tax. There was no income tax allocated to the foreign currency translation adjustment in Other Comprehensive Income (Loss) for the period ended December 31, 2018 and 2017. The cumulative foreign currency translation adjustment reported in Other Comprehensive Income (Loss) was $(3.9) million and $19.8 million for the period ended December 31, 2018 and 2017, respectively.

Inventory

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company's products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Cost is determined using the first-in, first-out method (FIFO) for all inventories. The Company’s inventory primarily consisted of finished goods as of December 31, 2018 and 2017. The Company establishes reserves as necessary for obsolescence and excess inventory. The Company records a reserve for excess and obsolete inventory based on the expected future product sales volumes and the projected expiration of inventory and specifically identified obsolete inventory. The Company recorded a charge for excess and obsolete inventory of $8.4 million and $0.7 million for the years ended December 31, 2018 and 2017, respectively.

Ampyra

The cost of Ampyra inventory manufactured by Alkermes plc (Alkermes) is based on agreed upon pricing with Alkermes. In the event Alkermes does not manufacture the products, Alkermes is entitled to a compensating payment for the quantities of product provided by Patheon, the Company’s alternative manufacturer. This compensating payment is included in the Company’s inventory balances.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation, except for assets acquired in a business combination, which are recorded at fair value as of the acquisition date. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which ranges from one to seven years. Leasehold improvements are recorded at cost, less accumulated amortization, which is computed on a straight-line basis over the shorter of the useful lives of the assets or the remaining lease term. Expenditures for maintenance and repairs are charged to expense as incurred.

Goodwill

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired in a business combination accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. We perform our impairment testing at the reporting unit level where we have determined that we have a single reporting unit and operating segment. We test goodwill for impairment using a quantitative method (primarily based on market capitalization). The impairment test for goodwill uses a two-step approach. Step one compares the estimated fair value of the reporting unit including goodwill to its carrying value. If the carrying value of the reporting unit exceeds the estimated fair value of the reporting unit, step two must be performed. Step two compares the carrying value of the reporting unit to the fair value of all of the assets and liabilities of the reporting unit as if the reporting unit was acquired in a business combination. If the carrying value of the reporting unit’s goodwill exceeds the implied fair value of its goodwill calculated in this manner, an impairment loss is recognized in an amount equal to the excess of the carrying value over the implied fair value. See Note 4 for a discussion of goodwill.

Intangible Assets

Intangible Assets

In Process Research and Development

The Company has indefinite lived intangible assets for the value of acquired in-process research and development. The cost of in-process research and development (IPR&D) acquired directly in a transaction other than a business combination is capitalized if the project will be further developed or have an alternative future use; otherwise it is expensed. The estimated fair value of IPR&D projects acquired in a business combination is capitalized. Several methods may be used to determine the estimated fair value of the IPR&D assets acquired in a business combination. The Company utilizes the "income method” which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, estimated pricing and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or impaired, as appropriate. These assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Events that could result in an impairment, or trigger an interim impairment assessment, may include actions by regulatory authorities with respect to us or our competitors, the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug which could have a negative effect on cash flows and which could result in an impairment. If impairment indicators are present or changes in circumstance suggest that an impairment may exist, we perform an impairment analysis by comparing the sum of the estimated discounted future cash flows, or fair value, of each intangible asset to its carrying value on the consolidated balance sheet. We will recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value.

Finite-Lived Intangible Assets

The Company has finite lived intangible assets that are amortized on a straight line basis over the period in which the Company expects to receive economic benefit and are reviewed for impairment when facts and circumstances indicate that the carrying value of the asset may not be recoverable. The determination of the expected life will be dependent upon the use and underlying characteristics of the intangible asset. In the Company’s evaluation of the intangible assets, it considers the term of the underlying asset life and the expected life of the related product line. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the intangible asset and recognize an impairment loss in the statement of operations if the carrying value of the intangible asset exceeds its fair value. Fair value is generally estimated based on either appraised value or other valuation techniques. Events that could result in an impairment, or trigger an interim impairment assessment, may include actions by regulatory authorities with respect to us or our competitors, new or better products entering the market, changes in market share or market pricing, changes in the economic lives of the assets, changes in the legal framework covering patents, rights or licenses, and other market changes which could have a negative effect on cash flows and which could result in an impairment.

Contingent Consideration

Contingent Consideration

The Company may record contingent consideration as part of the cost of business acquisitions. Contingent consideration is recognized at fair value as of the date of acquisition and recorded as a liability on the consolidated balance sheet. The contingent consideration is re-valued on a quarterly basis using a probability weighted discounted cash-flow approach until fulfillment or expiration of the contingency. Changes in the fair value of the contingent consideration are recognized in the statement of operations. See Note 16 for discussion on the Alkermes ARCUS agreement.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful lives of its long-lived assets may warrant revision or that the carrying value of the assets may be impaired. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related assets. Any write‑downs are treated as permanent reductions in the carrying amount of the assets.

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties

As of October 1, 2017, the Company completed a royalty purchase agreement with HealthCare Royalty Partners, or HCRP (“Royalty Agreement”). In exchange for the payment of $40 million to the Company, HCRP obtained the right to receive Fampyra royalties payable by Biogen under the Collaboration and Licensing Agreement between the Company and Biogen, up to an agreed upon threshold of royalties. When this threshold is met, if ever, the Fampyra royalty revenue will revert back to the Company and the Company will continue to receive the Fampyra royalty revenue from Biogen until the revenue stream ends. The transaction does not include potential future milestones to be paid by Biogen to Acorda.

The Company maintained the rights under the license and collaboration agreement with Biogen, therefore, the Royalty Agreement has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement, in accordance with the relevant accounting guidance. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future net royalty payments to be made to HCRP over the term of the agreement up to the agreed upon threshold of royalties. The total threshold of net royalties to be paid, less the net proceeds received will be recorded as interest expense over the life of the liability. The Company imputes interest on the unamortized portion of the liability using the effective interest method and records interest expense based on the timing of the payments received over the term of the royalty agreement. The Company’s estimate of the interest rate under the arrangement is based on forecasted net royalty payments expected to be made to HCRP over the life of the royalty agreement. The Company estimated an effective annual interest rate of approximately 15%. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of net royalty revenue recognized and changes in forecasted revenue. On a quarterly basis, the Company will reassess the effective interest rate and adjust the rate prospectively as required. Non-cash royalty revenue is reflected as royalty revenue and non-cash interest expense is reflected as interest and amortization of debt discount expense in the Statement of Operations.

Patent Costs

Patent Costs

Patent application and maintenance costs are expensed as incurred.

Research and Development

Research and Development

Research and development expenses include the costs associated with the Company’s internal research and development activities, including salaries and benefits, occupancy costs, and research and development conducted for it by third parties, such as contract research organizations (CROs), sponsored university-based research, clinical trials, contract manufacturing for its research and development programs, and regulatory expenses. In addition, research and development expenses include the cost of clinical trial drug supply shipped to the Company’s clinical study vendors. For those studies that the Company administers itself, the Company accounts for its clinical study costs by estimating the patient cost per visit in each clinical trial and recognizes this cost as visits occur, beginning when the patient enrolls in the trial. This estimated cost includes payments to the trial site and patient-related costs, including laboratory costs related to the conduct of the trial. Cost per patient varies based on the type of clinical trial, the site of the clinical trial, and the length of the treatment period for each patient. For those studies for which the Company uses a CRO, the Company accounts for its clinical study costs according to the terms of the CRO contract. These costs include upfront, milestone and monthly expenses as well as reimbursement for pass through costs. As actual costs become known to the Company, it adjusts the accrual; such changes in estimate may be a material change in its clinical study accrual, which could also materially affect its results of operations. All research and development costs are expensed as incurred except when accounting for nonrefundable advance payments for goods or services to be used in future research and development activities. These payments are capitalized at the time of payment and expensed ratably over the period the research and development activity is performed.

Accounting for Income Taxes

Accounting for Income Taxes

The Company provides for income taxes in accordance with ASC Topic 740 (ASC 740). Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance for the amounts of any tax benefits which, more likely than not, will not be realized.

In determining whether a tax position is recognized for financial statement purposes, a two-step process is utilized whereby the threshold for recognition is a more likely-than-not test that the tax position will be sustained upon examination and the tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Revenue Recognition

Revenue Recognition

On January 1, 2018, the Company adopted the new accounting standard ASC 606, “Revenue from Contracts with Customers” (Topic 606) (“ASC 606”) and the related amendments to all contracts with customers that were not completed as of the date of adoption using the modified retrospective method. ASC 606 supersedes prior revenue guidance under ASC 605 “Revenue Recognition” (“ASC 605”) and requires entities to recognize revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company completed its assessment of the new guidance and evaluated the new requirements as applied to its existing revenue contracts not completed as of the date of initial application. As a result of the assessment, with the exception of the changes to our recognition of license revenue as further described below, the Company determined that adoption of the new standard did not have a significant impact on its revenue recognition methodology. In accordance with ASC 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the good or service.

The Company determined that the revenue recognition methodology for the deferred license revenue changed as a result of the adoption of ASC 606. License revenue recorded by the Company prior to January 1, 2018 related exclusively to the recognition of the upfront payment received from Biogen upon the execution of the License and Collaboration agreement that granted Biogen an exclusive non sub-licensable license to sell Fampyra outside of the U.S. License revenue recorded prior to January 1, 2018 was recognized under ASC 605 on a pro rata basis as the Company’s obligations were satisfied throughout the duration of the license and collaboration agreement. As of January 1, 2018, the Company adopted ASC 606 which changed the Company’s determination of its distinct performance obligations resulting in an acceleration of the recognition of the revenue in the arrangement. The material performance obligations were completed prior to January 1, 2018, and as a result, the Company recognized its previously deferred license revenue and the associated deferred costs as a cumulative effect adjustment of $27.6 million within the accumulated deficit on the consolidated balance sheet as of January 1, 2018.

 

The cumulative effect of applying ASC 606 to the company’s consolidated balance sheet was as follows:

(In thousands)

 

Balance as of December 31, 2017

 

 

Net Adjustments

 

 

Balance as of

January 1, 2018

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

1,983

 

 

$

(634

)

 

$

1,349

 

Non-current portion of deferred cost of license revenue

 

 

1,638

 

 

 

(1,638

)

 

 

 

    Total Assets

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

23,398

 

 

 

(23,398

)

 

 

 

Deferred tax liability

 

 

22,459

 

 

 

2,600

 

 

 

25,059

 

Accumulated deficit

 

 

(455,108

)

 

 

27,583

 

 

 

(427,525

)

    Total liabilities and stockholders' equity

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

 

The impact of the adoption of ASC 606 on the Company’s consolidated balance sheet as of December 31, 2018 was as follows:

(In thousands)

 

Balance as of

December 31, 2018

Prior to Adoption

of ASC 606

 

 

Net Adjustments

 

 

Balance as of

December 31, 2018

as Reported

Under ASC 606

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

10,828

 

 

$

(634

)

 

$

10,194

 

Non-current portion of deferred cost of license revenue

 

 

1,004

 

 

 

(1,004

)

 

 

 

    Total Assets

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

14,341

 

 

 

(14,341

)

 

 

 

Deferred tax liability

 

 

6,988

 

 

 

495

 

 

 

7,483

 

Accumulated deficit

 

 

(415,108

)

 

 

21,265

 

 

 

(393,843

)

    Total liabilities and stockholders' equity

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

 

The impact of the adoption of ASC 606 on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:

(In thousands)

 

Year Ended December 31, 2018

Balance Prior to

Adoption of ASC 606

 

 

Effect of Change

 

 

Year Ended December 31, 2018

Balance as Reported

Under ASC 606

 

License revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Cost of license revenue

 

 

634

 

 

 

(634

)

 

 

 

Operating income (loss)

 

$

46,909

 

 

$

(8,423

)

 

$

38,486

 

(Benefit from) provision for income taxes

 

 

(15,364

)

 

 

2,105

 

 

 

(13,259

)

Net income (loss)

 

$

40,000

 

 

$

(6,318

)

 

$

33,682

 

Net income (loss) per share—basic

 

$

0.85

 

 

$

(0.13

)

 

$

0.72

 

Net income (loss) per share—diluted

 

$

0.84

 

 

$

(0.13

)

 

$

0.71

 

 

ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities.

ASC 606 outlines a five-step process for recognizing revenue from contracts with customers: i) identify the contract with the customer, ii) identify the performance obligations in the contract, (iii) determine the transaction price, iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company determines the performance obligations that are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to each respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon receipt of the product by the customer.

ASC 606 requires entities to record a contract asset when a performance obligation has been satisfied or partially satisfied, but the amount of consideration has not yet been received because the receipt of the consideration is conditioned on something other than the passage of time. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g. receivable), before the entity transfers a good or service to the customer. We did not have any contract assets or liabilities as of December 31, 2018.

Product Revenue, Net

Ampyra

Ampyra is available primarily through a network of specialty pharmacy providers that provide the medication to patients by mail and ASD Specialty Healthcare, Inc. (an AmerisourceBergen affiliate), which distributes Ampyra to the U.S. Bureau of Prisons, the U.S. Department of Defense, the U.S. Department of Veterans Affairs, or VA, and other federal agencies.

Qutenza

Prior to the sale of Qutenza assets, Qutenza was distributed in the U.S. by Besse Medical, Inc., a specialty distributor that furnishes the medication to physician offices; and by ASD Specialty Healthcare, Inc., a specialty distributor that furnishes the medication to hospitals and clinics.

Net revenue from product sales is recognized at the transaction price when the customer obtains control of the Company’s products, which occurs at a point in time, typically upon receipt of the product by the customer. The Company’s products are sold primarily to a network of specialty providers which are contractually obligated to hold no more than an agreed upon number of days of inventory. The Company’s payment terms are between 30 to 35 days.

The Company’s net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded for the Company’s estimate of cash consideration expected to be given by the Company to a customer that is presumed to be a reduction of the transaction price of the Company’s products and, therefore, are characterized as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remaining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.

Discounts and Allowances

Revenue from product sales are recorded at the transaction price, which includes estimates for discounts and allowances for which reserves are established and includes cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. Actual discounts and allowances are recorded following shipment of product and the appropriate reserves are credited. These reserves are classified as reductions of accounts receivable (if the amount is payable to the Customer and right of offset exists) or a current liability (if the amount is payable to a party other than a Customer). These allowances are established by management as its best estimate based on historical experience and data points available and are adjusted to reflect known changes in the factors that impact such reserves. Allowances for customer credits, chargebacks, rebates, data fees and wholesaler fees for services, returns, and discounts are established based on contractual terms with customers and analyses of historical usage of these items. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The nature of our allowances and accruals requiring critical estimates, and the specific considerations it uses in estimating their amounts are as follows:

Government Chargebacks and Rebates: We contract for Medicaid and other U.S. Federal government programs to allow for our products to remain eligible for reimbursement under these programs. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. Based upon our contracts and the most recent experience with respect to sales through each of these channels, we provide an allowance for chargebacks and rebates. We monitor the sales trends and adjust the chargeback and rebate percentages on a regular basis to reflect the most recent chargebacks and rebate experience. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Managed Care Contract Rebates: We contract with various managed care organizations including health insurance companies and pharmacy benefit managers. These contracts stipulate that rebates and, in some cases, administrative fees, are paid to these organizations provided our product is placed on a specific tier on the organization’s drug formulary. Based upon our contracts and the most recent experience with respect to sales through managed care channels, we provide an allowance for managed care contract rebates. We monitor the sales trends and adjust the allowance on a regular basis to reflect the most recent rebate experience. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Copay Mitigation Rebates: We offer copay mitigation to commercially insured patients who have coverage for our products (in accordance with applicable law) and are responsible for a cost share. Based upon our contracts and the most recent experience with respect to actual copay assistance provided, we provide an allowance for copay mitigation rebates. We monitor the sales trends and adjust the rebate percentages on a regular basis to reflect the most recent rebate experience.

Cash Discounts: We sell directly to companies in our distribution network, which primarily includes specialty pharmacies and ASD Specialty Healthcare, Inc. We generally provide invoice discounts for prompt payment for our products. We estimate our cash discounts based on the terms offered to our customers. Discounts are estimated based on rates that are explicitly stated in the Company’s contracts as it is expected they will take the discount and are recorded as a reduction of revenue at the time of product shipment when product revenue is recognized. We adjust estimates based on actual activity as necessary.

Product Returns: We offer no right of return except for products damaged in shipping to Ampyra customers or a limited right of return based on the product’s expiration date to previous Zanaflex customers. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The company currently estimates product return liabilities using historical sales information and inventory remaining in the distribution channel.

Data Fees and Fees for Services Payable to Specialty Pharmacies: We have contracted with certain specialty pharmacies to obtain transactional data related to our products in order to develop a better understanding of our selling channel as well as patient activity and utilization by the Medicaid program and other government agencies and managed care organizations. We pay a variable fee to the specialty pharmacies to provide us the data. We also pay the specialty pharmacies a fee in exchange for providing distribution and inventory management services, including the provision of inventory management data to the Company. We estimate our fee for service accruals and allowances based on sales to each specialty pharmacy and the applicable contracted rate.

Royalty Revenue

Royalty revenue recorded by the Company relates exclusively to the Company’s License and Collaboration agreement with Biogen which provides for ongoing royalties based on sales of Fampyra outside of the U.S. The Company recognizes revenue for royalties under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the following: 1) sale or usage of the products or 2) satisfaction of the performance obligations. The Company has satisfied its performance obligations and therefore recognizes royalty revenue when the sales to which the royalties relate are completed.

License Revenue

License revenue relates to the License and Collaboration agreement with Biogen which provides for milestone payments for the achievement of certain regulatory and sales milestones during the term of the agreement. Regulatory milestones are contingent upon the approval of Fampyra for new indications outside of the U.S. Sales milestones are contingent upon the achievement of certain net sales targets for Fampyra sales outside of the U.S. The Company recognizes license revenue under ASC 606, which provides constraints for entities to recognize license revenue which is deemed to be variable by requiring the Company to estimate the amount of consideration to which it is entitled in exchange for transferring the promised goods or services to a customer. The Company recognizes an estimate of revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the milestone is achieved. For regulatory milestones, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. For sales-based milestones, the Company recognizes revenue upon the achievement of the specific sale milestones. The Company did not recognize any license revenue related to milestones for the years ended December 31, 2018, 2017 or 2016.

The following table disaggregates our revenue by major source (in thousands):

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Net product revenues

 

$

459,739

 

 

$

549,749

 

 

$

493,358

 

Royalty revenues

 

$

11,694

 

 

 

29,481

 

 

$

17,186

 

License revenue

 

$

 

 

 

9,057

 

 

$

9,057

 

Total net revenues

 

$

471,433

 

 

$

588,287

 

 

$

519,601

 

 

Concentration of Risk

Concentration of Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of investments in cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company does not require any collateral for its accounts receivable. The Company maintains cash, cash equivalents and restricted cash with approved financial institutions. The Company is exposed to credit risks and liquidity in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

The Company does not own or operate, and currently does not plan to own or operate, facilities for production and packaging of Ampyra or its other commercial product Qutenza. It relies and expects to continue to rely on third parties for the production and packaging of its commercial products and clinical trial materials for all of its products except Inbrija. The Company leases a manufacturing facility in Chelsea, Massachusetts which produces Inbrija for clinical trials and commercial supply.

The Company relies primarily on Alkermes for its supply of Ampyra. Under its supply agreement with Alkermes, the Company is obligated to purchase at least 75% of its yearly supply of Ampyra from Alkermes, and it is required to make compensatory payments if it does not purchase 100% of its requirements from Alkermes, subject to certain specified exceptions. The Company and Alkermes have agreed that the Company may purchase up to 25% of its annual requirements from Patheon, a mutually agreed-upon second manufacturing source, with compensatory payment. The Company and Alkermes also rely on a single third-party manufacturer, Regis, to supply dalfampridine, the active pharmaceutical ingredient, or API, in Ampyra. If Regis experiences any disruption in their operations, a delay or interruption in the supply of Ampyra product could result until Regis cures the problem or it locates an alternate source of supply.

The Company’s principal direct customers as of December 31, 2018 were a network of specialty pharmacies and ASD Specialty Healthcare, Inc. for Ampyra. The Company periodically assesses the financial strength of these customers and establishes allowances for anticipated losses, if necessary. Four customers individually accounted for more than 10% of the Company’s revenue or approximately 81% of total revenue in 2018. Four and Three customers individually accounted for more than 10% of the Company’s revenue in 2017 and 2016, respectively. Five customers individually accounted for more than 10% of the Company’s accounts receivable or approximately 88% of total accounts receivable as of December 31, 2018. Four customers individually accounted for more than 10% of the Company’s accounts receivable or approximately 69% of total accounts receivable as of December 31, 2017. The Company’s net product revenues are generated in the U.S.

Allowance for Cash Discounts

Allowance for Cash Discounts

An allowance for cash discounts is accrued based on historical usage rates at the time of product shipment. The Company adjusts accruals based on actual activity as necessary. Cash discounts are typically settled with customers within 34 days after the end of each calendar month. The Company provided cash discount allowances of $6.4 million and $6.9 million for the years ended December 31, 2018 and 2017, respectively. The Company’s reserve for cash discount allowances were $0.4 million and $0.8 million as of December 31, 2018 and 2017, respectively.

(in thousands)

 

Cash

discounts

 

Balance at December 31, 2016

 

$

594

 

Allowances for sales

 

 

6,898

 

Actual credits

 

 

(6,648

)

Balance at December 31, 2017

 

$

844

 

Allowances for sales

 

 

6,371

 

Actual credits

 

 

(6,820

)

Balance at December 31, 2018

 

$

395

 

 

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

A portion of the Company’s accounts receivable may not be collected. The Company provides reserves based on an evaluation of the aging of its trade receivable portfolio and an analysis of high-risk customers. The Company has not historically experienced material losses related to credit risk. The Company had no recognized allowance for doubtful accounts as of December 31, 2018 or December 31, 2017. There were no provisions and write-offs for the years ended December 31, 2018 and 2017. 

Allowance for Chargebacks

Allowance for Chargebacks

Based upon the Company’s contracts and the most recent experience with respect to sales with the US government, the Company provides an allowance for chargebacks. The Company monitors the sales trends and adjusts the chargebacks on a regular basis to reflect the most recent chargebacks experience. The Company recorded a charge of $18.9 million for the year ended December 31, 2018 for allowance related to chargebacks. The Company did not record any allowance for chargebacks for the year ended December 31, 2017. The Company made a payment of $16.7 million related to the chargebacks allowances for the year ended December 31, 2018. The Company’s reserve for chargebacks allowance was $2.2 million as of December 31, 2018.

Contingencies

Contingencies

The Company accrues for amounts related to legal matters if it is probable that a liability has been incurred and the amount is reasonably estimable. Litigation expenses are expensed as incurred.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. Significant differences can arise between the fair value and carrying amounts of financial instruments that are recognized at historical cost amounts. The Company considers that fair value should be based on the assumptions market participants would use when pricing the asset or liability.

The following methods are used to estimate the fair value of the Company’s financial instruments:

 

(a)

Cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these instruments;

 

(b)

Short-term investments are recorded based primarily on quoted market prices;

 

(c)

Acquired contingent consideration related to the Civitas acquisition is measured at fair value using a probability weighted, discounted cash flow approach;

 

(d)

Convertible Senior Notes were measured at fair value based on market quoted prices of the debt securities; and

 

(e)

Capital and R&D loans were measured at fair value based on a discounted cash flow approach.

Earnings per Share

Earnings per Share

Basic net income (loss) per share and diluted net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding during the period plus the effect of additional weighted average common equivalent shares outstanding during the period when the effect of adding such shares is dilutive. Common equivalent shares result from the assumed exercise of outstanding stock options (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury stock method), the vesting of restricted stock and the potential dilutive effects of the conversion option on the Company’s convertible debt. In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options that are in-the-money. This results in the “assumed” buyback of additional shares, thereby reducing the dilutive impact of stock options. See Note 18 for discussion on earnings (loss) per share.

Share-based Compensation

Share‑based Compensation

The Company has various share‑based employee and non-employee compensation plans, which are described more fully in Note 10.

The Company accounts for stock options and restricted stock granted to employees and non-employees by recognizing the costs resulting from all share-based payment transactions in the consolidated financial statements at their fair values. The Company estimates the fair value of each option on the date of grant using the Black‑Scholes closed-form option‑pricing model based on assumptions of expected volatility of its common stock, prevailing interest rates, an estimated forfeiture rate, and the expected term of the stock options, and the Company recognizes that cost as an expense ratably over the associated service period.

Foreign Currency Translation

Foreign Currency Translation

The functional currency of operations outside the United States of America is deemed to be the currency of the local country, unless otherwise determined that the United States dollar would serve as a more appropriate functional currency given the economic operations of the entity. Accordingly, the assets and liabilities of the Company’s foreign subsidiary, Biotie, are translated into United States dollars using the period-end exchange rate; and income and expense items are translated using the average exchange rate during the period; and equity transactions are translated at historical rates. Cumulative translation adjustments are reflected as a separate component of equity. Foreign currency transaction gains and losses are charged to operations.

Segment and Geographic Information

Segment and Geographic Information

The Company is managed and operated as one business which is focused on developing therapies that restore function and improve the lives of people with neurological disorders. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information to allocate resources to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment. Net product revenues reported to date are derived from the sales of Amypra and Qutenza in the U.S. for the year ended December 31, 2018 and Ampyra, Zanaflex and Qutenza in the U.S. for the years ended December 31, 2017 and 2016.

Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

Unrealized gains (losses) from the Company’s investment securities and adjustments for foreign currency translation are included in accumulated other comprehensive income within the consolidated balance sheet.

Recent Accounting Pronouncements - Adopted

Recent Accounting Pronouncements - Adopted

As noted above, in May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers” (Topic 606). This new standard replaced all previous U.S. GAAP guidance on this topic and eliminated all industry-specific guidance. The new standard requires the application of a five-step model to determine the amount and timing of revenue to be recognized. The underlying principle is that revenue is to be recognized for the transfer of goods or services to customers that reflects the amount of consideration that the Company expects to be entitled to in exchange for those goods or services. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. See discussion of the adoption above in Revenue Recognition.

In November 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows” (Topic 230); Restricted Cash (ASU 2016-18), which defines new requirements for the presentation of restricted cash and restricted cash equivalents in the statement of cash flows. The amendments in this ASU require retrospective application to each period presented. The Company adopted this guidance effective January 1, 2018 retrospectively. This ASU requires entities to present the statement of cash flows in a manner such that it reconciles beginning and ending totals of cash, cash equivalents, restricted cash or restricted cash equivalents. Also, when cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity should, for each period that a statement of financial position is presented, present on the face of the statement of cash flows or disclose in the notes to the financial statements, the line items and amounts of cash, cash equivalents, and restricted cash or restricted cash equivalents reported within the statement of financial position. The amounts, disaggregated by the line item in which they appear within the statement of financial position, shall sum to the total amount of cash, cash equivalents, and restricted cash or restricted cash equivalents at the end of the corresponding period shown in the statement of cash flows.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same amounts shown in the statement of cash flows:

 

 

December 31, 2018

 

 

December 31, 2017

 

 

December 31, 2016

 

(In thousands)

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

Cash and cash equivalents

 

$

307,068

 

 

$

293,564

 

 

$

158,537

 

 

$

307,068

 

 

$

153,204

 

 

$

158,537

 

Restricted cash

 

 

410

 

 

 

532

 

 

 

79

 

 

 

410

 

 

 

6,031

 

 

 

79

 

Restricted cash included in Other assets

 

 

560

 

 

 

255

 

 

 

255

 

 

 

560

 

 

 

 

 

 

255

 

Total Cash, cash equivalents and restricted cash per statement of cash flows

 

$

308,038

 

 

$

294,351

 

 

$

158,871

 

 

$

308,038

 

 

$

159,235

 

 

$

158,871

 

Amounts included in restricted cash represent those amounts required to be set aside to cover the Company’s self-funded employee health insurance. Restricted cash included in other assets on the statement of financial position relates to cash collateralized standby letters of credit in connection with obligations under facility leases, which is included with other assets in the consolidated balance sheet due to the long-term nature of the letters of credit.

In January 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” The main objective of this update is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The new guidance addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In August 2016, the FASB issued Accounting Standards Update ASU 2016-15 “Statement of Cash Flows” (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15), which specifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU requires retrospective application to all periods presented. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued Accounting Standards Update 2017-01, “Business Combinations” (Topic 805): Clarifying the Definition of a Business (ASU 2017-01), which provides additional clarification to aid in determining when a set of assets and activities is not a business. The amendments in this update require prospective applications. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued Accounting Standards Update 2017-09, “Compensation – Stock Compensation” (Topic 718): Scope of Modification Accounting (ASU 2017-09). This new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 allows for prospective application and is effective for fiscal years beginning after December 15, 2017, and interim periods therein with early adoption permitted for interim or annual periods. The Company adopted this guidance effective January 1, 2018. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements with employees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. ASC 505-50, before the amendments, differed significantly from ASC 718. However, FASB concluded that awards granted to employees are economically similar to awards granted to nonemployees and therefore two different accounting models were not justified. This ASU is effective for fiscal years beginning after December 15, 2018, and interim periods therein with early adoption permitted. The Company early adopted this guidance beginning April 1, 2018. The adoption of this guidance did not have an impact on its consolidated financial statements.   

In March 2018, the FASB issued ASU 2018-05, “Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118’. The ASU adds seven paragraphs to ASC 740, Income Taxes, that contain SEC guidance related to SAB 118 (codified as SEC SAB Topic 5.EE, “Income Tax Accounting Implications of the Tax Cuts and Jobs Act”), which provides guidance for companies that are not able to complete their accounting for the income tax effects of the Tax Cuts and Jobs Act in the period of enactment which is the period that includes December 22, 2017. The measurement period should not extend beyond one year from the enactment date. The Company completed its accounting for the income tax effects for the year ended December 31, 2018. See note 17 for a discussion of the impact of the guidance on the Company’s consolidated financial statements.

Recent Accounting Pronouncements - Not Yet Adopted

Recent Accounting Pronouncements – Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842). The main objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; ASU No. 2018-11, Targeted Improvements and ASU No. 2018-20, Narrow-Scope Improvements for Lessors. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement.

This ASU is effective for the Company on January 1, 2019. We expect to adopt the new standard on its effective date. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. We expect to adopt the new standard on January 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019.

The new standard provides a number of optional practical expedients in transition. We expect to elect the ‘package of practical expedients’, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We do not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.

While we continue to assess all of the effects of adoption, we currently believe the most significant effects relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate operating leases and (2) providing significant new disclosures for our leasing activities.

The new standard also provides practical expedients and certain exemptions for an entity’s ongoing accounting. We currently expect to elect the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. We also currently expect to elect the practical expedient to not separate lease and non-lease components for all of our leases. We have determined the completeness of our lease population as of January 1, 2019. We expect to complete our assessment of the full financial impact of ASC 842 during the first quarter of 2019, and will include all required presentation and disclosures under ASC 842 in our Form 10-Q for the three months ending March 31, 2019.

In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04). This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 allows for prospective application and is effective for fiscal years beginning after December 15, 2019, and interim periods therein with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating whether it will adopt this guidance early. The Company does not expect the adoption of this guidance to have a significant impact on its consolidated financial statements.

In February 2018, the FASB issued ASU 2018-02, ‘Income Statement—Reporting Comprehensive Income’ (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02). This new standard provides entities with an option to reclassify stranded tax effects within AOCI to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act (or portion thereof) is recorded. ASC 740-10-35-4 requires that deferred tax assets and liabilities should be adjusted to account for any changes in tax laws or rates within the period that the enactment of these changes occurs and any adjustments to flow through income from continuing operations. Since the adjustments due to the Tax Cuts and Jobs Act are required to flow through income from continuing operations, the tax effects of items within accumulated other comprehensive income known now as “stranded tax effects,” do not reflect the appropriate tax rate. As such, FASB issued ASU 2018-02, in order to address these stranded income tax effects. The new standard requires entities to disclose the following:

 

A description of the accounting policy for releasing income tax effects from AOCI;

 

Whether they elect to reclassify the stranded income tax effects from the Tax Cuts and Jobs Act, and

 

Information about the other income tax effects that are reclassified.

 

The ASU is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In July 2018, the FASB issued ASU 2018-09, “Codification Improvements.” The ASU’s amendments clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2018-09 are not expected to have a significant effect on current accounting practices. Some of the amendments in this update do not require transition guidance and will be effective upon issuance of this update. However, many of the amendments in this update do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. The Company does not expect this ASU to have a significant impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 “Fair Value Measurement (Topic 820): “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The amendments in this ASU eliminate, add and modify certain disclosure requirements for fair value measurements as part of its disclosure framework project. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public business entities will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The ASU clarifies certain aspects of ASU 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which was issued in April 2015. Specifically, the ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).” The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

In August 2018, the Securities Exchange Commission (“SEC”) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. The Company anticipates its first presentation of changes in stockholders’ equity as required under the new SEC guidance will be included in its Form 10-Q for the three-month period ended March 31, 2019.

In November 2018, the FASB issued ASU 2018-18, Collaborative arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The ASU is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company is currently evaluating the impact it may have on its consolidated financial statements.

Subsequent Events

Subsequent Events

Subsequent events are defined as those events or transactions that occur after the balance sheet date, but before the financial statements are filed with the Securities and Exchange Commission. The Company completed an evaluation of the impact of any subsequent events through the date these financial statements were issued, and determined there were no subsequent events that required disclosure in our financial statements.

v3.10.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2018
Disaggregation of Revenue

The following table disaggregates our revenue by major source (in thousands):

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

Year ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Net product revenues

 

$

459,739

 

 

$

549,749

 

 

$

493,358

 

Royalty revenues

 

$

11,694

 

 

 

29,481

 

 

$

17,186

 

License revenue

 

$

 

 

 

9,057

 

 

$

9,057

 

Total net revenues

 

$

471,433

 

 

$

588,287

 

 

$

519,601

 

Summary of Allowance for Cash Discounts

(in thousands)

 

Cash

discounts

 

Balance at December 31, 2016

 

$

594

 

Allowances for sales

 

 

6,898

 

Actual credits

 

 

(6,648

)

Balance at December 31, 2017

 

$

844

 

Allowances for sales

 

 

6,371

 

Actual credits

 

 

(6,820

)

Balance at December 31, 2018

 

$

395

 

 

Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same amounts shown in the statement of cash flows:

 

 

December 31, 2018

 

 

December 31, 2017

 

 

December 31, 2016

 

(In thousands)

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

 

Beginning of period

 

 

End of period

 

Cash and cash equivalents

 

$

307,068

 

 

$

293,564

 

 

$

158,537

 

 

$

307,068

 

 

$

153,204

 

 

$

158,537

 

Restricted cash

 

 

410

 

 

 

532

 

 

 

79

 

 

 

410

 

 

 

6,031

 

 

 

79

 

Restricted cash included in Other assets

 

 

560

 

 

 

255

 

 

 

255

 

 

 

560

 

 

 

 

 

 

255

 

Total Cash, cash equivalents and restricted cash per statement of cash flows

 

$

308,038

 

 

$

294,351

 

 

$

158,871

 

 

$

308,038

 

 

$

159,235

 

 

$

158,871

 

ASC 606  
Cumulative Effect and Impact of Adoption of ASC 606 on Consolidated Balance Sheet And Consolidated Statement Of Operations

The cumulative effect of applying ASC 606 to the company’s consolidated balance sheet was as follows:

(In thousands)

 

Balance as of December 31, 2017

 

 

Net Adjustments

 

 

Balance as of

January 1, 2018

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

1,983

 

 

$

(634

)

 

$

1,349

 

Non-current portion of deferred cost of license revenue

 

 

1,638

 

 

 

(1,638

)

 

 

 

    Total Assets

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

23,398

 

 

 

(23,398

)

 

 

 

Deferred tax liability

 

 

22,459

 

 

 

2,600

 

 

 

25,059

 

Accumulated deficit

 

 

(455,108

)

 

 

27,583

 

 

 

(427,525

)

    Total liabilities and stockholders' equity

 

$

1,197,969

 

 

$

(2,272

)

 

$

1,195,697

 

The impact of the adoption of ASC 606 on the Company’s consolidated balance sheet as of December 31, 2018 was as follows:

(In thousands)

 

Balance as of

December 31, 2018

Prior to Adoption

of ASC 606

 

 

Net Adjustments

 

 

Balance as of

December 31, 2018

as Reported

Under ASC 606

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Other current assets

 

$

10,828

 

 

$

(634

)

 

$

10,194

 

Non-current portion of deferred cost of license revenue

 

 

1,004

 

 

 

(1,004

)

 

 

 

    Total Assets

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

Current portion of deferred license revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Non-current portion of deferred license revenue

 

 

14,341

 

 

 

(14,341

)

 

 

 

Deferred tax liability

 

 

6,988

 

 

 

495

 

 

 

7,483

 

Accumulated deficit

 

 

(415,108

)

 

 

21,265

 

 

 

(393,843

)

    Total liabilities and stockholders' equity

 

$

1,301,304

 

 

$

(1,638

)

 

$

1,299,666

 

The impact of the adoption of ASC 606 on the Company’s consolidated statement of operations for the year ended December 31, 2018 was as follows:

(In thousands)

 

Year Ended December 31, 2018

Balance Prior to

Adoption of ASC 606

 

 

Effect of Change

 

 

Year Ended December 31, 2018

Balance as Reported

Under ASC 606

 

License revenue

 

$

9,057

 

 

$

(9,057

)

 

$

 

Cost of license revenue

 

 

634

 

 

 

(634

)

 

 

 

Operating income (loss)

 

$

46,909

 

 

$

(8,423

)

 

$

38,486

 

(Benefit from) provision for income taxes

 

 

(15,364

)

 

 

2,105

 

 

 

(13,259

)

Net income (loss)

 

$

40,000

 

 

$

(6,318

)

 

$

33,682

 

Net income (loss) per share—basic

 

$

0.85

 

 

$

(0.13

)

 

$

0.72

 

Net income (loss) per share—diluted

 

$

0.84

 

 

$

(0.13

)

 

$

0.71

 

v3.10.0.1
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2018
Business Combinations [Abstract]  
Schedule of Final Allocation of Purchase Price to Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table presents the final allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

 

(In thousands)

 

Preliminary Allocation, as adjusted through

December 31, 2016

 

 

Measurement

Period

Adjustments

 

 

Final Allocation, as of April 18, 2017

 

Cash and cash equivalents

 

$

73,854

 

 

$

 

 

$

73,854

 

Other current assets

 

 

1,878

 

 

 

 

 

 

1,878

 

Other long-term assets

 

 

4,962

 

 

 

 

 

 

4,962

 

Intangible assets (indefinite-lived)

 

 

260,500

 

 

 

 

 

 

260,500

 

Intangible assets (definite-lived)

 

 

65,000

 

 

 

 

 

 

65,000

 

Current liabilities

 

 

(18,572

)

 

 

3,837

 

 

 

(14,735

)

Deferred taxes

 

 

(89,908

)

 

 

(156

)

 

 

(90,064

)

Other long-term liabilities

 

 

(25,690

)

 

 

2,740

 

 

 

(22,950

)

Fair value of assets and liabilities acquired

 

 

272,024

 

 

 

6,421

 

 

 

278,445

 

Goodwill

 

 

103,876

 

 

 

(6,421

)

 

 

97,455

 

Total purchase price

 

 

375,900

 

 

 

 

 

 

375,900

 

Less: Noncontrolling interests

 

 

(25,736

)

 

 

 

 

 

(25,736

)

Purchase consideration on date of acquisition

 

$

350,164

 

 

$

 

 

$

350,164

 

Summary of Supplemental Pro Forma Financial Information

The unaudited pro forma financial information was prepared for comparative purposes only and is not necessarily indicative of what would have occurred had the acquisitions been made at those times or of results which may occur in the future

 

 

Year ended

 

 

December 31, 2016

 

(In thousands)

Reported

 

 

Pro Forma

 

Net revenues

$

519,601

 

 

$

520,658

 

Net loss from continuing operations

    attributable to Acorda

$

(34,618

)

 

$

(57,925

)

v3.10.0.1
Intangible Assets and Goodwill (Tables)
12 Months Ended
Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

 

 

 

 

 

December 31, 2018

 

 

December 31, 2017

 

(Dollars In thousands)

 

Estimated

Remaining

Useful Lives

(Years)

 

 

Cost

 

 

Accumulated

Amortization

 

 

Reclass to Definite-lived asset

 

 

Foreign

Currency

Translation

 

 

Net

Carrying

Amount

 

 

Cost

 

 

Accumulated

Amortization

 

 

Impairment

 

 

Foreign

Currency

Translation

 

 

Net

Carrying

Amount

 

In-process research &

   development (1)

 

Indefinite-lived

 

 

$

427,500

 

 

$

 

 

$

(423,000

)

 

$

(200

)

 

$

4,300

 

 

$

683,500

 

 

$

 

 

$

(257,317

)

 

$

1,317

 

 

$

427,500

 

Inbrija (2)

 

14

 

 

 

 

 

 

 

 

 

423,000

 

 

 

 

 

 

423,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selincro

 

n/a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

65,000

 

 

 

(27,932

)

 

 

(39,446

)

 

 

2,378

 

 

 

 

Ampyra milestones

 

n/a

 

 

 

5,750

 

 

 

(5,750

)

 

 

 

 

 

 

 

 

 

 

 

5,750

 

 

 

(4,438

)

 

 

 

 

 

 

 

 

1,312

 

Ampyra CSRO royalty

   buyout

 

n/a

 

 

 

3,000

 

 

 

(3,000

)

 

 

 

 

 

 

 

 

 

 

 

3,000

 

 

 

(2,642

)

 

 

 

 

 

 

 

 

358

 

Website development

   costs

 

3

 

 

 

13,857

 

 

 

(13,289

)

 

 

 

 

 

 

 

 

568

 

 

 

13,983

 

 

 

(12,816

)

 

 

 

 

 

 

 

 

1,167

 

Website development

   costs–in process

 

n/a

 

 

 

702

 

 

 

 

 

 

 

 

 

 

 

 

702

 

 

 

266

 

 

 

 

 

 

 

 

 

 

 

 

266

 

 

 

 

 

 

$

450,809

 

 

$

(22,039

)

 

$

 

 

$

(200

)

 

$

428,570

 

 

$

771,499

 

 

$

(47,828

)

 

$

(296,763

)

 

$

3,695

 

 

$

430,603

 

 

 

(1)

Includes the fair values of Inbrija: $423.0 million and BTT1023: $4.5 million as of December 31, 2017. 

 

(2)

In December 2018, the Company received FDA approval for Inbrija and accordingly reclassified the indefinite lived intangible assets to definite lived intangible assets with amortization scheduled to begin upon launch in 2019.

Schedule of Estimated Future Amortization Expense for Intangible Assets

 

(In thousands)

 

 

 

 

2019

 

$

30,796

 

2020

 

 

30,533

 

2021

 

 

30,424

 

2022

 

 

30,395

 

2023

 

 

30,395

 

Thereafter

 

 

271,024

 

 

 

$

423,567

 

Schedule of Changes in Carrying Amount of Goodwill

 

(In thousands)

 

 

 

 

Balance at December 31, 2017

 

$

286,611

 

Foreign currency translation adjustment

 

 

(4,552

)

Balance at December 31, 2018

 

$

282,059

 

v3.10.0.1
Investments (Tables)
12 Months Ended
Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]  
Schedule of Available-for-Sale Securities

The Company has determined that all of its investments are classified as available-for-sale. Available-for-sale debt securities are carried at fair value with interest on these investments included in interest income and are recorded based on quoted market prices. Available-for-sale investments consisted of the following at December 31, 2018:

 

Type

(In thousands)

 

Amortized

Cost

 

 

Gross

unrealized

gains

 

 

Gross

unrealized

losses

 

 

Estimated

fair

value

 

Commercial Paper

 

$

47,149

 

 

$

 

 

$

(41

)

 

$

47,108

 

Corporate Bonds

 

 

104,965

 

 

 

6

 

 

 

(90

)

 

 

104,881

 

Total Short-term Investments

 

$

152,114

 

 

$

6

 

 

$

(131

)

 

$

151,989

 

Schedule of Changes in Accumulated Other Comprehensive (Loss) Income The changes in AOCI associated with the unrealized holding losses on available-for-sale investments during the year ended December 31, 2018, were as follows (in thousands):

       

(In thousands)

 

Net Unrealized

Gains (Losses) on

Short-term Investments

 

Balance at December 31, 2017

 

$

 

Other comprehensive loss before reclassifications:

 

 

(125

)

Amounts reclassified from accumulated other

   comprehensive loss

 

 

 

Net current period other comprehensive loss

 

 

(125

)

Balance at December 31, 2018

 

 

(125

)

v3.10.0.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2018
Property Plant And Equipment [Abstract]  
Schedule of property and equipment

Property and equipment consisted of the following:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

 

Estimated

useful lives used

Machinery and equipment

 

$

24,798

 

 

$

24,956

 

 

2-7 years

Leasehold improvements

 

 

25,047

 

 

 

23,978

 

 

Lesser of useful life or

remaining lease term

Computer equipment

 

 

21,472

 

 

 

21,560

 

 

1-3 years

Laboratory equipment

 

 

9,021

 

 

 

8,542

 

 

2-5 years

Furniture and fixtures

 

 

2,599

 

 

 

2,635

 

 

4-7 years

Construction in progress

 

 

34,489

 

 

 

4,995

 

 

 

 

 

 

117,426

 

 

 

86,666

 

 

 

Less accumulated depreciation

 

 

(56,907

)

 

 

(49,997

)

 

 

 

 

$

60,519

 

 

$

36,669

 

 

 

v3.10.0.1
Common Stock Options and Restricted Stock (Tables)
12 Months Ended
Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Schedule of Weighted Average Assumptions Using the Black-Scholes Option Pricing Model

The fair value of each option granted is estimated on the date of grant using the Black‑Scholes option‑pricing model with the following weighted average assumptions:

 

 

 

Year ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

Employees and directors:

 

 

 

 

 

 

 

 

 

 

 

 

Estimated volatility%

 

 

52.29

%

 

 

48.02

%

 

 

44.63

%

Expected life in years

 

 

6.16

 

 

 

6.15

 

 

 

5.99

 

Risk free interest rate%

 

 

2.76

%

 

 

2.08

%

 

 

1.46

%

Dividend yield

 

 

 

 

 

 

 

 

 

Schedule of Share-based Compensation Expense The following table summarizes share-based compensation expense included within the Company’s consolidated statements of operations:

 

 

 

Year ended December 31,

 

(In thousands)

 

2018

 

 

2017

 

 

2016

 

Research and development

 

$

5,560

 

 

$

9,683

 

 

$

10,610

 

Selling, general and administrative

 

 

15,692

 

 

 

23,131

 

 

 

25,777

 

Total

 

$

21,252

 

 

$

32,814

 

 

$

36,387

 

Schedule of Stock Option Activity

A summary of share‑based compensation activity for the year ended December 31, 2018 is presented below:

 

 

 

Number

of Shares

(In thousands)

 

 

Weighted Average

Exercise Price

 

 

Weighted Average

Remaining

Contractual Term

 

 

Intrinsic

Value

(In thousands)

 

Balance at December 31, 2017

 

 

8,929

 

 

$

29.46

 

 

 

 

 

 

 

 

 

Granted

 

 

781

 

 

 

24.81

 

 

 

 

 

 

 

 

 

Forfeited and expired

 

 

(784

)

 

 

29.26

 

 

 

 

 

 

 

 

 

Exercised

 

 

(733

)

 

 

20.74

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

 

8,193

 

 

$

29.81

 

 

 

5.5

 

 

$

162,119

 

Vested and expected to vest at December 31, 2018

 

 

8,168

 

 

$

29.83

 

 

 

5.5

 

 

$

162,050

 

Vested and exercisable at December 31, 2018

 

 

6,842

 

 

$

30.40

 

 

 

5.0

 

 

$

160,597

 

Schedule of Stock Options Activity, By Exercise Price Range

 

 

 

Options Outstanding

 

 

Options Exercisable

 

Range of exercise price

 

Outstanding

as of

December 31,

2018

(In thousands)

 

 

Weighted-

average

remaining

contractual life

 

 

Weighted-

average

exercise price

 

 

Exercisable

as of

December 31,

2018

(In thousands)

 

 

Weighted-

average

exercise price

 

$13.80 - $24.35

 

 

1,857

 

 

 

6.4

 

 

$

20.60

 

 

 

1,281

 

 

$

19.74

 

$24.45 - $28.15

 

 

1,682

 

 

 

5.9

 

 

 

26.84

 

 

 

1,216

 

 

 

26.79

 

$28.30 - $32.55

 

 

1,642

 

 

 

4.4

 

 

 

30.79

 

 

 

1,587

 

 

 

30.84

 

$32.56 - $35.74

 

 

1,952

 

 

 

5.4

 

 

 

35.21

 

 

 

1,722

 

 

 

35.18

 

$35.84 - $44.50

 

 

1,061

 

 

 

5.2

 

 

 

39.19

 

 

 

1,036

 

 

 

39.21

 

 

 

 

8,194

 

 

 

5.5

 

 

$

29.81

 

 

 

6,842

 

 

$

30.40

 

 

Schedule of Restricted Stock Activity

 

Restricted Stock

 

Number of Shares

(In thousands)

 

Nonvested at December 31, 2017

 

 

698

 

Granted

 

 

 

Vested

 

 

(334

)

Forfeited

 

 

(132

)

Nonvested at December 31, 2018

 

 

232

 

 

v3.10.0.1
Debt (Tables)
12 Months Ended
Dec. 31, 2018
Debt Disclosure [Abstract]  
Summary of Outstanding Note Balances

The outstanding note balance as of December 31, 2018 and 2017 consisted of the following:

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Liability component:

 

 

 

 

 

 

 

 

Principal

 

$

345,000

 

 

$

345,000

 

Less: debt discount and debt issuance costs , net

 

 

(26,330

)

 

 

(36,195

)

Net carrying amount

 

 

318,670

 

 

$

308,805

 

Equity component

 

$

61,195

 

 

$

61,195

 

Schedule of Interest Expense Recognized Related to the Notes The following table sets forth total interest expense recognized related to the Notes for the years ended December 31, 2018 and 2017:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

Contractual interest expense

 

$

6,038

 

 

$

6,038

 

Amortization of debt issuance costs

 

 

913

 

 

 

871

 

Amortization of debt discount

 

 

8,952

 

 

 

8,539

 

Total interest expense

 

$

15,903

 

 

$

15,448

 

v3.10.0.1
Liability Related to Sale of Future Royalties (Tables)
12 Months Ended
Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]  
Schedule of Activity Within Liability Related to Sale of Future Royalties

The following table shows the activity within the liability account from the inception of the royalty agreement in November 2017 to December 31, 2017 and December 2018.

(In thousands)

 

December 31, 2018

 

 

Inception Date through

December 31, 2017

 

Liability related to sale of future royalties - beginning balance

 

$

35,788

 

 

$

 

Proceeds from sale of future royalties

 

 

 

 

 

40,000

 

Deferred transaction costs amortized

 

 

784

 

 

 

(2,115

)

Non-cash royalty revenue payable to HCRP

 

 

(10,291

)

 

 

(2,705

)

Non-cash interest expense recognized

 

 

4,435

 

 

 

608

 

Liability related to sale of future royalties - ending balance

 

$

30,716

 

 

$

35,788

 

v3.10.0.1
Corporate Restructuring (Tables)
12 Months Ended
Dec. 31, 2018
Restructuring And Related Activities [Abstract]  
Summary of Restructuring Costs

A summary of the restructuring costs for the years ended December 31, 2018 and 2017 is as follows:

(In thousands)

 

Restructuring Costs

 

Restructuring Liability as of December 31, 2016

 

$

 

2017 Restructuring costs

 

 

7,646

 

2017 Payments

 

 

(7,142

)

Restructuring Liability as of December 31, 2017

 

$

504

 

2018 Restructuring costs

 

 

1,316

 

2018 Payments

 

 

(1,820

)

Restructuring Liability as of December 31, 2018

 

$

 

v3.10.0.1
Accrued Expenses and Other Current Liabilities (Tables)
12 Months Ended
Dec. 31, 2018
Accrued Expenses And Other Current Liabilities [Abstract]  
Schedule of Accrued Expenses and Other Current liabilities

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Product allowances accruals

 

$

26,931

 

 

$

37,604

 

Bonus payable

 

 

18,381

 

 

 

10,730

 

Accrued inventory

 

 

14,254

 

 

 

15,324

 

Sales force commissions and incentive payments payable

 

 

3,453

 

 

 

1,654

 

Administrative expenses

 

 

2,651

 

 

 

2,276

 

Vacation accrual

 

 

2,395

 

 

 

2,449

 

Research and development expense accruals

 

 

2,374

 

 

 

9,092

 

Commercial and Marketing expense accruals

 

 

1,933

 

 

 

1,643

 

Royalties payable

 

 

509

 

 

 

3,707

 

Other accrued expenses

 

 

4,001

 

 

 

15,371

 

Total

 

$

76,882

 

 

$

99,850

 

v3.10.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]  
Summary of Minimum Significant Contractual Obligations

 

 

 

Payments due by period (1) (3) (7)

 

(In thousands)

 

Total

 

 

Less than

1 year

 

 

1-3 years

 

 

4-5 years

 

Convertible Senior Notes (2)

 

$

359,214

 

 

$

6,038

 

 

$

353,176

 

 

$

 

Research and development loans (4)

 

 

1,848

 

 

 

616

 

 

 

1,232

 

 

 

 

Operating leases (5)

 

 

36,090

 

 

 

7,382

 

 

 

15,538

 

 

 

13,170

 

Inventory purchase commitments (6)

 

 

2,281

 

 

 

2,281

 

 

 

 

 

 

 

Total

 

$

399,433

 

 

$

16,317

 

 

$

369,946

 

 

$

13,170

 

 

(1)

Excludes a liability for uncertain tax positions totaling $7.7 million. This liability has been excluded because the Company cannot currently make a reliable estimate of the period in which the liability will be payable, if ever.

(2)

Represents the future payments of principal and interest to be made on the Convertible Senior Notes issued in June 2014. The Notes will mature and will be payable on June 15, 2021. See Note 10.

(3)

Excludes a liability for the non-convertible capital loans totaling $23.2 million. The non-convertible capital loans have a stated maturity of less than one year. However, the repayment of the non-convertible capital loans and payment of accrued interest thereon are governed by a restrictive condition, according to which the loan principal may only be repaid if Biotie’s consolidated restricted equity is fully covered. Accrued interest may only be paid if Biotie, including its subsidiaries, has sufficient funds for profit distribution as of the most recently ended fiscal year. Interest accrues in the interim. This liability has been excluded because the Company cannot currently make a reliable estimate of the period in which the liability will be payable, if ever.

(4)

Represents the future principal payments on the R&D loans acquired with Biotie. The repayment is made in equal annual installment with last payment due in January 2021. See Note 10.

(5)

Represents payments for the operating leases of the Company’s Ardsley, NY headquarters, the Company’s manufacturing facility in Chelsea, MA, and lab and office space in Waltham, MA, and excludes field auto leases which are for a one year term.

(6)

Represents Ampyra inventory commitments. The Ampyra inventory commitment is an estimate as the price paid for Ampyra inventory is based on a percentage of the net product sales during the quarter Alkermes ships inventory to us. Under our supply agreement with Alkermes, we provide Alkermes with monthly written 18-month forecasts, and with annual written five-year forecasts for our supply requirements of Ampyra. In each of the three months for Ampyra following the submission of our written 18-month forecast we are obligated to purchase the quantity specified in the forecast, even if our actual requirements are greater or less. We have agreed to purchase at least 75% of our annual requirements of Ampyra from Alkermes, unless Alkermes is unable or unwilling to meet its requirements, for a percentage of net product sales and the quantity of product shipped by Alkermes to us.

(7)

Pursuant to the UCB Termination and Transition Agreement, Biotie is required to pay up to $4.1 million (€ 3.9 million) to UCB. The amount that will be paid will be determined based on a percentage of future consideration Biotie will receive from tozadenant. The liability is excluded as the Company cannot currently estimate the period in which the liability will be payable, if ever.

Schedule of Future Minimum Commitments under All Non-Cancelable Operating Leases

 

(In thousands)

 

 

 

2019

$

7,382

 

2020

 

7,669

 

2021

 

7,869

 

2022

 

10,071

 

2023

 

3,100

 

Later years

 

7,769

 

 

$

43,860

 

v3.10.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2018
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 and December 31, 2017, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

 

(In thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

Assets Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,586

 

 

$

 

 

$

 

Commercial paper

 

 

 

 

 

47,108

 

 

 

 

Corporate bonds

 

 

 

 

 

104,881

 

 

 

 

Liabilities Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Acquired contingent consideration

 

 

 

 

 

 

 

 

168,000

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

Assets Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

9,163

 

 

$

 

 

$

 

Liabilities Carried at Fair Value:

 

 

 

 

 

 

 

 

 

 

 

 

Acquired contingent consideration

 

 

 

 

 

 

 

 

113,000

 

Contingent Consideration Liability  
Schedule of Contingent Liabilities

The following table presents additional information about assets and/or liabilities measured at fair value on a recurring basis and for which the Company utilizes Level 3 inputs to determine fair value.

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

Acquired contingent consideration:

 

 

 

 

 

 

 

 

Balance, beginning of period

 

$

113,000

 

 

$

72,100

 

Fair value change to contingent consideration (unrealized)

   included in the statement of operations

 

 

55,000

 

 

 

40,900

 

Balance, end of period

 

$

168,000

 

 

$

113,000

 

v3.10.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Schedule of Domestic and Foreign Components of (Loss) Income Before Income Taxes

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Domestic

 

$

19,211

 

 

$

(172,560

)

 

$

(36,454

)

Foreign

 

 

1,211

 

 

 

(79,325

)

 

 

(5,814

)

Total

 

$

20,422

 

 

$

(251,885

)

 

$

(42,268

)

Schedule of Benefit from (Provision for) Income Taxes

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

2,991

 

 

$

(11,948

)

 

$

(852

)

State

 

 

(4,143

)

 

 

(12,653

)

 

 

(4,517

)

Foreign

 

 

(93

)

 

 

(91

)

 

 

781

 

 

 

 

(1,245

)

 

 

(24,692

)

 

 

(4,588

)

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

13,790

 

 

 

42,322

 

 

 

9,465

 

State

 

 

714

 

 

 

5,377

 

 

 

1,788

 

Foreign

 

 

 

 

 

5,519

 

 

 

 

 

 

 

14,504

 

 

 

53,218

 

 

 

11,253

 

Total benefit from (provision for) income taxes

 

$

13,259

 

 

$

28,526

 

 

$

6,665

 

Schedule of Reconciliation of the Statutory U.S. Federal Income Tax Rate to the Entity's Effective Income Tax Rate

 

 

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

U.S. federal statutory tax rate

 

 

21.0

%

 

 

35.0

%

 

 

35.0

%

State and local income taxes

 

 

8.7

%

 

 

(0.1

)%

 

 

(3.8

)%

Foreign income tax

 

 

 

 

 

 

 

 

1.2

%

Stock option compensation

 

 

0.7

%

 

 

(0.5

)%

 

 

(3.8

)%

Stock option shortfall

 

 

12.6

%

 

 

(1.5

)%

 

 

(6.5

)%

Research and development and orphan drug credits

 

 

5.6

%

 

 

1.2

%

 

 

28.9

%

Uncertain Tax Positions

 

 

(0.7

)%

 

 

(0.3

)%

 

 

(4.8

)%

Other nondeductible and permanent differences

 

 

(5.0

)%

 

 

(0.4

)%

 

 

(1.1

)%

Valuation allowance, net of foreign tax rate

    differential

 

 

(107.9

)%

 

 

(19.8

)%

 

 

(31.6

)%

Transaction cost

 

 

 

 

 

 

 

 

(5.9

)%

Gain or loss on hedging

 

 

 

 

 

 

 

 

8.2

%

NOL Write-off

 

 

16.6

%

 

 

 

 

 

 

Federal return to provision differences

 

 

(16.6

)%

 

 

 

 

 

 

Tax reform

 

 

 

 

 

(2.3

)%

 

 

 

Effective income tax rate

 

 

(65.0

)%

 

 

11.3

%

 

 

15.8

%

Schedule of Deferred Tax Assets and Liabilities

 

(In thousands)

 

December 31, 2018

 

 

December 31, 2017

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss and other carryforwards

 

$

51,543

 

 

$

53,632

 

Tax credits

 

 

19,401

 

 

 

31,699

 

Deferred revenue

 

 

 

 

 

5,597

 

Stock based compensation

 

 

22,733

 

 

 

24,531

 

Contingent consideration

 

 

38,594

 

 

 

26,041

 

Employee compensation

 

 

3,677

 

 

 

3,212

 

Legal reserve

 

 

 

 

 

 

Rebate and returns reserve

 

 

5,798

 

 

 

8,215

 

Capitalized R&D

 

 

10,791

 

 

 

11,295

 

Other

 

 

13,881

 

 

 

12,368

 

Total deferred tax assets

 

$

166,418

 

 

$

176,590

 

Valuation allowance

 

$

(71,570

)

 

$

(98,609

)

Total deferred tax assets net of valuation allowance

 

$

94,848

 

 

$

77,981

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Intangible assets

 

 

(94,771

)

 

 

(91,991

)

Convertible debt

 

 

(5,971

)

 

 

(8,449

)

Depreciation

 

 

(1,256

)

 

 

 

Other

 

 

(333

)

 

 

 

Total deferred tax liabilities

 

$

(102,331

)

 

$

(100,440

)

Net deferred tax liability

 

$

(7,483

)

 

$

(22,459

)

Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Beginning of period balance

 

$

7,397

 

 

$

6,856

 

 

$

4,835

 

Increases for tax positions taken during a prior period

 

 

55

 

 

 

687

 

 

 

570

 

Decreases for tax positions taken during a

    prior period

 

 

(194

)

 

 

(146

)

 

 

 

Increases for tax positions taken during the

    current period

 

 

 

 

 

 

 

 

1,451

 

 

 

$

7,258

 

 

$

7,397

 

 

$

6,856

 

Reconciliation of Beginning and Ending Amounts of Valuation Allowances

The beginning and ending amounts of valuation allowances reconcile as follows:

 

 

 

Balance at

 

 

 

 

 

 

 

 

 

 

Balance at

 

(In thousands)

 

Beginning of Period

 

 

Additions

 

 

Deductions

 

 

End of Period

 

Valuation allowance for deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2016

 

$

5,277

 

 

 

57,948

 

 

 

 

 

$

          63,225

 

Year ended December 31, 2017

 

$

63,225

 

 

 

39,007

 

 

 

(3,623

)

 

$

98,609

 

Year ended December 31, 2018

 

$

98,609

 

 

 

5,465

 

 

 

(32,504

)

 

$

71,570

 

v3.10.0.1
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2018, 2017 and 2016:

 

(In thousands, except per share data)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Basic and diluted

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

33,682

 

 

$

(223,359

)

 

$

(34,618

)

Weighted average common shares outstanding used in

   computing net income (loss) per share—basic

 

 

47,010

 

 

 

45,999

 

 

 

45,259

 

Plus: net effect of dilutive stock options and unvested

   restricted common shares

 

 

331

 

 

 

 

 

 

 

Weighted average common shares outstanding used in

   computing net income (loss) per share—diluted

 

 

47,341

 

 

 

45,999

 

 

 

45,259

 

Net income (loss) per share—basic

 

$

0.72

 

 

$

(4.86

)

 

$

(0.76

)

Net income (loss) per share—diluted

 

$

0.71

 

 

$

(4.86

)

 

$

(0.76

)

Schedule of Anti-dilutive Securities Excluded from Calculation of Net Income per Diluted Share

The following amounts were not included in the calculation of net income per diluted share because their effects were anti-dilutive:

 

(In thousands)

 

Year ended December 31,         2018

 

 

Year ended December 31,         2017

 

 

Year ended December 31,         2016

 

Denominator

 

 

 

 

 

 

 

 

 

 

 

 

Stock options and restricted common shares

 

 

7,370

 

 

 

8,804

 

 

 

7,749

 

Convertible note

 

 

 

 

 

 

 

 

10

 

v3.10.0.1
Quarterly Consolidated Financial Data (unaudited) (Tables)
12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Consolidated Financial Data Quarterly Consolidated Financial Data (unaudited)

 

(In thousands, except per share amounts)

 

2018

 

 

 

 

March 31

 

 

June 30

 

 

September 30

 

 

December 31

 

 

Total net revenues

 

$

106,165

 

 

$

153,302

 

 

$

142,814

 

 

$

69,152

 

 

Gross profit

 

 

84,815

 

 

 

122,208

 

 

 

117,423

 

 

 

47,678

 

 

Net (loss) income (1)

 

 

(8,199

)

 

 

46,197

 

 

 

(13,911

)

 

 

9,595

 

 

Net (loss) income per share—basic

 

$

(0.18

)

 

$

0.99

 

 

$

(0.29

)

 

$

0.20

 

 

Net (loss) income per share—diluted

 

$

(0.18

)

 

$

0.98

 

 

$

(0.29

)

 

$

0.20

 

 

 

 

 

2017

 

 

 

March 31

 

 

June 30

 

 

September 30

 

 

December 31

 

Total net revenues

 

$

119,386

 

 

$

139,438

 

 

$

141,065

 

 

$

188,398

 

Gross profit

 

 

94,044

 

 

 

109,614

 

 

 

110,914

 

 

 

137,999

 

Net loss (2) (3)

 

 

(18,904

)

 

 

(8,196

)

 

 

(25,195

)

 

 

(171,064

)

Net loss attributable to Acorda Therapeutics, Inc.

   —basic and diluted

 

 

(18,904

)

 

 

(8,196

)

 

 

(25,195

)

 

 

(171,064

)

Net loss per share—basic and diluted

 

$

(0.41

)

 

$

(0.18

)

 

$

(0.55

)

 

$

(3.70

)

 

  

(1) In the fourth quarter of 2018, the Company recognized a gain of approximately $7.8 million on the sale of Qutenza assets. See Note 5 for a discussion of the gain on the sale. In the fourth quarter of 2018, the Company recognized a charge of approximately $8.4 million related to inventory obsolescence reserve. See Note 2 for a discussion of the inventory reserve charges.

 

(2) In the third quarter of 2017, the Company recognized an asset impairment charge of $39.4 million. See Note 4 for a discussion of the impairment charges.

 

(3) In the fourth quarter of 2017, the Company recognized an asset impairment charge of $257.3 million. See Note 4 for a discussion of the impairment charges.

v3.10.0.1
Summary of Significant Accounting Policies - Additional Information (Details)
12 Months Ended
Oct. 01, 2017
USD ($)
Dec. 31, 2018
USD ($)
Customer
Segment
Dec. 31, 2017
USD ($)
Customer
Dec. 31, 2016
USD ($)
Customer
Jan. 01, 2018
USD ($)
Other Comprehensive Income (Loss)          
Foreign currency translation adjustment, Tax   $ 0 $ 0    
Foreign currency translation adjustment   (3,927,000) 19,759,000 $ (12,901,000)  
Charge for excess and obsolete inventory   8,400,000 700,000    
Revenue Recognition          
Accumulated deficit   $ (393,843,000) (455,108,000)    
Allowance for Cash Discounts          
Time period needed typically to settle cash discounts   34 days      
Allowance for cash discounts   $ 6,400,000 6,900,000    
Reserve for allowance for cash discounts   400,000 800,000    
Allowance for Doubtful Accounts          
Allowance for doubtful accounts, provisions   0 0    
Allowance for doubtful accounts, write-offs   0 0    
Allowance related to chargebacks   18,900,000 $ 0    
Payment related to chargebacks   16,700,000      
Reserve for chargebacks allowance   $ 2,200,000      
Segment and Geographic Information          
Number of operating segments | Segment   1      
Number of reportable operating segments | Segment   1      
Product revenue          
Revenue Recognition          
Number of customers | Customer   4 4 3  
Accounts receivable          
Revenue Recognition          
Number of customers | Customer   5 4    
Customers | Product revenue          
Revenue Recognition          
Concentration risk, percentage   81.00%      
Customers | Accounts receivable          
Revenue Recognition          
Concentration risk, percentage   88.00% 69.00%    
License Revenue          
Revenue Recognition          
Revenue related to milestones   $ 0 $ 0 $ 0  
ASC 606          
Revenue Recognition          
Accumulated deficit         $ (427,525,000)
ASC 606 | Net Adjustments          
Revenue Recognition          
Accumulated deficit   $ 21,265,000     $ 27,583,000
Royalty Agreement          
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties          
Non cash royalty payment received $ 40,000,000        
Estimated effective annual interest rate   15.00%      
Minimum          
Property and Equipment          
Estimated useful lives   1 year      
Revenue Recognition          
Product revenue payment term   30 days      
Minimum | Supply agreement | Alkermes License Agreement          
Revenue Recognition          
Compensatory Payments Purchase Requirements Threshold Percentage   75.00%      
Maximum          
Property and Equipment          
Estimated useful lives   7 years      
Revenue Recognition          
Product revenue payment term   35 days      
Maximum | Supply agreement | Alkermes License Agreement          
Revenue Recognition          
Compensatory Payments Purchase Requirements Threshold Percentage   100.00%      
Maximum | Supply agreement | Patheon Inc Second Manufacturing agreement          
Revenue Recognition          
Compensatory Payments Purchase Requirements Threshold Percentage   25.00%      
Letters of Credit          
Restricted Cash          
Restricted Cash and Cash Equivalents   $ 300,000      
v3.10.0.1
Summary of Significant Accounting Policies - Cumulative Effect and Impact of Adoption of ASC 606 on Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Jan. 01, 2018
Dec. 31, 2017
Assets      
Other current assets $ 10,194   $ 1,983
Non-current portion of deferred cost of license revenue     1,638
Total Assets 1,299,666   1,197,969
Liabilities and Stockholders’ Equity      
Current portion of deferred license revenue     9,057
Non-current portion of deferred license revenue     23,398
Deferred tax liability 7,483   22,459
Accumulated deficit (393,843)   (455,108)
Total liabilities and stockholders' equity 1,299,666   $ 1,197,969
ASC 606      
Assets      
Other current assets   $ 1,349  
Total Assets   1,195,697  
Liabilities and Stockholders’ Equity      
Deferred tax liability   25,059  
Accumulated deficit   (427,525)  
Total liabilities and stockholders' equity   1,195,697  
ASC 606 | Net Adjustments      
Assets      
Other current assets (634) (634)  
Non-current portion of deferred cost of license revenue (1,004) (1,638)  
Total Assets (1,638) (2,272)  
Liabilities and Stockholders’ Equity      
Current portion of deferred license revenue (9,057) (9,057)  
Non-current portion of deferred license revenue (14,341) (23,398)  
Deferred tax liability 495 2,600  
Accumulated deficit 21,265 27,583  
Total liabilities and stockholders' equity (1,638) $ (2,272)  
ASC 606 | Prior to Adoption of ASC 606      
Assets      
Other current assets 10,828    
Non-current portion of deferred cost of license revenue 1,004    
Total Assets 1,301,304    
Liabilities and Stockholders’ Equity      
Current portion of deferred license revenue 9,057    
Non-current portion of deferred license revenue 14,341    
Deferred tax liability 6,988    
Accumulated deficit (415,108)    
Total liabilities and stockholders' equity $ 1,301,304    
v3.10.0.1
Summary of Significant Accounting Policies - Impact of Adoption of ASC 606 on Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue Initial Application Period Cumulative Effect Transition [Line Items]                      
License revenue $ 69,152 $ 142,814 $ 153,302 $ 106,165 $ 188,398 $ 141,065 $ 139,438 $ 119,386 $ 471,433 $ 588,287 $ 519,601
Type of Revenue [Extensible List]                 us-gaap:LicenseMember    
Cost of license revenue                 $ 99,310 135,080 107,475
Type of Cost, Good or Service [Extensible List]                 us-gaap:LicenseMember    
Operating income (loss)                 $ 38,486 (232,814) (35,982)
(Benefit from) provision for income taxes                 (13,259) (28,526) (6,665)
Net income (loss) $ 9,595 $ (13,911) $ 46,197 $ (8,199) $ (171,064) $ (25,195) $ (8,196) $ (18,904) $ 33,682 $ (223,359) $ (34,618)
Net income (loss) per share—basic $ 0.20 $ (0.29) $ 0.99 $ (0.18)         $ 0.72 $ (4.86) $ (0.76)
Net income (loss) per share—diluted $ 0.20 $ (0.29) $ 0.98 $ (0.18)         $ 0.71 $ (4.86) $ (0.76)
ASC 606 | Prior to Adoption of ASC 606                      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]                      
License revenue                 $ 9,057    
Type of Revenue [Extensible List]                 us-gaap:LicenseMember    
Cost of license revenue                 $ 634    
Type of Cost, Good or Service [Extensible List]                 us-gaap:LicenseMember    
Operating income (loss)                 $ 46,909    
(Benefit from) provision for income taxes                 (15,364)    
Net income (loss)                 $ 40,000    
Net income (loss) per share—basic                 $ 0.85    
Net income (loss) per share—diluted                 $ 0.84    
ASC 606 | Net Adjustments                      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]                      
License revenue                 $ (9,057)    
Type of Revenue [Extensible List]                 us-gaap:LicenseMember    
Cost of license revenue                 $ (634)    
Type of Cost, Good or Service [Extensible List]                 us-gaap:LicenseMember    
Operating income (loss)                 $ (8,423)    
(Benefit from) provision for income taxes                 2,105    
Net income (loss)                 $ (6,318)    
Net income (loss) per share—basic                 $ (0.13)    
Net income (loss) per share—diluted                 $ (0.13)    
v3.10.0.1
Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation Of Revenue [Line Items]                      
Total net revenues $ 69,152 $ 142,814 $ 153,302 $ 106,165 $ 188,398 $ 141,065 $ 139,438 $ 119,386 $ 471,433 $ 588,287 $ 519,601
Net Product Revenues                      
Disaggregation Of Revenue [Line Items]                      
Total net revenues                 459,739 549,749 493,358
Royalty Revenues                      
Disaggregation Of Revenue [Line Items]                      
Total net revenues                 $ 11,694 29,481 17,186
License Revenue                      
Disaggregation Of Revenue [Line Items]                      
Total net revenues                   $ 9,057 $ 9,057
v3.10.0.1
Summary of Significant Accounting Policies - Summary of Allowance for Cash Discounts (Details) - Cash discounts - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Valuation And Qualifying Accounts Disclosure [Line Items]    
Beginning balance $ 844 $ 594
Allowances for sales 6,371 6,898
Actual credits (6,820) (6,648)
Ending balance $ 395 $ 844
v3.10.0.1
Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accounting Policies [Abstract]        
Cash and cash equivalents $ 293,564 $ 307,068 $ 158,537 $ 153,204
Restricted cash 532 410 79 $ 6,031
Restricted cash included in Other assets $ 255 $ 560 $ 255  
Restricted cash, noncurrent, statement of financial position [extensible list] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Total Cash, cash equivalents and restricted cash per statement of cash flows $ 294,351 $ 308,038 $ 158,871 $ 159,235
v3.10.0.1
Acquisitions - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 8 Months Ended 12 Months Ended 20 Months Ended
May 04, 2016
Sep. 30, 2016
Apr. 18, 2016
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Jun. 30, 2016
Acquisitions                                  
Net revenues       $ 69,152 $ 142,814 $ 153,302 $ 106,165 $ 188,398 $ 141,065 $ 139,438 $ 119,386   $ 471,433 $ 588,287 $ 519,601    
Net income (loss)                         $ 33,682 (223,359) (35,603)    
Biotie Therapies Corp.                                  
Acquisitions                                  
Voting interest acquired (as a percent)     93.00%                            
Aggregate equity purchase price     $ 350,000                            
Additional voting interest acquired (as a percent) 4.00% 3.00%                              
Purchase consideration for subsequent acquisition $ 14,500                                
Voting interest acquired including subsequent acquisition (as a percent)   100.00%                             97.00%
Payment of cash security deposit   $ 13,500                              
Proceeds from refund of cash security deposit                           2,700      
Acquisition-related expenses                           600 17,600 $ 18,600  
Net revenues                       $ 2,700          
Net income (loss)                       (37,500)          
Biotie Therapies Corp. | Foreign currency option                                  
Acquisitions                                  
Notional value of foreign currency option               $ 0       $ 0   0 0 $ 0  
Biotie Therapies Corp. | Foreign currency option | Other income                                  
Acquisitions                                  
Realized gain on foreign currency options                             $ 9,900    
Biotie Therapies Corp. | Final Measurement Period Adjustments                                  
Acquisitions                                  
Final measurement period adjustments                           6,400      
Increase in deferred tax liabilities                           200      
Biotie Therapies Corp. | Final Measurement Period Adjustments | Non-convertible Capital Loans                                  
Acquisitions                                  
Final measurement period adjustments                           (2,700)      
Biotie Therapies Corp. | Final Measurement Period Adjustments | Convertible Capital Loans                                  
Acquisitions                                  
Final measurement period adjustments                           $ (3,800)      
v3.10.0.1
Acquisitions - Schedule of Final Allocation of Purchase Price to Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Apr. 18, 2017
Dec. 31, 2016
Final allocation of purchase price to estimated fair values of assets acquired and liabilities assumed        
Goodwill $ 282,059 $ 286,611    
Biotie Therapies Corp.        
Final allocation of purchase price to estimated fair values of assets acquired and liabilities assumed        
Cash and cash equivalents     $ 73,854 $ 73,854
Other current assets     1,878 1,878
Other long-term assets     4,962 4,962
Intangible assets (indefinite-lived) $ 260,500   260,500 260,500
Intangible assets (definite-lived)     65,000 65,000
Current liabilities     (14,735) (18,572)
Deferred taxes     (90,064) (89,908)
Other long-term liabilities     (22,950) (25,690)
Fair value of assets and liabilities acquired     278,445 272,024
Goodwill     97,455 103,876
Total purchase price     375,900 375,900
Less: Noncontrolling interests     (25,736) (25,736)
Purchase consideration on date of acquisition     350,164 $ 350,164
Biotie Therapies Corp. | Measurement Period Adjustments        
Final allocation of purchase price to estimated fair values of assets acquired and liabilities assumed        
Current liabilities     3,837  
Deferred taxes     (156)  
Other long-term liabilities     2,740  
Fair value of assets and liabilities acquired     6,421  
Goodwill     $ (6,421)  
v3.10.0.1
Acquisitions - Summary of Supplemental Pro Forma Financial Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Acquisitions                      
Net loss from continuing operations attributable to Acorda, Reported $ 9,595 $ (13,911) $ 46,197 $ (8,199) $ (171,064) $ (25,195) $ (8,196) $ (18,904) $ 33,682 $ (223,359) $ (34,618)
Biotie Therapies Corp.                      
Acquisitions                      
Net revenues, Pro Forma                     520,658
Net (loss) income from continuing operations attributable to Acorda, Pro Forma                     (57,925)
Net revenues, Reported                     519,601
Net loss from continuing operations attributable to Acorda, Reported                     $ (34,618)
v3.10.0.1
Intangible Assets and Goodwill - Additional Information (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
Nov. 30, 2017
EUR (€)
Jan. 31, 2010
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2017
EUR (€)
Sep. 30, 2017
USD ($)
Dec. 31, 2018
USD ($)
Item
Dec. 31, 2017
USD ($)
Apr. 18, 2017
USD ($)
Dec. 31, 2016
USD ($)
Intangible Assets                    
Non-cash impairment charge       $ 257,300   $ 39,400        
Amortization expense             $ 2,400 $ 25,100    
Finite-lived intangible asset, net             $ 423,567      
Weighted-average remaining useful lives of all amortizable assets             17 years      
Biotie Therapies Corp.                    
Intangible Assets                    
Value allocated to indefinite-lived intangible asset             $ 260,500   $ 260,500 $ 260,500
Ampyra CSRO royalty buyout                    
Intangible Assets                    
Finite-lived intangible asset, Cost     $ 3,000 3,000     $ 3,000 3,000    
Estimated Remaining Useful Lives (Years)             1 year      
Finite-lived intangible asset, net       358       358    
Selincro                    
Intangible Assets                    
Finite-lived intangible asset, Cost       65,000     $ 65,000 65,000    
Estimated Remaining Useful Lives (Years)             6 years      
Non cash Impairment charges of finite-lived intangible assets               39,400    
Amortization expense       14,700 € 12.4          
Finite-lived intangible asset, net       0       0    
Selincro | Lundbeck                    
Intangible Assets                    
Cash received from licensees for license fees $ 13,000 € 11.0                
IPR&D                    
Intangible Assets                    
Indefinite-lived intangible asset, Cost       683,500     $ 427,500 683,500    
Inbrija | IPR&D                    
Intangible Assets                    
Indefinite-lived intangible asset, Cost       $ 423,000     $ 423,000 423,000    
Ampyra | Alkermes License Agreement                    
Intangible Assets                    
Number of milestone payments | Item             2      
Milestone payments made under agreement     2,500              
Additional payments based on the successful achievement of future regulatory or sales milestones     $ 2,500              
Period for milestone payment     2 years              
Aggregate milestone payments made under agreement     $ 5,750              
Ampyra | Rush Agreement                    
Intangible Assets                    
Milestone payments made under agreement     $ 800              
Tozadenant                    
Intangible Assets                    
Non-cash impairment charge $ 233,500                  
SYN120                    
Intangible Assets                    
Non-cash impairment charge               $ 23,800    
v3.10.0.1
Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Jan. 31, 2010
Intangible Assets      
Finite-lived intangible asset, Accumulated Amortization $ (22,039) $ (47,828)  
Finite-lived intangible asset, Impairment   (296,763)  
Finite-lived intangible asset, Net Carrying Amount 423,567    
Intangible asset, Cost 450,809 771,499  
Intangible asset, Foreign Currency Translation Adjustments (200) 3,695  
Intangible asset, Net Carrying Amount $ 428,570 430,603  
Inbrija      
Intangible Assets      
Estimated Remaining Useful Lives (Years) 14 years    
Reclass to Definite-lived asset $ 423,000    
Finite-lived intangible asset, Net Carrying Amount $ 423,000    
Selincro      
Intangible Assets      
Estimated Remaining Useful Lives (Years) 6 years    
Finite-lived intangible asset, Cost $ 65,000 65,000  
Finite-lived intangible asset, Accumulated Amortization   (27,932)  
Finite-lived intangible asset, Impairment   (39,446)  
Finite-lived intangible assets, Foreign Currency Translation   2,378  
Finite-lived intangible asset, Net Carrying Amount   0  
Ampyra milestones      
Intangible Assets      
Estimated Remaining Useful Lives (Years) 1 year    
Finite-lived intangible asset, Cost $ 5,750 5,750  
Finite-lived intangible asset, Accumulated Amortization $ (5,750) (4,438)  
Finite-lived intangible asset, Net Carrying Amount   1,312  
Ampyra CSRO royalty buyout      
Intangible Assets      
Estimated Remaining Useful Lives (Years) 1 year    
Finite-lived intangible asset, Cost $ 3,000 3,000 $ 3,000
Finite-lived intangible asset, Accumulated Amortization $ (3,000) (2,642)  
Finite-lived intangible asset, Net Carrying Amount   358  
Website development costs      
Intangible Assets      
Estimated Remaining Useful Lives (Years) 3 years    
Finite-lived intangible asset, Cost $ 13,857 13,983  
Finite-lived intangible asset, Accumulated Amortization (13,289) (12,816)  
Finite-lived intangible asset, Net Carrying Amount 568 1,167  
Website development costs - in process      
Intangible Assets      
Finite-lived intangible asset, Cost 702 266  
Finite-lived intangible asset, Net Carrying Amount 702 266  
IPR&D      
Intangible Assets      
Indefinite-lived intangible asset, Cost 427,500 683,500  
Indefinite-lived intangible asset, Impairment   (257,317)  
Reclass to Definite-lived asset (423,000)    
Indefinite-lived intangible assets, Foreign Currency Translation (200) 1,317  
Indefinite-lived intangible assets, Net Carrying Amount $ 4,300 $ 427,500  
v3.10.0.1
Intangible Assets and Goodwill - Schedule of Intangible Assets (Parenthetical) (Details) - IPR&D - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Intangible Assets    
Indefinite-lived intangible asset, Cost $ 427,500 $ 683,500
Inbrija    
Intangible Assets    
Indefinite-lived intangible asset, Cost $ 423,000 423,000
BTT-1023    
Intangible Assets    
Indefinite-lived intangible asset, Cost   $ 4,500
v3.10.0.1
Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Estimated future amortization expense  
2019 $ 30,796
2020 30,533
2021 30,424
2022 30,395
2023 30,395
Thereafter 271,024
Finite-lived intangible asset, Net Carrying Amount $ 423,567
v3.10.0.1
Intangible Assets and Goodwill - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
Changes in carrying amount of goodwill  
Beginning balance $ 286,611
Foreign currency translation adjustment (4,552)
Ending balance $ 282,059
v3.10.0.1
Qutenza and Zanaflex Asset Sales - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
May 22, 2018
Nov. 13, 2017
Dec. 31, 2018
Dec. 31, 2017
Qutenza        
Purchase price related to sale of rights and interests of assets     $ 7,884  
Gain on sale of assets     7,837  
Additional consideration entitled to receive upon achievement of specified sales milestones     35,000  
Qutenza | Discontinued Operations, Disposed of by Sale | Asset Purchase Agreement        
Purchase price related to sale of rights and interests of assets $ 7,900      
Gain on sale of assets     $ 7,800  
Zanaflex        
Purchase price related to sale of rights and interests of assets       $ 3,663
Gain on sale of assets       3,534
Zanaflex | Discontinued Operations, Disposed of by Sale | Asset Purchase Agreement        
Purchase price related to sale of rights and interests of assets   $ 4,000    
Gain on sale of assets       $ 3,500
v3.10.0.1
Investments - Schedule of Available-for-Sale Securities (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost $ 152,114
Gross unrealized gains 6
Gross unrealized losses (131)
Estimated fair value value 151,989
Commercial Paper  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 47,149
Gross unrealized losses (41)
Estimated fair value value 47,108
Corporate Bonds  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 104,965
Gross unrealized gains 6
Gross unrealized losses (90)
Estimated fair value value $ 104,881
v3.10.0.1
Investments - Additional Information (Details) - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]    
Long-term Investments $ 0 $ 0
Short-term investments 151,989,000 $ 0
Short-term investments classified as cash equivalents 9,600,000  
Short Term Investments    
Schedule Of Available For Sale Securities [Line Items]    
Fair value of short-term investments in an unrealized loss position $ 139,600,000  
v3.10.0.1
Investments - Schedule of Changes in Accumulated Other Comprehensive (loss) Income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Accumulated Other Comprehensive Income Loss [Line Items]      
Balance at December 31, 2017 $ 6,858    
Net current period other comprehensive loss (4,052) $ 19,759 $ (12,782)
Balance at December 31, 2018 2,806 $ 6,858  
Net Unrealized Gains (Losses) on Marketable Securities      
Accumulated Other Comprehensive Income Loss [Line Items]      
Other comprehensive loss before reclassifications (125)    
Net current period other comprehensive loss (125)    
Balance at December 31, 2018 $ (125)    
v3.10.0.1
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Property and Equipment    
Property and equipment $ 117,426 $ 86,666
Less accumulated depreciation (56,907) (49,997)
Property and equipment, net $ 60,519 36,669
Minimum    
Property and Equipment    
Estimated useful lives used 1 year  
Maximum    
Property and Equipment    
Estimated useful lives used 7 years  
Machinery and equipment    
Property and Equipment    
Property and equipment $ 24,798 24,956
Machinery and equipment | Minimum    
Property and Equipment    
Estimated useful lives used 2 years  
Machinery and equipment | Maximum    
Property and Equipment    
Estimated useful lives used 7 years  
Leasehold improvements    
Property and Equipment    
Property and equipment $ 25,047 23,978
Estimated useful lives used Lesser of useful life or remaining lease term  
Computer equipment    
Property and Equipment    
Property and equipment $ 21,472 21,560
Computer equipment | Minimum    
Property and Equipment    
Estimated useful lives used 1 year  
Computer equipment | Maximum    
Property and Equipment    
Estimated useful lives used 3 years  
Laboratory equipment    
Property and Equipment    
Property and equipment $ 9,021 8,542
Laboratory equipment | Minimum    
Property and Equipment    
Estimated useful lives used 2 years  
Laboratory equipment | Maximum    
Property and Equipment    
Estimated useful lives used 5 years  
Furniture and fixtures    
Property and Equipment    
Property and equipment $ 2,599 2,635
Furniture and fixtures | Minimum    
Property and Equipment    
Estimated useful lives used 4 years  
Furniture and fixtures | Maximum    
Property and Equipment    
Estimated useful lives used 7 years  
Construction In Progress    
Property and Equipment    
Property and equipment $ 34,489 $ 4,995
v3.10.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Property Plant And Equipment [Abstract]    
Depreciation and amortization expense $ 9.0 $ 11.0
v3.10.0.1
Preferred Stock - Additional Information (Details)
12 Months Ended
Aug. 31, 2017
Right
$ / shares
shares
Dec. 31, 2018
Right
$ / shares
shares
Dec. 31, 2017
$ / shares
shares
Class Of Stock [Line Items]      
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001
Preferred stock, par value | $ / shares   $ 0.001 $ 0.001
Preferred stock, shares authorized   1,000,000 1,000,000
Preferred stock, shares issued   0 0
Stockholder Rights Plan      
Class Of Stock [Line Items]      
Dividend declared, Description   one preferred share purchase right (Right) for each outstanding share of common stock, par value $0.001 per share, of the Company.  
Common stock, par value (in dollars per share) | $ / shares $ 0.001    
Number of preferred share right for each common share outstanding | Right 1    
Dividend payable, date of record Sep. 11, 2017    
Preferred stock, shares authorized   1,000,000 1,000,000
Preferred stock, shares issued   0  
Preferred stock, shares outstanding   0  
Additional number of preferred share purchase right attached to each common share | Right   1  
Description of dividend distribution date   The Distribution Date is the close of business on the tenth day after the first date of public announcement that any person has become an Acquiring Person or such earlier date as a majority of the Board becomes aware of the existence of an Acquiring Person.  
Preferred stock, voting rights   Until a Right is exercised, the holder thereof, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends.  
Preferred share purchase rights, expiration date   Aug. 31, 2018  
Stockholder Rights Plan | Series A Junior Participating Preferred Stock      
Class Of Stock [Line Items]      
Preferred stock, participation rights   Each Right, when it becomes exercisable, entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company at a price of $110 per one one-thousandth of a Preferred Share, subject to adjustment.  
Number of share entitles up on exercisable 1.001    
Preferred stock, par value | $ / shares $ 0.001    
Preferred stock, price per share | $ / shares $ 110    
Stockholder Rights Plan | Common Stock      
Class Of Stock [Line Items]      
Minimum ownership percentage of shares required for dilution 15.00%    
Minimum exemption of ownership percentage 15.00%    
v3.10.0.1
Common Stock Options and Restricted Stock - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Apr. 14, 2016
Share-based compensation expense        
Options granted (in shares) 781,000      
Weighted average exercise price $ 29.81 $ 29.46    
Share-based compensation expense recognized $ 21,252,000 $ 32,814,000 $ 36,387,000  
Total unrecognized compensation costs related to unvested stock options and restricted stock awards that the company expects to recognize $ 19,300,000      
Weighted average period 1 year 8 months 12 days      
Stock Options | Employees and Directors        
Share-based compensation expense        
Weighted average fair value of options granted (in dollars per share) $ 12.71 $ 10.70 $ 13.26  
Options granted (in shares) 781,135      
Weighted average exercise price $ 24.81      
Total compensation charge to be recognized over service period $ 9,200,000      
Share-based compensation expense recognized $ 2,900,000      
Stock Options | Non Employee        
Share-based compensation expense        
Options granted (in shares) 0 0 0  
Stock Options and Restricted Stock Awards        
Share-based compensation expense        
Compensation costs capitalized in inventory balances $ 0      
Stock Options and Restricted Stock Awards | Employees and Directors        
Share-based compensation expense        
Share-based compensation expense recognized $ 21,300,000 $ 32,800,000 $ 36,400,000  
The 2006 Plan        
Share-based compensation expense        
Expiration period 10 years      
Number of shares authorized for issuance 14,912,048      
Annual automatic increase in common stock available for issuance (as a percent) 4.00%      
Aggregate restricted stock granted (in shares) 11,398,450      
Remaining restricted stock subject to outstanding options (in shares) 5,037,630      
The 2015 Plan        
Share-based compensation expense        
Expiration period 10 years      
Number of shares authorized for issuance 8,100,000      
Aggregate restricted stock granted (in shares) 4,595,489      
Remaining restricted stock subject to outstanding options (in shares) 3,116,439      
The 2016 Plan        
Share-based compensation expense        
Number of shares authorized for issuance       366,950
Aggregate restricted stock granted (in shares) 147,850      
Remaining restricted stock subject to outstanding options (in shares) 40,000      
v3.10.0.1
Common Stock Options and Restricted Stock - Schedule of Weighted Average Assumptions Using the Black-Scholes Option Pricing Model (Details) - Stock Options
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Estimated volatility (as a percent) 52.29% 48.02% 44.63%
Expected life 6 years 1 month 28 days 6 years 1 month 24 days 5 years 11 months 26 days
Risk free interest rate (as a percent) 2.76% 2.08% 1.46%
v3.10.0.1
Common Stock Options and Restricted Stock - Schedule of Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Share-based compensation expense recognized $ 21,252 $ 32,814 $ 36,387
Research and development      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Share-based compensation expense recognized 5,560 9,683 10,610
Selling, general and administrative      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Share-based compensation expense recognized $ 15,692 $ 23,131 $ 25,777
v3.10.0.1
Common Stock Options and Restricted Stock - Schedule of Stock Options Activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
$ / shares
shares
Stock Option Activity  
Beginning balance (in shares) | shares 8,929
Granted (in shares) | shares 781
Forfeited and expired (in shares) | shares (784)
Exercised (in shares) | shares (733)
Ending balance (in shares) | shares 8,193
Vested and expected to vest at the end of the period | shares 8,168
Vested and exercisable at the end of the period | shares 6,842
Weighted Average Exercise Price  
Balance at the beginning of the period (in dollars per share) | $ / shares $ 29.46
Granted (in dollars per share) | $ / shares 24.81
Forfeited and expired (in dollars per share) | $ / shares 29.26
Exercised (in dollars per share) | $ / shares 20.74
Balance at the end of the period (in dollars per share) | $ / shares 29.81
Vested and expected to vest at the end of the period (in dollars per share) | $ / shares 29.83
Vested and exercisable at the end of the period (in dollars per share) | $ / shares $ 30.40
Weighted Average Remaining Contractual Term  
Balance at the end of the period 5 years 6 months
Vested and expected to vest at the end of the period 5 years 6 months
Vested and exercisable at the end of the period 5 years
Intrinsic Value  
Balance at the end of the period | $ $ 162,119
Vested and expected to vest at the end of the period | $ 162,050
Vested and exercisable at the end of the period | $ $ 160,597
v3.10.0.1
Common Stock Options and Restricted Stock - Schedule of Stock Options Activity, By Exercise Price Range (Details)
shares in Thousands
12 Months Ended
Dec. 31, 2018
$ / shares
shares
Options Outstanding  
Outstanding ending balance (in shares) | shares 8,194
Weighted-average remaining contractual life 5 years 6 months
Weighted-average exercise price (in dollars per share) $ 29.81
Options Exercisable  
Exercisable ending balance (in shares) | shares 6,842
Weighted-average exercise price (In dollars per share) $ 30.40
Range $13.80 - $24.35  
Range of Exercise Price  
Stock option, exercise price range, lower limit (in dollars per share) 13.80
Stock option, exercise price range, upper limit (in dollars per share) $ 24.35
Options Outstanding  
Outstanding ending balance (in shares) | shares 1,857
Weighted-average remaining contractual life 6 years 4 months 24 days
Weighted-average exercise price (in dollars per share) $ 20.60
Options Exercisable  
Exercisable ending balance (in shares) | shares 1,281
Weighted-average exercise price (In dollars per share) $ 19.74
Range $24.45 - $28.15  
Range of Exercise Price  
Stock option, exercise price range, lower limit (in dollars per share) 24.45
Stock option, exercise price range, upper limit (in dollars per share) $ 28.15
Options Outstanding  
Outstanding ending balance (in shares) | shares 1,682
Weighted-average remaining contractual life 5 years 10 months 24 days
Weighted-average exercise price (in dollars per share) $ 26.84
Options Exercisable  
Exercisable ending balance (in shares) | shares 1,216
Weighted-average exercise price (In dollars per share) $ 26.79
Range $28.30 - $32.55  
Range of Exercise Price  
Stock option, exercise price range, lower limit (in dollars per share) 28.30
Stock option, exercise price range, upper limit (in dollars per share) $ 32.55
Options Outstanding  
Outstanding ending balance (in shares) | shares 1,642
Weighted-average remaining contractual life 4 years 4 months 24 days
Weighted-average exercise price (in dollars per share) $ 30.79
Options Exercisable  
Exercisable ending balance (in shares) | shares 1,587
Weighted-average exercise price (In dollars per share) $ 30.84
Range $32.56 - $35.74  
Range of Exercise Price  
Stock option, exercise price range, lower limit (in dollars per share) 32.56
Stock option, exercise price range, upper limit (in dollars per share) $ 35.74
Options Outstanding  
Outstanding ending balance (in shares) | shares 1,952
Weighted-average remaining contractual life 5 years 4 months 24 days
Weighted-average exercise price (in dollars per share) $ 35.21
Options Exercisable  
Exercisable ending balance (in shares) | shares 1,722
Weighted-average exercise price (In dollars per share) $ 35.18
Range $35.84 - $44.50  
Range of Exercise Price  
Stock option, exercise price range, lower limit (in dollars per share) 35.84
Stock option, exercise price range, upper limit (in dollars per share) $ 44.50
Options Outstanding  
Outstanding ending balance (in shares) | shares 1,061
Weighted-average remaining contractual life 5 years 2 months 12 days
Weighted-average exercise price (in dollars per share) $ 39.19
Options Exercisable  
Exercisable ending balance (in shares) | shares 1,036
Weighted-average exercise price (In dollars per share) $ 39.21
v3.10.0.1
Common Stock Options and Restricted Stock - Schedule of Restricted Stock Activity (Details) - Restricted Stock
shares in Thousands
12 Months Ended
Dec. 31, 2018
shares
Restricted Stock Activity  
Nonvested at the beginning of the period (in shares) 698
Vested (in shares) (334)
Forfeited (in shares) (132)
Nonvested at the end of the period (in shares) 232
v3.10.0.1
Debt - Additional Information (Details)
$ / shares in Units, € in Millions
12 Months Ended
Jun. 17, 2014
USD ($)
Dec. 31, 2018
USD ($)
Loan
$ / shares
Dec. 31, 2017
USD ($)
Apr. 18, 2016
USD ($)
Apr. 18, 2016
EUR (€)
Letters of Credit          
Debt Instrument [Line Items]          
Restricted Cash and Cash Equivalents   $ 300,000      
Research and development loans          
Debt Instrument [Line Items]          
Principal   $ 1,800,000      
Fair value of debt       $ 2,900,000 € 2.6
Finland's Ministry of Finance | Research and development loans          
Debt Instrument [Line Items]          
Basis Spread to be reduced (as a percent)   3.00%      
Loan repayment beginning period   2017-01      
Period in which equal annual installments to be paid   5 years      
Loan repayment ending period   2021-01      
Minimum | Finland's Ministry of Finance | Research and development loans          
Debt Instrument [Line Items]          
Effective interest rate on liability component (as a percent)   1.00%      
Notes          
Debt Instrument [Line Items]          
Interest rate (as a percent) 1.75%        
Net proceeds from offering, after deducting Underwriter's discount and estimated offering expenses payable $ 337,500,000        
Principal $ 345,000,000 $ 345,000,000 $ 345,000,000    
Notes maturity date   Jun. 15, 2021      
Notes frequency of periodic payment   semiannually in arrears in cash      
Period to comply with covenants   270 days      
Debt issuance costs   $ 7,500,000      
Debt issuance costs allocated to equity component   1,300,000      
Debt issuance costs allocated to liability component   $ 6,200,000      
Term of debt   7 years      
Debt fair value amount   $ 289,400,000      
Remaining contractual life   2 years 6 months      
Effective interest rate on liability component (as a percent)   4.80%      
Notes | Debt Conversion Terms upon Occurrence of Certain Fundamental Company Changes          
Debt Instrument [Line Items]          
Principal amount of Notes or an integral multiple thereof in which holder may repurchase the Notes   $ 1,000,000      
Notes | Debt Conversion Event Term          
Debt Instrument [Line Items]          
Minimum percentage of aggregate principal amount held by bondholders to declare notes due and payable   25.00%      
In event of default arising out of certain bankruptcy events, percentage of principal amount due and payable   100.00%      
Notes | Convertible Debt Holder          
Debt Instrument [Line Items]          
Initial conversion rate of common stock   23.4968      
Initial conversion price of convertible notes into common stock (in dollars per share) | $ / shares   $ 42.56      
Non-Convertible Capital Loan          
Debt Instrument [Line Items]          
Principal   $ 23,200,000      
Fair value of debt       $ 20,500,000 € 18.2
Number of loans | Loan   14      
Non-Convertible Capital Loan | Finland's Ministry of Finance          
Debt Instrument [Line Items]          
Basis Spread to be reduced (as a percent)   1.00%      
Non-Convertible Capital Loan | Minimum          
Debt Instrument [Line Items]          
Term of debt   8 years      
Non-Convertible Capital Loan | Minimum | Finland's Ministry of Finance          
Debt Instrument [Line Items]          
Effective interest rate on liability component (as a percent)   3.00%      
Non-Convertible Capital Loan | Maximum          
Debt Instrument [Line Items]          
Term of debt   10 years      
v3.10.0.1
Debt - Summary of Outstanding Note Balances (Details) - Notes - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Jun. 17, 2014
Debt Instrument [Line Items]      
Principal $ 345,000 $ 345,000 $ 345,000
Less: debt discount and debt issuance costs , net (26,330) (36,195)  
Net carrying amount 318,670 308,805  
Equity component $ 61,195 $ 61,195  
v3.10.0.1
Debt - Schedule of Interest Expense Recognized Related to the Notes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Debt Instrument [Line Items]      
Total interest expense $ 21,597 $ 18,664 $ 16,527
Notes      
Debt Instrument [Line Items]      
Contractual interest expense 6,038 6,038  
Amortization of debt issuance costs 913 871  
Amortization of debt discount 8,952 8,539  
Total interest expense $ 15,903 $ 15,448  
v3.10.0.1
Liability Related to Sale of Future Royalties - Additional Information (Details) - Royalty Purchase Agreement - USD ($)
$ in Thousands
1 Months Ended
Oct. 01, 2017
Dec. 31, 2017
Liability Related to Sale of Future Royalties [Line Items]    
Payment from royalties $ 40,000 $ 40,000
Royalty liability 40,000  
Net of transaction costs $ 2,200  
v3.10.0.1
Liability Related to Sale of Future Royalties - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 01, 2017
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Liability Related to Sale of Future Royalties [Line Items]        
Non-cash royalty revenue payable to HCRP     $ (10,291) $ (2,705)
Royalty Purchase Agreement        
Liability Related to Sale of Future Royalties [Line Items]        
Liability related to sale of future royalties - beginning balance     35,788  
Proceeds from sale of future royalties $ 40,000 $ 40,000    
Deferred transaction costs amortized   (2,115) 784  
Non-cash royalty revenue payable to HCRP   (2,705) (10,291)  
Non-cash interest expense recognized   608 4,435  
Liability related to sale of future royalties - ending balance   $ 35,788 $ 30,716 $ 35,788
v3.10.0.1
Corporate Restructuring - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Restructuring and Related Activities [Abstract]    
Restructuring activities, description On April 5, 2017, the Company announced a corporate restructuring to reduce its cost structure and focus its resources on its then late-stage program, Inbrija.  
Approximate percentage of headcount reduction 20.00%  
Pre-tax charges for severance and employee separation related costs $ 1,300 $ 7,600
Payments for restructuring 1,820 7,142
Employee Severance    
Restructuring and Related Activities [Abstract]    
Payments for restructuring 1,100 6,600
Stock Compensation Charges    
Restructuring and Related Activities [Abstract]    
Non-cash settlements 200 1,000
Research and Development Expense    
Restructuring and Related Activities [Abstract]    
Pre-tax charges for severance and employee separation related costs 1,200 5,500
Selling, General and Administrative Expenses    
Restructuring and Related Activities [Abstract]    
Pre-tax charges for severance and employee separation related costs $ 100 $ 2,100
v3.10.0.1
Corporate Restructuring - Summary of Restructuring Costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Restructuring And Related Activities [Abstract]    
Restructuring Liability   $ 504
Restructuring costs $ 1,316 7,646
Payments $ (1,820) $ (7,142)
v3.10.0.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Accrued Expenses And Other Current Liabilities [Abstract]    
Product allowances accruals $ 26,931 $ 37,604
Bonus payable 18,381 10,730
Accrued inventory 14,254 15,324
Sales force commissions and incentive payments payable 3,453 1,654
Administrative expenses 2,651 2,276
Vacation accrual 2,395 2,449
Research and development expense accruals 2,374 9,092
Commercial and Marketing expense accruals 1,933 1,643
Royalties payable 509 3,707
Other accrued expenses 4,001 15,371
Total $ 76,882 $ 99,850
v3.10.0.1
Commitments and Contingencies - Summary of Minimum Significant Contractual Obligations (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Operating leases  
Total $ 36,090
Less than 1 year 7,382
1-3 years 15,538
4-5 years 13,170
Inventory purchase commitments  
Total 2,281
Less than 1 year 2,281
Total  
Total 399,433
Less than 1 year 16,317
1-3 years 369,946
4-5 years 13,170
Convertible Senior Notes  
Long term debt  
Net carrying amount 359,214
Less than 1 year 6,038
1-3 years 353,176
Research and development loans  
Long term debt  
Net carrying amount 1,848
Less than 1 year 616
1-3 years $ 1,232
v3.10.0.1
Commitments and Contingencies - Summary of Minimum Significant Contractual Obligations (Parenthetical) (Details) - 12 months ended Dec. 31, 2018
USD ($)
EUR (€)
Commitment And Contingencies [Line Items]    
Liability for uncertain tax position $ 7,700,000  
Biotie Therapies Corp. | Maximum    
Commitment And Contingencies [Line Items]    
Required amount to be paid to UCB for Termination and Transition Agreement $ 4,100,000 € 3,900,000
Alkermes | Ampyra    
Commitment And Contingencies [Line Items]    
Monthly written forecasts (in months) 18 months 18 months
Annual written forecasts (in years) 5 years 5 years
Period for obligation to purchase quantity specified in forecasts (in months) 3 months 3 months
Minimum agreed percentage of annual requirements for purchase 75.00% 75.00%
Convertible Senior Notes    
Commitment And Contingencies [Line Items]    
Notes maturity date Jun. 15, 2021 Jun. 15, 2021
Long-term liability $ 359,214,000  
Non-convertible Capital Loans    
Commitment And Contingencies [Line Items]    
Long-term liability $ 23,200,000  
v3.10.0.1
Commitments and Contingencies - Additional Information (Details)
12 Months Ended
Dec. 31, 2018
USD ($)
ft²
Item
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Oct. 31, 2016
USD ($)
ft²
Dec. 31, 2014
ft²
Oct. 22, 2014
ft²
Jun. 30, 2011
ft²
Commitment And Contingencies [Line Items]              
Rent expense under operating leases $ 8,200,000 $ 8,100,000 $ 6,000,000        
Ampyra license agreement              
Commitment And Contingencies [Line Items]              
Purchase commitments 2,300,000            
Maximum              
Commitment And Contingencies [Line Items]              
Maximum milestone payments 51,600,000            
Alkermes License Agreement | Maximum              
Commitment And Contingencies [Line Items]              
Maximum milestone payments $ 15,000,000            
Lease for Office and Laboratory Space in Ardsley, New York              
Commitment And Contingencies [Line Items]              
Lease term             15 years
Area of leased property | ft²             138,000
Number of additional periods | Item 3            
Lease options duration 5 years            
Termination option period 10 years            
Additional lease option rights (in square feet) | ft² 95,000            
Additional Lease Option Rights Exercised (In Square Feet) | ft²         25,405    
Base rent $ 4,600,000            
Annual rent increase percentage 2.50%            
Lease for Manufacturing Facility in Chelsea, MA              
Commitment And Contingencies [Line Items]              
Area of leased property | ft² 95,000            
Annual rent $ 1,700,000            
Lease for Manufacturing Facility in Chelsea, MA | Civitas Therapeutics              
Commitment And Contingencies [Line Items]              
Area of leased property | ft²           90,000  
Number of additional periods | Item 2            
Lease options duration 5 years            
Base rent $ 1,500,000 $ 500,000          
Annual rent increase percentage 2.50% 3.00%          
Lease for office space in Waltham, MA              
Commitment And Contingencies [Line Items]              
Lease term       10 years      
Area of leased property | ft²       26,000      
Base rent       $ 1,000,000      
v3.10.0.1
Commitments and Contingencies - Schedule of Future Minimum Commitments under all Non-Cancelable Operating Leases (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Operating Leases  
2019 $ 7,382
Total 36,090
Biotie Therapies Corp.  
Operating Leases  
2019 7,382
2020 7,669
2021 7,869
2022 10,071
2023 3,100
Later years 7,769
Total $ 43,860
v3.10.0.1
Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Level 1 | Money Market Funds    
Assets Carried at Fair Value:    
Assets, Fair Value $ 9,586 $ 9,163
Level 2 | Commercial Paper    
Assets Carried at Fair Value:    
Assets, Fair Value 47,108  
Level 2 | Corporate Bonds    
Assets Carried at Fair Value:    
Assets, Fair Value 104,881  
Level 3    
Liabilities Carried at Fair Value:    
Acquired contingent consideration $ 168,000 $ 113,000
v3.10.0.1
Fair Value Measurements - Schedule of Contingent Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Assets and liabilities measured at fair value on a recurring basis utilizing Level 3 inputs    
Balance, beginning of period $ 113,000 $ 72,100
Fair value change to contingent consideration (unrealized) included in the statement of operations 55,000 40,900
Balance, end of period $ 168,000 $ 113,000
v3.10.0.1
Fair Value Measurements - Additional Information (Details)
Dec. 31, 2018
USD ($)
Fair Value Disclosures [Abstract]  
Milestone payment, minimum (as a percent) 26.30%
Milestone payment, maximum (as a percent) 100.00%
Milestone payment, minimum $ 0
Milestone payment, maximum $ 70,000,000
v3.10.0.1
License, Research and Collaboration Agreements - Alkermes License - Additional Information (Details) - Alkermes License Agreement
12 Months Ended
Dec. 31, 2003
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
License termination period 15 years  
Percentage of products under supply agreement   100.00%
v3.10.0.1
License, Research and Collaboration Agreements - Supply Agreement - Additional Information (Details)
12 Months Ended
Dec. 31, 2018
USD ($)
Ampyra | Alkermes  
Supply Agreement  
Minimum agreed percentage of annual requirements for purchase 75.00%
Supply agreement  
Supply Agreement  
Compensatory payment $ 0
Supply agreement | Maximum | Patheon Inc Second Manufacturing agreement  
Supply Agreement  
Purchase requirements threshold percentage 25.00%
Supply agreement | Alkermes License Agreement | Ampyra | Alkermes  
Supply Agreement  
Minimum agreed percentage of annual requirements for purchase 75.00%
Supply agreement | Alkermes License Agreement | Maximum  
Supply Agreement  
Purchase requirements threshold percentage 100.00%
v3.10.0.1
License, Research and Collaboration Agreements - Rush Agreement - Additional Information (Details) - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Rush Agreement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Amount or royalty payments made or accrued $ 66.6 $ 59.9 $ 48.1
v3.10.0.1
License, Research and Collaboration Agreements - Biogen Agreement - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Aug. 31, 2011
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Jul. 31, 2009
Jun. 30, 2009
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Cost of sales   $ 99,310,000 $ 135,080,000 $ 107,475,000      
Accumulated deficit   (393,843,000) (455,108,000)        
ASC 606              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Accumulated deficit         $ (427,525,000)    
ASC 606 | Net Adjustments              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Cost of sales   (634,000)          
Accumulated deficit   21,265,000     27,583,000    
License Revenue              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Amortized license revenue   0 0 0      
Biogen              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Additional payments based on the successful achievement of future regulatory or sales milestones $ 25,000,000            
Deferred Revenue           $ 110,000,000 $ 110,000,000
Amount of significant and incremental discount related to the supply agreement   0          
Identified non-contingent deliverables value on standalone basis, if sold separately   $ 0          
Amortized license revenue     9,100,000 9,100,000      
Biogen | ASC 606 | Net Adjustments              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Accumulated deficit         $ 27,600,000    
Alkermes License Agreement              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Cost of license payable     7,700,000 7,700,000     $ 7,700,000
Alkermes License Agreement | License Revenue              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Cost of sales     600,000 600,000      
Actavis/Watson | Zanaflex Capsules Royalty              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Revenue recognized     2,600,000 3,900,000      
Actavis/Watson | Zanaflex Capsules              
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]              
Cost of sales     3,000,000 2,700,000      
Revenue recognized     $ 3,000,000 $ 2,700,000      
v3.10.0.1
Income Taxes - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax [Line Items]          
US federal corporate tax rate   21.00% 35.00% 35.00%  
Tax Cuts and Jobs Act of 2017, benefit from remeasurement of deferred tax assets and liabilities $ 1,600,000 $ 14,800,000      
Tax Cuts And Jobs Act Of2017 Accounting Complete   true      
Alternative minimum tax credit carry-forwards     $ 4,800,000 $ 4,800,000  
Unused tax credit, period of refund     4 years    
Alternative minimum tax credit carry-forwards expected to be utilized 4,500,000 $ 4,500,000      
Alternative minimum tax credit carry-forwards, unused credits 300,000 $ 300,000      
Limitation on use of carryforwards, cumulative change of control ownership interests, threshold percentage   50.00%      
Limitation on use of carryforwards, cumulative change of control ownership interests, measurement period   3 years      
Unused federal net operating loss carryforwards 31,500,000 $ 31,500,000      
Unused federal net operating loss carryforwards expiring 5,100,000 5,100,000      
Valuation allowance 71,570,000 71,570,000 $ 98,609,000 63,225,000 $ 5,277,000
Benefit from income taxes   $ (13,259,000) (28,526,000) (6,665,000)  
Minimum          
Recent Accounting Pronouncements          
Expiration term for statute of limitations   3 years      
Maximum          
Recent Accounting Pronouncements          
Expiration term for statute of limitations   5 years      
Research and development and orphan drug          
Income Tax [Line Items]          
Tax credit carry-forwards 17,100,000 $ 17,100,000 34,500,000    
Tax credit carry-forward, expiration beginning year   2031      
Federal          
Income Tax [Line Items]          
Operating loss carryforwards 131,600,000 $ 131,600,000      
Operating loss, expected expiration beginning year   2026      
Operating loss carryforwards additional 16,000,000 $ 16,000,000      
Federal | Biotie Therapies Corp.          
Income Tax [Line Items]          
Valuation allowance 3,800,000 3,800,000      
State          
Income Tax [Line Items]          
Operating loss carryforwards 170,100,000 $ 170,100,000 $ 167,900,000 $ 170,900,000  
Operating loss, expected expiration beginning year   2027      
Outside U.S.          
Income Tax [Line Items]          
Operating loss carryforwards 67,600,000 $ 67,600,000      
Operating loss, expected expiration beginning year   2019      
Outside U.S. | Biotie Therapies Corp.          
Income Tax [Line Items]          
Valuation allowance 700,000 $ 700,000      
Federal and State | Biotie Therapies Corp.          
Income Tax [Line Items]          
Valuation allowance $ 23,100,000 23,100,000      
Biotie U.S and Foreign          
Income Tax [Line Items]          
Benefit from income taxes   $ 0      
v3.10.0.1
Income Taxes - Schedule of Domestic and Foreign Components of (Loss) Income Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax [Line Items]      
(Loss) income before taxes $ 20,422 $ (251,885) $ (42,268)
Domestic      
Income Tax [Line Items]      
(Loss) income before taxes 19,211 (172,560) (36,454)
Foreign      
Income Tax [Line Items]      
(Loss) income before taxes $ 1,211 $ (79,325) $ (5,814)
v3.10.0.1
Income Taxes - Schedule of Benefit from (Provision for) Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Current:      
Federal $ 2,991 $ (11,948) $ (852)
State (4,143) (12,653) (4,517)
Foreign (93) (91) 781
Total (1,245) (24,692) (4,588)
Deferred:      
Federal 13,790 42,322 9,465
State 714 5,377 1,788
Foreign   5,519  
Total 14,504 53,218 11,253
Total benefit from (provision for) income taxes $ 13,259 $ 28,526 $ 6,665
v3.10.0.1
Income Taxes - Schedule of Reconciliation of the Statutory U.S. Federal Income Tax Rate to the Entity's Effective Income Tax Rate (Details)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Reconciliation of statutory federal income tax rate to effective income tax rate      
U.S. federal statutory tax rate 21.00% 35.00% 35.00%
State and local income taxes 8.70% (0.10%) (3.80%)
Foreign income tax     1.20%
Stock option compensation 0.70% (0.50%) (3.80%)
Stock option shortfall 12.60% (1.50%) (6.50%)
Research and development and orphan drug credits 5.60% 1.20% 28.90%
Uncertain Tax Positions (0.70%) (0.30%) (4.80%)
Other nondeductible and permanent differences (5.00%) (0.40%) (1.10%)
Valuation allowance, net of foreign tax rate differential (107.90%) (19.80%) (31.60%)
Transaction cost     (5.90%)
Gain or loss on hedging     8.20%
NOL Write-off 16.60%    
Federal return to provision differences (16.60%)    
Tax reform   (2.30%)  
Effective income tax rate (65.00%) 11.30% 15.80%
v3.10.0.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Deferred tax assets:        
Net operating loss and other carryforwards $ 51,543 $ 53,632    
Tax credits 19,401 31,699    
Deferred revenue   5,597    
Stock based compensation 22,733 24,531    
Contingent consideration 38,594 26,041    
Employee compensation 3,677 3,212    
Rebate and returns reserve 5,798 8,215    
Capitalized R&D 10,791 11,295    
Other 13,881 12,368    
Total deferred tax assets 166,418 176,590    
Valuation allowance (71,570) (98,609) $ (63,225) $ (5,277)
Total deferred tax assets net of valuation allowance 94,848 77,981    
Deferred tax liabilities:        
Intangible assets (94,771) (91,991)    
Convertible debt (5,971) (8,449)    
Depreciation (1,256)      
Other (333)      
Total deferred tax liabilities (102,331) (100,440)    
Net deferred tax liability $ (7,483) $ (22,459)    
v3.10.0.1
Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Reconciliation of unrecognized tax benefits      
Beginning of period balance $ 7,397 $ 6,856 $ 4,835
Increases for tax positions taken during a prior period 55 687 570
Decreases for tax positions taken during a prior period (194) (146)  
Increases for tax positions taken during the current period     1,451
Ending period balance $ 7,258 $ 7,397 $ 6,856
v3.10.0.1
Income Taxes - Reconciliation of Beginning and Ending Amounts of Valuation Allowances (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]      
Valuation allowance for deferred tax assets, Balance at Beginning of Period $ 98,609 $ 63,225 $ 5,277
Valuation allowance for deferred tax assets, Additions 5,465 39,007 57,948
Valuation allowance for deferred tax assets, Deductions (32,504) (3,623)  
Valuation allowance for deferred tax assets, Balance at End of Period $ 71,570 $ 98,609 $ 63,225
v3.10.0.1
Earnings Per Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Basic and diluted                      
Net income (loss) $ 9,595 $ (13,911) $ 46,197 $ (8,199) $ (171,064) $ (25,195) $ (8,196) $ (18,904) $ 33,682 $ (223,359) $ (34,618)
Weighted average common shares outstanding used in computing net income (loss) per share—basic                 47,010 45,999 45,259
Plus: net effect of dilutive stock options and unvested restricted common shares                 331    
Weighted average common shares outstanding used in computing net income (loss) per share—diluted                 47,341 45,999 45,259
Net income (loss) per share—basic $ 0.20 $ (0.29) $ 0.99 $ (0.18)         $ 0.72 $ (4.86) $ (0.76)
Net income (loss) per share—diluted $ 0.20 $ (0.29) $ 0.98 $ (0.18)         $ 0.71 $ (4.86) $ (0.76)
v3.10.0.1
Earnings Per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Income Per Diluted Share (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Stock options and restricted common shares      
Antidilutive Securities      
Anti-dilutive securities excluded from computation of earnings per share (in shares) 7,370 8,804 7,749
Convertible note      
Antidilutive Securities      
Anti-dilutive securities excluded from computation of earnings per share (in shares)     10
v3.10.0.1
Employee Benefit Plan - Additional Information (Details) - 401(k) plan - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Defined Contribution Plan Disclosure [Line Items]      
Percentage of employee earnings eligible for additional company contribution 6.00%    
Additional company contribution for each dollar of employee contribution (as a percent) 50.00%    
Company expense related to the defined contribution plan $ 2.4 $ 2.4 $ 2.6
v3.10.0.1
Quarterly Consolidated Financial Data (unaudited) - Schedule of Quarterly Consolidated Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]                      
Total net revenues $ 69,152 $ 142,814 $ 153,302 $ 106,165 $ 188,398 $ 141,065 $ 139,438 $ 119,386 $ 471,433 $ 588,287 $ 519,601
Gross profit 47,678 117,423 122,208 84,815 137,999 110,914 109,614 94,044      
Net (loss) income $ 9,595 $ (13,911) $ 46,197 $ (8,199) (171,064) (25,195) (8,196) (18,904) $ 33,682 $ (223,359) $ (34,618)
Net (loss) income per share—basic $ 0.20 $ (0.29) $ 0.99 $ (0.18)         $ 0.72 $ (4.86) $ (0.76)
Net (loss) income per share—diluted $ 0.20 $ (0.29) $ 0.98 $ (0.18)         $ 0.71 $ (4.86) $ (0.76)
Net loss attributable to Acorda Therapeutics, Inc. —basic and diluted         $ (171,064) $ (25,195) $ (8,196) $ (18,904)      
Net loss per share—basic and diluted         $ (3.70) $ (0.55) $ (0.18) $ (0.41)      
v3.10.0.1
Quarterly Consolidated Financial Data (unaudited) - Schedule of Quarterly Consolidated Financial Data (Parenthetical) (Details) - USD ($)
$ in Millions
3 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Quarterly Consolidated Financial Data [Line Items]      
Inventory obsolescence reserve $ 8.4    
Asset impairment charge   $ 257.3 $ 39.4
Discontinued Operations, Disposed of by Sale | Qutenza Assets and NP-1998 Development Program      
Quarterly Consolidated Financial Data [Line Items]      
Gain on sale of assets $ 7.8